Official Protocol Title:
NCT number:
Document Date:
A Randomized, Double-Blind, Phase 3 Study of  Pemetrexed + Platinum 
Chemotherapy with or  without Pembrolizumab (MK-3475) in TKI-
resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small 
Cell Lung Cancer  (NSCLC) Participants (KEYNOTE-789)
[STUDY_ID_REMOVED] 
24-July-[ADDRESS_321797]:   MK-3475 1
Protocol/Amendment No.: 789-0 8
MK-3475 -789-08 Final Protocol 24-Jul-2023
ConfidentialTitle Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME LLC, RAHWAY, NJ, [LOCATION_003] (MSD).
Protocol Title: A Randomized, Double -Blind, Phase 3 Study of Pemetrexed + Platinum 
Chemotherapy with or without Pembrolizumab (MK- 3475) in TKI -resistant EGFR -mutated 
Tumors in Metastatic Non -squamous Non- small Cell Lung Cancer (NSCLC) Participants 
(KEYNOTE -789)
Protocol Number: 789-08
Compound Number: MK-3475
Sponsor Name [CONTACT_29560]: 
[COMPANY_006] Sharp & Dohme LLC
(hereafter called the Sponsor or MSD)
[ADDRESS_321798], NJ [ZIP_CODE] [LOCATION_003]
Regulatory Agency Identifying Number(s):
IND NUMBER:   116,[ADDRESS_321799] NUMBER: 2017 -004188 -11 
Approval Date:  [ADDRESS_321800]:   MK-3475 2
Protocol/Amendment No.: 789-0 8
MK-3475 -789-08 Final Protocol 24-Jul-2023
ConfidentialSponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor contact [CONTACT_171546] (or equivalent). 
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
08FZ0N
Product:   MK-3475 3
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialDOCUMENT HISTORY
Document Date of Issue Overall Rationale
MK-3475 -789-08 24-JUL-2023 Global amendment. To allow participants to rollover to the extension study (MK -3475 -
587).
MK-3475 -789-07 20-SEP-2022 Global amendment. To provide additional text to specify that IA3 will become the final 
analysis if the observed number of events at IA3 is too close to the target number of 
events at FA .
MK-3475 -789-06 17-JUN-2021 Global amendment. To update the dose modification and toxicity management guidelines 
for immune -related adverse events ( irAEs ).
MK-3475 -789-05 25-JAN-2021 Global amendment. The overall survival ( OS)assumption of this protocol was based on 
the IMPRESS study ,which comprised patients who failed only first-line gefitinib .In this 
population, the median OS was 19.5 months ;however, a recent small retrospective study
show eda much lower median OS of 7.8 months in patients who failed osimertinib and 
switched to another therapy (primarily chemotherapy). Since KEYNOTE -[ADDRESS_321801] -line TKIs (if T790M -),the original assumption of OS will 
likely overestimate the survival in this study. Therefore, this amendment update sthe OS 
design based on the characteristics of the population that was actually enrolled , chang ing
the control assumption of median OS from 19.[ADDRESS_321802]:   MK-3475 4
Protocol/Amendment No.: 789-[ADDRESS_321803] ratio ( HR)assumption is likely to be too aggressive. To 
relax the HR for both OS and progression -free survival ( PFS), and to maintain the same 
sample size, alpha allocation from objective response rate ( ORR )needed to be 
redistributed. This amendment removes alpha from ORR and redistributes equally 
between PFS and OS , changes the assumption of the HR for PFS and OS from 0.65 to 
0.7, and from 0.7 to 0.72, respectively , and r emoves ORR -only interim analysis ( IA)
reducing the number of IAs from [ADDRESS_321804] be conducted monthly, and testing for human immunodeficiency virus 
(HIV), hepatiti s B virus ( HBV ), hepatitis C virus ( HCV )and tuberculosis ( TB)at 
screening is required for residents of [LOCATION_013] .
MK-[ADDRESS_321805] 
(IRB)/Independent Ethics Committee (IEC)when the protocol is amended or terminated .
MK-[ADDRESS_321806]:   MK-3475 5
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialSUMMARY OF CHANGES
PRIMARY REASON (S)FOR THIS AMENDMENT:
Section Number (s) Section Title(s) Description of Change (s) Rationale
1.1 Synopsis Added text related to extension 
study enrollment .To allow participants to 
rollover to the extension 
study (MK -3475 -587).
'4.4 Beginning and End of the Trial Added text related to extension 
study enrollment. To allow participants to 
rollover to the extension 
study (MK -3475 -587) .
ADDITIONAL CHANGE (S)FOR THIS AMENDMENT:
Section Number (s) Section Title(s) Description of Change (s) Rationale
Throughout Document Minor administrative, 
formatting, grammatical, and/or 
typographical changes were 
made throughout the document.To ensure clarity and 
accurate interpretation of the 
intent of the protocol.
08FZ0N
Product:   MK-3475 6
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialTable of Contents
DOCUMENT HISTORY ................................ ................................ ................................ ........ 3
SUMMARY OF CHANGES ................................ ................................ ................................ ...5
1. Protocol Summary ................................ ................................ ................................ .....16
Synopsis ................................ ................................ ................................ .................... 16
Schema ................................ ................................ ................................ ..................... 22
Schedule of Activities (SoA) ................................ ................................ ................... 25
Schedule of Activities for Initial Treatment Phase ................................ .............. 25
Schedule of Activities for Crossover Treatment Phase ................................ .......40
Schedule of Activities for Second Course Retreatment Phase ............................ 47
2. Introduction ................................ ................................ ................................ ................ 50
Study Rationale ................................ ................................ ................................ .......50
PD1/PD -L1 Inhibitors in EGFR -mutant NSCLC ................................ ................ 52
Background ................................ ................................ ................................ .............. 53
Pharmaceutical and Therapeutic Background ................................ ..................... 53
Benefit/Risk Assessment ................................ ................................ ......................... 54
3. Objectives/Hypotheses and Endpoints ................................ ................................ .....[ADDRESS_321807] for Immune -based Therapeutics (iRECIST) ........... [ADDRESS_321808]:   MK-3475 7
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Future Biomedical Research ................................ ................................ ......... 65
Rationale for the Use of Comparator/Placebo ................................ ..................... 65
Justification for Dose ................................ ................................ .............................. 66
Rationale for Pembrolizumab Dosing Regimen ................................ .................. 66
Rationale for Chemotherapy Dosing Regimens ................................ ................... 67
Beginning and End of Study Definition ................................ ................................ 67
Clinical Criteria for Early Study Termination ................................ ..................... 67
5. Study Population ................................ ................................ ................................ ........ 67
Inclusion Criteria ................................ ................................ ................................ ....68
Exclusion Criteria ................................ ................................ ................................ ...70
Lifestyle Considerations ................................ ................................ ......................... 73
Meals and Dietary Restricti ons................................ ................................ ............ 73
Contraception ................................ ................................ ................................ .......73
Pregnancy ................................ ................................ ................................ ............. 73
Use in Nursing Women ................................ ................................ ........................ 74
Screen Failures ................................ ................................ ................................ ........ 74
Participant Replacement Strategy ................................ ................................ ......... 74
6. Treatments ................................ ................................ ................................ .................. 74
Treatments Administered ................................ ................................ ....................... 74
Preparation/Handling/Storage/Accountability ................................ .................... 77
Dose Preparation ................................ ................................ ................................ ..77
Handling, Storage and Accountability ................................ ................................ .78
Measures to Minimize Bias: Randomization and Bl inding ................................ .[ADDRESS_321809]:   MK-3475 8
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Antiemetic Use ................................ ................................ .............................. 82
Colony -Stimulating Factors ................................ ................................ .......... 82
Pemetrexed Premedication ................................ ................................ ............ 82
Cisplatin Premedication ................................ ................................ ................ 83
Dose Modification (Escalation/Titration/Other) ................................ .................. 83
Dose Modification for Pembrolizumab ................................ ............................ 84
Immune -Related Events and Dose Modification ( Withhold, Treat, 
Discontinue) ................................ ................................ ................................ ..[ADDRESS_321810] to Follow -up................................ ................................ ................................ ....94
8. Study Assessments and Procedures ................................ ................................ .......... 94
Administrative and General Procedures ................................ .............................. 95
Informed Consent ................................ ................................ ................................ .95
General Informed Consent ................................ ................................ ............ 95
Consent and Collection of Specimens for Future Biomedical 
Research ................................ ................................ ................................ ........ 96
Inclusion/Exclusion Criteria ................................ ................................ ................ [ADDRESS_321811] ................................ ................................ ............. 96
Medical History ................................ ................................ ................................ ...96
Prior and Concomitant Medications Review ................................ ....................... 96
Prior Medications ................................ ................................ .......................... 96
Concomitant Medications ................................ ................................ ............. 97
Subsequent Anti -Cancer Therapy Status ................................ ...................... 97
Assignment of Screening Number ................................ ................................ .......97
Treatment Eligibi lity Assessment (TEA) Form ................................ ............ 97
Assignment of Treatment/Randomization Number ................................ ............. [ADDRESS_321812]:   MK-3475 9
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Timing of Dose Administration ................................ ................................ ....98
Timing of Dose Administration of Pembrolizumab/ Saline 
Placebo ................................ ................................ ................................ ...98
Pemetrexed ................................ ................................ ............................. 99
Cisplatin ................................ ................................ ................................ .99
Carboplatin ................................ ................................ ............................. 99
Discontinuation and Withd rawal ................................ ................................ ......... 99
Withdrawal From Future Biomedical Research ................................ ........... 99
Participant Blinding/Unblinding ................................ ................................ ........ 100
Calibration of Equipment ................................ ................................ ................... 100
Efficacy Assessments ................................ ................................ ............................. 101
Tumor Imaging and Assessment of Disease ................................ ...................... 101
Initial Tumor Imaging ................................ ................................ ................. 101
Tumor Imaging During the Study ................................ ............................... 102
End of Treatment and Follow -up Tumor Imaging ................................ ......102
Second Course (Retreatment) and Crossover Tumor Imaging ................... [ADDRESS_321813] Assessment of Disease ................................ ................................ 104
Patient Reported Outcomes ................................ ................................ ................ 106
Safety Assessments ................................ ................................ ................................ 106
Physical Examinations ................................ ................................ ....................... 107
Vital Signs ................................ ................................ ................................ .......... 107
Electrocardiograms ................................ ................................ ............................ 107
Clinical Safety Laboratory Asse ssments ................................ ............................ 107
Laboratory Safety Evaluations (Hematology, Chemistry, and 
Urinalysis) ................................ ................................ ................................ ...[ADDRESS_321814] ................................ ................................ ............................ 108
Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events ................................ ................................ ..................... [ADDRESS_321815]:   MK-3475 10
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Disease -related Events and/or Disease -related Outcomes Not 
Qualifying as AEs or SAEs ................................ ................................ ................ [ADDRESS_321816] (ECIs) ................................ ................................ ......[ADDRESS_321817]-Study ................................ ................................ ................................ .......... 118
Safety Follow -up Visit ................................ ................................ ................ 118
Follow -up Visits ................................ ................................ .......................... 118
Survival Follow -up Assessments ................................ ................................ 118
Survival Status ................................ ................................ ................................ ...119
9. Statistical Analysis Plan ................................ ................................ .......................... 119
Statistical Analysis Plan Summary ................................ ................................ ......120
Responsibility for Analyses/In -house Blinding ................................ ................... 122
Hypothe ses/Estimation ................................ ................................ ......................... [ADDRESS_321818]:   MK-3475 11
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Safety Analysis Populations ................................ ................................ .............. 123
PRO Analysis Populations ................................ ................................ ................. 124
Statistical Methods ................................ ................................ ................................ 124
Statistical Methods for Efficacy Analyses ................................ ......................... 124
Progression -free Survival (PFS) ................................ ................................ .124
Overall Survival (OS) ................................ ................................ ................. 126
Objective Response Rate (ORR) and Duration of Response (DOR) .......... 126
Analysis Strategy for Key Efficacy Endpoints ................................ ........... 127
Statistical Methods for Safety Anal yses ................................ ............................ 128
Statistical Methods for PRO Analyses ................................ ............................... 130
Summaries of Baseline Characteristics, Demographics, and Other 
Analyses ................................ ................................ ................................ ............. 131
Demogra phic and Baseline Characteristics ................................ ................ 131
Interim Analyses ................................ ................................ ................................ ...131
Efficacy Interim Analyses ................................ ................................ .................. 131
Safety Interim Analyses ................................ ................................ ..................... 132
Multiplicity ................................ ................................ ................................ ............ 132
Objective Response Rate ................................ ................................ ................... 133
Progression -Free Survival ................................ ................................ .................. 134
Overall Survival ................................ ................................ ................................ .135
Safety Analyses ................................ ................................ ................................ ..136
Sample Size and Power Calculations ................................ ................................ ..137
Subgroup Analyses ................................ ................................ ................................ 137
Extent of Exposure ................................ ................................ ................................ 138
10. Supporting Documentation and Operational Considerations ............................. 139
Appendix 1:  Regulatory, Ethical and Study Oversight Considerations ......... [ADDRESS_321819] for Interventional Clinical Trials ................................ ........... 139
Financial Disclosure ................................ ................................ ........................... 141
Data Protection ................................ ................................ ................................ ...141
Confidentiality of Data ................................ ................................ ...................... 142
Confidentiality of Participant Records ................................ ............................... 142
Confidentiality of IRB/IEC Information ................................ ............................ [ADDRESS_321820]:   MK-3475 12
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Committees Structure ................................ ................................ ......................... 142
Executive Oversight Committee ................................ ................................ .142
Data Monitoring Committee ................................ ................................ .......142
Publication Policy ................................ ................................ .............................. 143
Compliance with Study Registration and Results Posting Requirements ......... 143
Compliance with Law, Audit, and Debarment ................................ ........... 143
Data Quality Assurance ................................ ................................ .............. 144
Source Documents ................................ ................................ ...................... 145
Study and Site Closure ................................ ................................ ................ 145
Appendix 2:  Collection and Management of Specimens for Future 
Biomedical Research ................................ ................................ ............................. 146
Appendix 3:  Contraceptive Guidance and Pregnancy Testing ........................ 150
Definitions ................................ ................................ ................................ .......... 150
Contraception Requirements ................................ ................................ .............. 151
Pregnancy Testing ................................ ................................ .............................. 153
Appendix 4: Adverse Events:  Definitions and Procedures for 
Reco rding, Evaluating, Follow -up, and Reporting ................................ ............ 154
Definition of AE ................................ ................................ ................................ 154
Definition of SAE ................................ ................................ .............................. 155
Additional Events Reported in the Same Manner as SAE ................................ .156
Recording AE and SAE ................................ ................................ ..................... 156
Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ................................ ................................ ................................ .............. 160
Appendix 5:  Clinical Laboratory Tests ................................ .............................. 162
Appendix 6: Eastern Cooperative Oncology Group (ECOG) 
Performance Status ................................ ................................ ............................... 164
Appendix 7:  MASCC 2016 Guidelines ................................ ............................... 165
Appendix 8: Calculated Creatinine Clearance ................................ ................... 166
Appendix 9:  Abbreviations ................................ ................................ ................. 167
Appendix 10: Description of the iRECIST Process for Assessment of 
Disease Progression ................................ ................................ ............................... 171
Appendix 11: Common Terminology Criteria for Adverse Events 
V4.0 (CTCAE) ................................ ................................ ................................ .......175
Appendix 12: Country -specific Requirements ................................ ................... [ADDRESS_321821]:   MK-3475 13
Protocol/Amendment No.: 789-[ADDRESS_321822]:   MK-3475 14
Protocol/Amendment No.: 789-[ADDRESS_321823] OF TABLES
Table 1 Adequate Organ Function Laboratory Values ................................ ...................... 70
Table 2 Study Treatment(s) ................................ ................................ ............................... [ADDRESS_321824] Radiologic Evidence of Progressive 
Disease ................................ ................................ ................................ ................ 105
Table 9 Reporting Time Periods and Time Frames for Adverse Events and 
Other Reportable Safety Events ................................ ................................ .......... 110
Table 10 Censoring Rules for Primar y and Sensitivity Analyses of Progression -
free Survival ................................ ................................ ................................ ........ 125
Table 11 Censoring Rules for DOR ................................ ................................ ................... 127
Table 12 Analysis Strategy for Key Efficacy Variables ................................ .................... 127
Table 13 Analysis Strategy for Safety Parameters ................................ ............................ 130
Table 14 Summary of Interim and Final Analyse s Strategies ................................ ........... 132
Table 15 Possible Alpha -levels and Approximate Objective Response Rate 
(ORR) Difference Required to Demonstrate Efficacy for ORR at 
Interim Analy sis 1................................ ................................ ............................... [ADDRESS_321825]:   MK-3475 15
Protocol/Amendment No.: 789-[ADDRESS_321826] OF FIGURES
Figure 1 Eligibility Diagram ................................ ................................ ............................... 22
Figure 2 Initial and Crossover Treatment Phases ................................ ............................... 23
Figure 3 Initial/Crossover Treatment Phase –Progressive Disease Decision Flow 
Diagram ................................ ................................ ................................ ................ 24
Figure 4 Completion/Attainment of CR Decision Flow Diagram ................................ ......[ADDRESS_321827]:   MK-3475 16
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential1.Protocol Summary
Synopsis
Protocol Title:
A Randomized, Double -Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy 
with or without Pembrolizumab (MK -3475) in TKI -resistant EGFR -mutated Tumors in 
Metastatic Non -squamous Non -small C ell Lung Cancer (NSCLC) Participants 
(KEYNOTE -789)
Short Title:
Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab 
(MK -3475) in TKI -resistant EGFR -mutated Tumors in Metastatic Non -Squamous NSCLC
Objectives/Hypothes es and Endpoints:
Inadult particip ants with TKI -resistant epi[INVESTIGATOR_3506] ( EGFR )-mutat ed
tumor sin metastatic non -squamous NSCLC :
Objective/Hypothesis Endpoint
Primary
Objective: To compare PFS per 
Response Evaluation Criteria in Solid 
Tumors 1.1 (RECIST 1.1) based on 
blinded independent central review 
(BICR) of the combinations of 
pembrolizumab + chemotherapy versus 
saline placebo + chemotherapy.
Hypothesis (H 1): The combination 
of pembrolizumab + chemotherapy 
has superior PFS per RECIST 1.1 
based on BICR compared to saline 
placebo + chemotherapyProgression -free survival (PFS) is the time 
from randomization to the first documented 
progressive disease (PD) or death due to 
any cause, whichever occurs first.
Objective: To compare overall survival 
(OS)of the combinations of 
pembrolizumab + chemotherapy versus 
saline placebo + chemoth erapy.
Hypothesis (H 2): The combination 
ofpembrolizumab + chemotherapy 
has superior OS compared to saline 
placebo + chemotherapy.OS is defined as the time from 
randomization to death due to any cause.
08FZ0N
Product:   MK-3475 17
Protocol/Amendment No.: 789-[ADDRESS_321828] met its success criteria if the combination of 
pembrolizumab + chemotherapy is superior to saline placebo + chemotherapy in PFS or 
OS.
Secondary
Objective: To compare objective 
response rate (ORR) per RECIST 1.1 
based on BICR of the combinations of 
pembrolizumab + chemotherapy versus 
saline placebo + chemotherapy.
Hypothesis (H 3): The combination 
of pembrolizumab + chemotherapy 
has superior ORR per RECIST 1.1 
based on BICR compared to saline 
placebo + chemotherapy .Objective response is a confirmed 
complete response (CR) or partial 
response (PR).
Objective: To evaluate duration of 
response ( DOR)of the combinations of 
pembrolizumab + chemotherapy versus 
saline placebo + chemotherapy.DOR is defined as the time from the 
earliest date of qualifying response until 
earliest date of disease progression or 
death from any cause, whichever comes 
first, per RECIST 1.1 based on BICR.
Objective: To evaluate the patient 
reported outcomes (PROs) mean score 
changes from baseline in global health 
status and quality of life scale between 
pembrolizumab + chemotherapy versus 
saline placebo + chemotherapy.European Organization for Research and 
Treatment of Cancer (EORTC) Quality of 
Life Questionnaire -Core 30 items (QLQ -
C30) global health status (item 29) and 
quality of life scale (item 30).
Objective: To evaluate the PROs time 
to true deterioration (TTD) i n the 
composite e ndpoint of cough, chest 
pain or dyspnea between 
pembrolizumab + chemotherapy versus 
saline placebo + chemotherapy.TTD is the time from baseline to first 
onset of 10 points or more deterioration
from baseline with confirmation by [CONTACT_264805] 10 points or more 
deterioration from baseline of the 
composite endpoint of cough [EORTC 
QLQ -Lung Cancer Module 13 (LC13) 
item 1], chest pain [EORTC QLQ -LC13 
item 10], or dyspnea [EORTC QLQ -
LC30 item 8] . 
Objective: To evaluate the safety and 
tolerability of the combination of 
pembrolizumab + chemotherapy and 
saline placebo + chemotherapy.Adverse events (AEs) and study drug 
discontinuation due to AEs.
08FZ0N
Product:   MK-3475 18
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialOverall Design:
Study Phase Phase 3
Clinical Indication Treatment of Metastatic Non-squamous Non-small Cell Lung 
Cancer
Population Adult pa rticipant s with TKI-resistant EGFR -mutated tumors in 
metastatic non-squamous NSCLC including:
TKI-failures (including osimertinib failure) with 
T790M -negative mutation tumors
T790M -positive mutation tumors with prior exposure 
to osimertinib
First-line osimertinib failure regardless of T790M 
mutation status
Study Type Interventional
Type of Design Randomized , active -control with placebo , parallel -group, 
multi -site, double -blind
Type of Control Active control with placebo
Study Blinding Double -blind
Estimated Duration 
of StudyThe Sponsor estimates that the study will require 
approximately 7years from the time the first participant 
provides documented informed consent until the last 
participant’s last study -related contact . 
Number of Participant s:
Approximately 492participants will be randomized.
08FZ0N
Product:   MK-3475 19
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialTreatment Groups and Duration :
Treatment Groups There are 2 treatment arms:
Arm 1: Pembrolizumab (MK -3475) plus pemetrexed plus 
carboplatin or cisplatin
Arm 2: Saline placebo plus pemetrexed plus carboplatin 
or cisplatin
Duration of 
ParticipationEach participant will participate in the study from the time the 
participant provides documented informed consent through the 
final protocol -specified contact.  
After a screening phase of up to 42 days, each eligible 
participant will be assigned to receive study treatment until 
reaching a discontinuation criteri on(Section 7.1), examples of 
which in clude: disease progression is radiographically 
documented and verified by [CONTACT_19375] 
(BICR), when clinically appropriate, confirmed by [CONTACT_264806] 1.1 for 
immune -based therapeut ics (iRECIST), unacceptable adverse 
event(s) (AEs), intercurrent illness that prevents further 
administration of treatment, investigator’s decision to withdraw 
the participant, participant withdraws consent, pregnancy of 
participant , noncompliance with stu dy treatment or procedure 
requirements or administrative reasons requiring cessation of 
treatment, or until the participant has received 35 administrations 
of pembrolizumab /saline placebo (approximately 2 years). 
Maintenance pemetrexed may continue for p articipants past 35 
cycles until reaching a discontinuation criterion (Section 7.1), as 
long as the participant is receiving benefit and per local 
regulations, whereas pembrolizumab/saline placebo are limited 
to [ADDRESS_321829] 1.1 (Section 8.2.1 ), participants may have 
treatment assignment unblinded (Figure 3). Participants who 
received saline placebo in combination with chemotherapy per 
their randomized treatment assignment may be eligible to 
receive pembrolizumab monotherapy for a total of 35 
administrations in the Crossover Treatment Phase (Section 
8.11.3 ). Tumor imaging is to be re -baselined and RECIST 1.1 
criteria used for participant assessments (Sections [IP_ADDRESS] and 
[IP_ADDRESS] ).
08FZ0N
Product:   MK-3475 20
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialParticipants who received pembrolizumab in combination with 
chemot herapy, but are deemed to be benefiting clinically despi[INVESTIGATOR_264781], may continue study treatment beyond 
progression and receive pembrolizumab monotherapy in the 
Crossover Treatment Phase (Section 8.11.3 ) to complete a total 
of up to [ADDRESS_321830] criteria 
(Sections 8.2.1 and 10.10 ) until iRECIST confirmed PD ( iCPD )
is established. 
Study treatment may continue until reaching a discontinuation 
criteri on(Section 7.1).
Alternatively, participants may have treatment assignment 
remain blinded at the time of BICR -verified progression and 
may continue receiving the study treatment per their randomized 
treatment assignment as long as they continue to be clinically 
stable (Figure 3). 
Blinded study treatment can continue beyond verified 
progression at the Investigator’s discretion. Repeat imaging 
should occur at appropriate interval s per iRECIST criteria 
(Sections 8.2.1 and 10.10 ) until iCPD is established. Once iCPD 
is established, the participant may then have treatment 
assignment unblinded , but may not continue study treatment in 
the Crossover Treatment Phase (Section 8.11.3 ) as d escribed 
above.
Participants on the pembrolizumab plus chemother apy arm who 
have been on study treatment for ≥ 6 months and who attain a 
complete response (CR) may consider stoppi[INVESTIGATOR_262] . 
These participants ,as well as those who stop study treat ment 
after receiving 35 administrations of pembrolizumab for reasons 
other than disease progression or intolerability ,may be eligible 
for up to 17 additional administrations of open -label 
pembrolizumab monotherapy (approximately 1 year) in the 
Second Cour seRetreatment Phase upon experiencing 
subsequent disease progression (Section 8.2.1 ). Second Course 
Retreatment Phase is at the discretion of the investigator 
according to the criteria in Section 8.11.[ADDRESS_321831]:   MK-3475 21
Protocol/Amendment No.: 789-[ADDRESS_321832] survival status to be assessed at 
additional time points and ente red into the database during the 
course of the study. For example, survival status may be 
requested prior to, but not limited to, an external Data 
Monitoring Committee (eDMC) review.
All participant s will be followed for overall survival until death, 
withd rawal of consent, or the end of the study. Survival status 
can be done in a variety of ways including phone, email, chart 
review, or review of public records. Survival status information 
(whether by [CONTACT_756], review of public records, etc.) should be 
officially documented by [CONTACT_779]. Upon study completion, 
participants are discontinued and may be enrolled in a 
pembrolizumab extension study, if available. 
Study Governance:
Study Governance 
Committees Committee Included in this study?
Steering CommitteeN
Executive Oversight 
CommitteeY
Data Monitoring CommitteeY
Clinical Adjudication 
CommitteeN
Study governance considerations are outlined in Section 
10.1.
A list of abbreviations used in this document can be found in Section 10.9.
08FZ0N
Product:   MK-3475 22
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Schema
The Study Eligibility Diagram is depi[INVESTIGATOR_6517] 1, Initial and Crossover Treatment 
Phase sis depi[INVESTIGATOR_6517] 2, Initial Treatment Phase –Progressive Disease Decision Flow 
Diagram is depi[INVESTIGATOR_6517] 3.Completion/Attainment of CR Decision Flow Diagram is 
depi[INVESTIGATOR_6517] 4.
Figure 1Eligibility Diagram
08FZ0N
Product:   MK-3475 23
Protocol/Amendment No.: 789-[ADDRESS_321833]:   MK-3475 24
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialFigure 3Initial/Crossover Treatment Phase –Progressive Disease Decision Flow Diagram
Figure 4Completion/Attainment of CR Decision Flow Diagram
08FZ0N
Product:   MK-3475 25
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Schedule of Activities (SoA)
Schedule of Activities for Initial Treatment P hase
Details regarding the procedures listed in this table are outlined in Section 8. 
Study PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321834] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
Administrative Procedures
Informed Consent Form 
(ICF)3X
ICFfor Future Biomedical 
Research ( FRB) (optional)XDocumented 
informed 
consent for 
FBR is 
optional and is 
not required to 
participate in 
the study
Inclusion/Exclusion 
CriteriaX
Participant ID Card X
Demographics and Medical 
HistoryX
Prior/Concomitant Meds X X X X X X X X X X X X4Record a ll 
concomitant 
medications 
received within 
[ADDRESS_321835]:   MK-3475 26
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321836] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
NSCLC Disease Details 
and Prior TreatmentX
Treatment Eligibility 
Assessment (TEA)XThe 
investigator 
must complete 
this form to 
document the 
rationale for 
the choice of 
carboplatin or 
cisplatin prior 
to 
randomization .
Obtain randomization 
number using IRTX
Subsequent Anti-neoplastic 
Therapy StatusX X X XIf participant 
discontinues 
study treatment 
for any reason 
other than PD, 
imaging should 
continue to be 
collected and 
sent to the 
central imaging 
vendor for 
possible 
retrospective 
review
08FZ0N
Product:   MK-3475 27
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321837] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
Survival Status XUpon Sponsor 
request, 
participants 
may be 
contact[CONTACT_264807].
Clinical Procedures / Assessments
Review Adverse Events X X X X X X X X X X X XReport non -
serious AEs 
occurring 
within [ADDRESS_321838]:   MK-3475 28
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321839] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
Directed Physical 
Exam inationX X X X X X X X X
Vital Signs , Height, and 
WeightX X X X X X X X X X XHeight at 
Screening only. 
BSA 
calculations 
required for 
chemo dosing.
12-Lead ECG X X
ECOG Performance Status X X5X X X X X X X X XAt Screening, 
perform within 
[ADDRESS_321840] dose of 
study treatment 
but before 
randomization .
To be assessed 
prior to dosing 
at each cycle 
(Section 10.6)
Labor atory Procedures / Assessments: Analysis Performed by [CONTACT_264808] –Highly 
Sensitive Urine or Serum 
HCGX XWOCBP 
require negative 
test within [ADDRESS_321841]:   MK-3475 29
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321842] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
Hepatitis B & C Serology XTesting for 
Hepatitis B and 
Hepatitis C is 
not required 
unless 
mandated by 
[CONTACT_19387].
Refer to 
Section 10.12
for country -
specific 
requirements.
Hepatitis B 
surface 
antigen, HBV -
DNA , HCV -
RNA (or HCV 
antibody if 
HCV -RNA is 
not the local 
SOC). 
08FZ0N
Product:   MK-3475 30
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321843] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
HIV testing XTesting for 
HIV is not 
required unless 
mandated by 
[CONTACT_19387].
Refer to 
Section 10.12 
for country -
specific 
requirements.
PT/INR and aPTT/PTT XPerform 
eligibility labs 
within 10 days 
prior to Cycle 1.
PT/INR and 
aPTT/PTT to be 
tested at 
Screening for all 
participants. 
Any participant 
receiving 
anticoagulant 
therapy should 
have 
coagulation 
factors 
monitored 
closely 
throughout the 
study.
08FZ0N
Product:   MK-3475 31
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321844] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
Hematology: CBC with 
DifferentialX X X X X X X X X XPerform 
eligibility labs 
within [ADDRESS_321845] 
up to 3 days 
prior to dosing.Chemistry Panel X X X X X X X X X X
Creatinine Clearance 
CalculationX X X X
Urinalysis X X X X X X X XPerform within 
10 days prior 
to Cycle 1, 
then every 2nd
cycle through 
Cycle 6 , then 
every 6thcycle 
thereafter 
(Cycle s2, 4, 6, 
12, 18, etc. ).
After Cycle 1, 
may collect up 
to [ADDRESS_321846]:   MK-3475 32
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321847] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
T3/FT3, FT4 ,and TSH X X X X X X X XPerform within 
10 days prior 
to Cycle 1, 
then e very 2nd
cycle (Cycles 
2, 4, 6, 8, etc.) . 
May use
central lab only 
if local lab is 
not capable .
After Cycle 1, 
may collect up 
to [ADDRESS_321848] if a 
documented 
law or 
regulation 
prohibits or 
local IRB/IEC 
does not 
approve.
08FZ0N
Product:   MK-3475 33
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321849] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
Blood for RNA Analys is X X XCollect pre -
dose
Blood for ctDNA Analysis X
Blood for Serum/Plasma 
Biomarker AnalysisX
Tumor Tissue Collection
Newly Obtained or 
Archival  Tissue forPD-L1 
AnalysisXMay use an 
archival tissue
sample that 
was obtained 
prior to 
screening 
period as part 
of the 
participant’s 
standard care.
08FZ0N
Product:   MK-3475 34
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321850] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
Tissue/Plasma Collection 
after 1st disease 
progression for T790M 
Molecular StatusXMay send 
tumor tissue to 
central lab for 
T790M testing 
if status is 
unknown and 
cannot be 
determined 
locally.
Participants
with negative 
T790M mutati
on using 
plasma 
specimens will 
be required to 
have tissue 
biopsy
confirmation of 
negative 
T790M 
mutation prior 
to enrollment .
Participants 
with osimertinib 
treatment as 1st
line therapy are 
not required to 
have T790M 
status.
08FZ0N
Product:   MK-3475 35
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321851] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
Efficacy Measurements
Submission of Pre -trial 
Tumor ImagingXThe site’s study 
team must have 
reviewed pre -trial 
images that are of 
diagnostic quality 
from at least [ADDRESS_321852]:   MK-3475 36
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321853] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
Tumor Imaging X X X X X X X6X6Perform imaging at 
Baseline, and 6 
weeks after 
randomization, then 
Q9W through 5 1
weeks, and Q12W 
after randomization 
subsequently (all 
imaging after 
baseline has a ±7 
day window). 
Schedule should be 
followed regardless 
of treatment delays.
If participant 
discontinues study 
treatment for any 
reason other than 
PD, imaging should 
continue to be 
collected and sent 
to the central 
imaging vendor for 
possible retro -
spective review
If participant 
discontinues study 
treatment for PD, 
and imaging was 
obtained within [ADDRESS_321854]:   MK-3475 37
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321855] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
Brain MRI X
Study Drug Administration –Per Randomized Assignment
Pembrolizumab (MK -3475) 
or Saline PlaceboX X X X X X X
Pemetrexed X X X X X X X XPremedication 
should also be 
dosed per the 
approved 
product labels 
and as 
described in 
Section 6.5.3.Carboplatin or Cisplatin X X X X
08FZ0N
Product:   MK-3475 38
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321856] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
Patient Reported Outcomes (PROs)
EQ-5D-5L X X X X X X X X XPerform every 
cycle through 
Cycle 7, then 
every 3rd cycle 
through Cycle 
19, then every 
4th cycle through 
Cycle 35 (eg, 
Cycles 1 -7, 10, 
13, 16, 19, 23, 
27, 31 and 35.). 
PROs will also 
be obtained at the 
Treatment 
Discontinuation 
visit and [ADDRESS_321857] dose of study 
treatment, at the 
time of the 
mandatory Safety 
Follow -up visit, 
PROs do not 
need to be 
repeated. 
Perform ePROs 
in the order listed 
in the SoA (EQ -
5D-5L first).EORTC QLQ -C30 X X X X X X X X X
EORTC QLQ -LC13 X X X X X X X X X
08FZ0N
Product:   MK-3475 39
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy PeriodScreening 
PhaseTreatment Cycles  (3-Week Cycles)End of 
Treatment
(EOT)Post Treatment Visits
Notes
Treatment CycleScreening 
(Visit 1)1 2 3 4 56 to 
1718 to 
3536+ DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -up
Scheduling Window
(Days):-42 
to -1-28 
to -1+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At Time of 
Discon (+3)[ADDRESS_321858] 
Discon
(+14)Every 
12 
Weeks       
(±7)Every 12 
Weeks
(±14)
Notes: 
1. If Discontinuation visit occurs ≥[ADDRESS_321859] dose of study treatment, a Safety Follow -up Visit is not required.
2. Follow -Up visits may be scheduled to coincide with Follow -Up imaging (eg, [ADDRESS_321860] imaging time point).
3. Informed consent must be obtained prior to sending any of the following: (a) plasma/tumor tissue samples to the central lab for PD -L1/EGFR T790M testing; (b) pretrial tumor 
imaging to the central imaging vendor for confirmation of diagnostic quality 
4. After the Safety Follow -up Visit, record all medications taken for SAEs and ECIs as defined in Section 10.4.
5. Does not have to be done if Screening ECOG was performed within [ADDRESS_321861] dose of study treatment in Cycle 1.
6. For participants discontinuing for reasons other than BICR -verified PD, follow -up visits and imaging continue until BICR -verified PD(these images should continue to be sent 
to the central imaging vendor), the start of new anti-cancer treatment, withdrawing consent, or becoming lost to follow -up. Participants discontinuing treatment with BICR -
verified PD proceed directly to survival follow -upor Crossover Treatment Phase, if applicable . Follow -up Visits may be scheduled to coincide with Follow -up imaging (eg, [ADDRESS_321862] imaging if after Week 51).
Abbreviations: AE=adverse event; aPTT=activated partial thromboplastin time; BICR=blinded independent central (imaging) revie w; BSA=body surface area; CBC=complete 
blood count; ctDNA=circulating tumor deoxyribonucleic acid; CXDX=Cycle X Day X; d=days; DC/Discon =discontinuation; DNA = deoxyribonucleic acid; 
ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; EORTC=European Organisation for Research and Treatment of Cancer; EOT=end of treatment; 
ePRO=electronic patient reported outcome; EQ-5D-5L=E uroQol 5-dimension, 5-level Questionnaire; FRB=future biomedical research; FT4= free thyroxine; H/hr=hours; 
HBV/HCV=hepatitis B/C virus; HCG=human chorionic gonadotropin; HIV=human immunodeficiency virus; ICF=informed consent form; ID=identification; INR=i nternational 
normalized ratio; IRB/IEC= Institutional Review Board/Independent Ethics Committee; min=minutes; IRT=interactive response technology; MRI=magnetic resonance imaging;
NSCLC=non -small cell lung cancer; PD=progressive disease; PD-L1=programmed cell death ligand 1; PRO=patient -reported outcome; PT=prothrombin time; PTT=partial 
thromboplastin time; Q=every; QLQ -C30=Quality of Life Questionnaire Core 30; QLQ -LC13=Quality of Life Question naire and Lung Cancer Module 13 ; RNA=ribonucleic acid; 
SAE=serio us adverse event; SoA=schedule of activities ; T3/FT3= free or total triiodothyronine; TSH= thyroid stimulating hormone; V=visit; W=weeks; WOCBP=woman of 
child -bearing potential.
08FZ0N
Product:   MK-3475 40
Protocol/Amendment No.: 789-[ADDRESS_321863] BICR-verified progressive disease andarequalified for the Crossover Phase.Details 
regarding the procedures listed in thi s table are outlined in Section 8. 
Study Period Treatment Cycles  (3-Week Cycles) EOT Post Treatment Visits Notes
Treatment Cycle 1 2 3 4 5 6 7 8 9 10 11 12 1314 
thru
35DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -
up
Scheduling 
Window (Days) :+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At 
Time 
of 
Discon 
(+3)[ADDRESS_321864] 
Discon 
(+14)Every 12 
Weeks      
(±7)Every 12 
Weeks 
(±14)
Administrative Procedures
Eligibility Criteria X
Prior/Concomitant 
MedsX X X X X X X X X X X X X X X X X3
Subsequent Anti-
neoplastic Therapy 
StatusX X X X
Survival Status XUpon Sponsor 
request, 
participants 
may be 
contact[CONTACT_264807].
08FZ0N
Product:   MK-3475 41
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy Period Treatment Cycles  (3-Week Cycles) EOT Post Treatment Visits Notes
Treatment Cycle 1 2 3 4 5 6 7 8 9 10 11 12 1314 
thru
35DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -
up
Scheduling 
Window (Days) :+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At 
Time 
of 
Discon 
(+3)[ADDRESS_321865] 
Discon 
(+14)Every 12 
Weeks      
(±7)Every 12 
Weeks 
(±14)
Clinical Procedures/Assessments
Review Adverse 
Events X X X X X X X X X X X X X X X X XReport non -
serious AEs 
occurring 
within [ADDRESS_321866]:   MK-3475 42
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy Period Treatment Cycles  (3-Week Cycles) EOT Post Treatment Visits Notes
Treatment Cycle 1 2 3 4 5 6 7 8 9 10 11 12 1314 
thru
35DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -
up
Scheduling 
Window (Days) :+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At 
Time 
of 
Discon 
(+3)[ADDRESS_321867] 
Discon 
(+14)Every 12 
Weeks      
(±7)Every 12 
Weeks 
(±14)
ECOG Performance 
StatusX X X X X X X X X X X X X X X XTo be assessed 
prior to dosing 
at each cycle
(Section 10.6) .
Labora tory Procedures / Assessments: A nalysis Performed by [CONTACT_264808] –
Highly Sensitive 
Urine or Serum 
HCGX XWOCBP 
require 
negative test 
within [ADDRESS_321868] 
monthly if 
required by 
[CONTACT_13133].
Refer to 
Section 10. 12 
for country -
specific 
requirements. 
Hematology: CBC  
with DifferentialX X X X X X X X X X X X X X X X
08FZ0N
Product:   MK-3475 43
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy Period Treatment Cycles  (3-Week Cycles) EOT Post Treatment Visits Notes
Treatment Cycle 1 2 3 4 5 6 7 8 9 10 11 12 1314 
thru
35DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -
up
Scheduling 
Window (Days) :+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At 
Time 
of 
Discon 
(+3)[ADDRESS_321869] 
Discon 
(+14)Every 12 
Weeks      
(±7)Every 12 
Weeks 
(±14)
PT/INR and 
aPTT/PTT XPT/INR and 
aPTT/PTT to be 
tested at Cycle [ADDRESS_321870] 
coagulation 
factors 
monitored 
closely 
throughout the 
study.
Chemistry Panel X X X X X X X X X X X X X X X X
Urinalysis X X X X X X X XPerform prior to 
Cycle 1 and 
Cycle 2, then 
every 2ndcycle 
through Cycle 
6, then every 6th
cycle thereafter 
(Cycles 2, 4, 6, 
12, 18, etc.) . 
After Cycle 1, 
may collect up 
to [ADDRESS_321871]:   MK-3475 44
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy Period Treatment Cycles  (3-Week Cycles) EOT Post Treatment Visits Notes
Treatment Cycle 1 2 3 4 5 6 7 8 9 10 11 12 1314 
thru
35DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -
up
Scheduling 
Window (Days) :+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At 
Time 
of 
Discon 
(+3)[ADDRESS_321872] 
Discon 
(+14)Every 12 
Weeks      
(±7)Every 12 
Weeks 
(±14)
T3/FT3, FT4 ,and 
TSHX X X X X X X X X XPerform prior 
to Cycle 1 and 
Cycle 2, then 
every 2ndcycle 
(Cycles 2, 4, 6, 
8, etc.) . May 
usecentral lab 
only if local 
lab is not 
capable .After 
Cycle 1, may 
collect up to 
3days prior to 
dosing.
Efficacy Measurements
Brain MRI XPerfo rm at time 
of crossover if 
participant has 
history of brain 
metastases.
Tumor Imaging X X X X X X X XBlinded central 
review 
verifying 
progressive 
disease is 
required for 
crossover, 
without 
exception
08FZ0N
Product:   MK-3475 45
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy Period Treatment Cycles  (3-Week Cycles) EOT Post Treatment Visits Notes
Treatment Cycle 1 2 3 4 5 6 7 8 9 10 11 12 1314 
thru
35DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -
up
Scheduling 
Window (Days) :+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At 
Time 
of 
Discon 
(+3)[ADDRESS_321873] 
Discon 
(+14)Every 12 
Weeks      
(±7)Every 12 
Weeks 
(±14)
Study Drug Administration
Pembrolizumab 
(MK -3475)X X X X X X X X X X X X X XTreatment with 
Pembro should 
not initiate 
until at least [ADDRESS_321874] dose of 
chemo 
regardless of 
the time of 
progression.  
Participants 
originally 
assigned to 
pembro + 
chemo arm will 
complete up to 
a total of 35 
admin of 
pembro and 
participan ts 
from the saline 
placebo + 
chemo arm will 
receive up to 
[ADDRESS_321875]:   MK-3475 46
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy Period Treatment Cycles  (3-Week Cycles) EOT Post Treatment Visits Notes
Treatment Cycle 1 2 3 4 5 6 7 8 9 10 11 12 1314 
thru
35DisconSafety 
Follow -
up1Follow -
up2Survival 
Follow -
up
Scheduling 
Window (Days) :+3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3At 
Time 
of 
Discon 
(+3)[ADDRESS_321876] 
Discon 
(+14)Every 12 
Weeks      
(±7)Every 12 
Weeks 
(±14)
Notes: 
1. If Discontinuation visit occurs ≥[ADDRESS_321877] dose of study treatment, a Safety Follow -up Visit is not required.
2. Follow -Up visits may be scheduled to coincide with Follow -Up imaging (eg, [ADDRESS_321878] imaging time point).
3. After the Safety Follow -up Visit, record all medications taken for SAEs and ECIs as defined in Section 10.4
Abbreviations: AE=adverse event; aPTT=activated partial thromboplastin time; CBC=complete blood count; CXDX=Cycle X Day X; d=days; DC /Discon =discontinuation; 
ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; EOT=end of treatment;  FT4= free thyroxine; H/hr=hours; HCG=human chorionic gonadotropin; 
INR=international normalized ratio; min=minutes; MRI=magnetic resonance imaging; PD=progressive disease; PT=prothrombin time; PTT=partial thromboplastin time; Q=every; 
SAE=serious adverse event; S oA=schedule of activities ; T3/FT3= free or total triiodothyr onine; TSH= thyroid stimulating hormone;  V=visit; WOCBP=woman of child -bearing 
potential.
08FZ0N
Product:   MK-3475 47
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Schedule of Activities for Second Course Retreatment Phase
Details regarding the procedures listed in this table are outlined in Section 8.Second course retreatme nt participants may receive up to 
17 cycles (approximately 1 year) of open -label pembrolizumab mono therapy.  
Study Period Treatment Cycles (3 -Week Cycles) EOT Post-Treatment Visits
NotesTreatment Cycle :1 2 3 4 5 6 to 17DisconSafety 
Follow -up1Follow -
up2Survival 
Follow -up
Scheduling Window (Days): +3 ± 3 ± 3 ± 3 ± 3 ± 3At DC 
(+3) [ADDRESS_321879]-DC 
(+14)Every 12
Weeks
( ±7)Every 12 
Weeks
(± 14)
Administrative Procedures
Eligibility Criteria X
Concomitant Medication Review X X X X X X X X
Subsequent Anti -neoplastic 
Therapy StatusX X X X
Survival Status XParticipants may be contact[CONTACT_264809].
Clinical Procedures/Assessments
Review Adverse Events X X X X X X X X XReport non -serious AEs occurring within [ADDRESS_321880]:   MK-3475 48
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy Period Treatment Cycles (3 -Week Cycles) EOT Post-Treatment Visits
NotesTreatment Cycle :1 2 3 4 5 6 to 17DisconSafety 
Follow -up1Follow -
up2Survival 
Follow -up
Scheduling Window (Days): +3 ± 3 ± 3 ± 3 ± 3 ± 3At DC 
(+3) [ADDRESS_321881]-DC 
(+14)Every 12
Weeks
( ±7)Every 12 
Weeks
(± 14)
Laboratory Procedures/Assessments: Analysis Performed by [CONTACT_264810] –Highly Sensitive 
Urine or Serum HCGX XWOCBP require negative test within 72 hours
prior to Second Course (SC) Cycle [ADDRESS_321882] 
monthly if required by [CONTACT_427] .Refer to 
Section 10. 12 for country -specific requirements. 
PT/INR and aPTT /PTT XPT/INR and aPTT/PTT tobe tested at Cycle [ADDRESS_321883] coagulation factors 
monitored closely throughout the study .
Hematology: CBC with Differential X X X X X X X X Perform within [ADDRESS_321884] up to 3 d aysprior to 
dosing . Chem istry Panel X X X X X X X X
Urinalysis X X X X X XEvery 2 cycles through SC Cycle 5, then every 6 
cycles ( SC Cycle s1, 3, 5, 11, 17).After SC 
Cycle 1, may collect up to 3 days prior to dosing.
T3/FT3, FT4, TSH X X X X X XPerform within 10 days prior to SC Cycle 1. 
Repeat e very 2cycle s(SC Cycles 1, 3, 5, 7, etc.) . 
May use central lab if local lab is not capable .
After SC Cycle 1, may collect up to 3 days prior 
to dosing.
Efficacy Measurements
Tumor Imaging X X X X X X3SC baseline imaging within 28 days prior to SC 
Cycle 1. Perform imaging Q 12W(±7 d ays) from 
SC Cycle 1 (after w eeks12, 24, 36, 48 ). Schedule 
should be followed regardless of treatment 
delays. If imaging was obtained with in [ADDRESS_321885]:   MK-3475 49
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy Period Treatment Cycles (3 -Week Cycles) EOT Post-Treatment Visits
NotesTreatment Cycle :1 2 3 4 5 6 to 17DisconSafety 
Follow -up1Follow -
up2Survival 
Follow -up
Scheduling Window (Days): +3 ± 3 ± 3 ± 3 ± 3 ± 3At DC 
(+3) [ADDRESS_321886]-DC 
(+14)Every 12
Weeks
( ±7)Every 12 
Weeks
(± 14)
Study Drug Administration
Pembrolizumab (MK -3475) X X X X X XPembro can be administered for up to 17 
administrations (approximately 1 year).
Notes: 
1. If Discontinuation visit occurs ≥[ADDRESS_321887] dose of study treatment, a Safety Follow -up Visit is not required.
2. For participants discontinuing second course for reasons other than PD, follow -up visits and imaging continue until the start of new anti-cancer treatment, PD, withdrawal of 
consent, death or end of the study Participants discontinuing second course trea tment with PD proceed directly to survival follow -up.
Abbreviations: AE=adverse events; aPTT=activated partial thromboplastin time; CBC=complete blood count; CXDX= Cycle X Day X; DC/Discon =discontinuation; 
ECG=electrocardiogram; ECOG=Eastern Cooperative On cology Group; EOT=end of treatment; FT4= free thyroxine; H/hr=hours; HCG=human chorionic gonadotropin; 
INR=international normalized ratio; PD=progressive disease; PT=prothrombin time; PTT=partial thromboplastin time; Q=every;  SAE=serious adverse event; SC=Second Course; 
SC C1D1 =Second Course Cycle 1 Day 1 ; T3/FT3=free or total triiodothyronine; TSH=thyroid stimulating hormone; W=weeks; WOCBP=woman of child -bearing potential.
08FZ0N
Product:   MK-3475 50
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential2.Introduction
Study Rationale 
The global incidence of lung cancer was 1.8 million in 2012, resulting in an estimated 
1.6million deaths [World Health Organization 2012] . In the [LOCATION_002], the 2016 
estimated incidence of new diagnoses was 224,400 and estimated number of deaths was 
158,100 [National Ca ncer Institute 2016] . Non -small cell lung cancer (NSCLC) represents 
approximately 80% to 85% of all lung cancers. Of the patients with NSCLC, tumor histology 
is approximately 40% to 60% adenocarcinoma, 10% to 15% squamous, 5% neuroendocrine, 
and the res t “not otherwise specified” [Sulpher, J. A., et al 2013] . 
Approximately 70% of patients with NSCLC have advanced disease not amenable to surgical 
resection at the time of diagnosis. The 5 -year relative survival for patients with any lung 
cancer overall and metastatic lung cancer specifically has been reported to be 17.7% and 
4.3%, respectively [National Cancer Institute 2016] .
The standard of care (SOC) for metastatic NSCLC has changed in recent years with the 
development of immunotherapy agents. In the Phase 3 study KEYNOTE -024, 
pembrolizumab, a programmed cell death protein 1 ( PD-1) inhibitor, showed statistically 
significant increases in overall survival (OS) and pr ogression -free survival (PFS) compared 
to SOC platinum -based chemotherapy for treatment -naïve participants with metastatic 
NSCLC whose tumors expressed high levels of the programmed cell death ligand 1 (PD -L1) 
(tumor proportion score [TPS] ≥50%) with no ep idermal growth factor receptor (EGFR ) or 
anaplastic lymphoma kinase (ALK ) genomic tumor aberrations , leading to regulatory 
approval for this indication in the US and other countries around the world. Approximately 
30% of patients with newly diagnosed, advanced NSCLC highly express PD -L1 to a TPS 
≥50% [Reck, M., et al 2016] .
In the Phase 2 study KEYNOTE -021 Cohort G, pembrolizumab plus pemetrexed and 
carboplatin showed statistically significant incr eases in objective response rate (ORR) and 
PFS compared to pemetrexed and carboplatin alone in participants with non -squamous 
advanced NSCLC, regardless of PD -L1 status. These results established pembrolizumab plus 
chemotherapy as an efficacious option for first-line (1L) therapy in patients with NSCLC; 
these findings are being further evaluated in the ongoing Phase 3 studies KEYNOTE -189 
(non-squamous) and KEYNOTE -407 (squamous) (see the I nvestigator’s Brochure [IB]).
The EGFR is a transmembrane receptor wi th tyrosine kinase activity (TK) involved in the 
regulation of cell proliferation, survival, differentiation and other crucial processes through 
activation of multiple downstream signaling cascades, including PI3K/AKT, 
RAS/RAF/mitogen -activated protein kin ase (MAPK) and STAT pathways. EGFR pathway is 
often deregulated in NSCLC. The overall prevalence for EGFR mutations in patients with 
NSCLC is 30%, ranging from 38% in China to 14% in Europe .The most common mutations 
are the in -frame exon 19 deletion and the exon 21 point mutation L858R (substitution from 
leucine to arginine at amino acid 858) accounting for about 90% of all mutations. Somatic 
activating mutations of EGFR are predominant in adenocarcinoma; the prevalence of EGFR
mutations is higher in never -smokers, females and patients of East Asian ethnicity [Zhan g, Y. 
L., et al 2016] .
08FZ0N
Product:   MK-3475 51
Protocol/Amendment No.: 789-[ADDRESS_321888] -generation, reversible EGFR tyrosine kinase inhibitors ( TKIs ), gefitinib and 
erlotinib, are orally bioavailable synthetic anilinoquinazolines designed to compete for 
adenosine triphosphate ( ATP )binding to the catalytic sit e of the receptor, switch off survival 
signals, leading to tumor cell death, whereas the second -generation inhibitors, including 
afatinib and dacomitinib, are irreversible inhibitors with greater affinity for the EGFR kinase 
domain and can also inhibit and block signaling from other members of the ErbB family, thus 
providing enhanced EGFR blockade.
Iressa Pan -Asia Study (IPASS) was the first study demonstrating the superiority of gefitinib 
with a significantly longer PFS and ORR compared with chemotherapy i n subgroup of 
patients with EGFR mutations NSCLC (hazard ratio [HR] for PFS, 0.48; 95% confidence 
interval ( CI):0.36,0.64; p<0.001) thus leading to its approval [Mok, T. S., et al 2009] .
Subsequent multiple, r andomized Phase 3trials, exclusively enrolling patients with EGFR -
mutated NSCLC, explored the use of gefitinib, erlotinib or afatinib as first -line treatment in 
comparison with standard platinum -based chemotherapy showed that EGFR TKIs improved 
ORRs ranging between 62% to 83%, and PFS ( median PFS ranging between 9 to 
13months), leading to approval of gefitinib, erlotinib ,and afatinib, as upfront therapi[INVESTIGATOR_264782]. Unfortunately, t he vast majority of patients 
will later develop progressive disease, generally within [ADDRESS_321889] been identified such as : 1)
secondary mutation of the EGFR target gene, such as T790M mutation ,which occurs in 
about 50% to 60% of EGFR TKI-resistant tumors, 2) by[CONTACT_264811], overexpre ssion of MET, HER2, and molecular alterations of downstream 
molecules of the PI3K/AKT/mammalian target of rapamycin (mTOR) or the 
RAS/RAF/MAPK pathways, and 3) histologic transformation , such as small cell lung cancer 
(SCLC )transformation and epi[INVESTIGATOR_018] –mesenchymal transition [Morgillo, F., et al 2016] .
The identification of EGFR T790M prompted the development of second -generation EGFR
TKIs such as afatinib and dacomitinib to overcome resistance ;however ,available clinical 
data have indicated a rather limited activity of these drugs in the setting of acquired 
resistance to first -generation TKIs. Subsequently ,third -generation, mutant EGFR -selective 
TKIs have been developed, including rociletinib and osime rtinib. Osimertinib was granted 
US FDA approval for the treatment of patients with metastatic EGFR T790M mutation -
positive NSCLC who have progressed on or after EGFR TKI therapy based on the AURA3 
study , which demonstrated improvement in PFS in patient streated with osimertinib v ersus 
chemotherapy, with an HRof 0.30 (95% CI :0.23,0.41;p<0.001 )andmedian PFS of 10.1 
months v ersus 4.4 months [Mok, T. S., et al 2017] .Recently, the AURA3 study has been 
update d to report a median OSof 26.8 month sin the osimertinib arm v ersus 22.5 month sin 
the chemotherapy arm[Papadimitrakopoulou, V. A., et al 2020] . While these results are 
encouraging, most patients eventually progressed and will die of their disease. There is very 
little data on the survival of patients with T790M+ NSCLC who were treated with 
chemotherapy after failed osimertinib in the second -line s etting . In asmall retrospective 
study of 91 subjects with T790M+ NSCLC treated with osimertinib beyond progression or
switch edto other therapi[INVESTIGATOR_014] (primarily chemotherapy ), the PFS and OS for those who 
switched therapi[INVESTIGATOR_264783] 4.7 months and 7.8 months ,
respectively [Cortellini, A., et al 2020] . 
08FZ0N
Product:   MK-3475 52
Protocol/Amendment No.: 789-[ADDRESS_321890] -line setting. In the 
Phase 3 FLAURA study of osimertinib v ersus gefitinib/erlotinib, the PFS HR was 0.46 (95% 
CI: 0.37, 0.57, p <0.001) and the medians were 18.9 months v ersus 10.2 months, 
respectively, with comparable sa fety profile sof osimertinib to erlotinib/gefitinib, but with 
lower rates of Grade ≥3 AEs and a lower discontinuation rate [Ramalingam, S., et al 2017] . 
Recently, the FLAURA study was updated to report a longer median OS of 38.[ADDRESS_321891]-line osimertinib versus 31.8 months in the erlotinib/gefitinib group , in 
which 47% of patients receive d osimertinib as the first subsequent therapy [Ramalingam, S. 
S., et al 2020] .
Despi[INVESTIGATOR_264784], m ost patients still 
ultimately progress . Prolonged survival rates remain very low with median OS between 1 to 
2 years [Yu, H. A., et al 2013] . Systemic chemotherapy treatment generally represented by 
[CONTACT_70101] -based doublet is currently considered the standard of care with only modest benefit 
of 20 % to 30% response rate. Furthermore, the Phase 3 IMPRESS study failed to 
demonstrate long -term benefit combining gefitinib with chemotherapy ( cisplatin and 
pemetrexed )compared with chemotherapy and placebo in patients who progres sedon first -
line gefitinib . There was no difference in PFS between groups, with median PFS of 5.4 
months in both groups (95% CI :4.5, 5.7 in the gefitinib group and 95% CI: 4.6,5.5 in the 
placebo group ), and the combination of gefitinib plus chemotherapy was detrimental to OS 
compared with chemotherapy alone , with median OS of 13.4 months versus 19.5 months 
(HR 1.44, 95% CI: 1.07, 1.94; p=0.016) [Soria, J. C., et al 2015] [Mok, T. S. K., et al 2017] . 
Alternative treatment strategies, inclu ding investigational drugs or novel combinations have 
been explored in clinical trials, but none of these has been approved as standard treatment in 
this setting, confirming the unmet medical need that exists in this patient population .Thus ,
further devel opment of new regimen and novel treatment strategies are urgently warranted. 
Recently, immune checkpoint inhibitors and anti -PD-1 (programmed death -1) and 
anti-PD-L1 (programmed death -ligand) antibodies demonstrated quite promising and durable 
response acr oss broad range of solid tumors including NSCLC.
PD1/PD -L1 Inhibitors in EGFR -mutant NSCLC
Pembrolizumab monotherapy is one of the current standard sof care (SOC) for the treatment 
of patients with good Eastern Cooperative Oncology Group (ECOG) performance status 
(ECOG 0 or 1) and previously treated, advanced, or metastatic NSCLC with a programmed 
cell death ligand 1 (PD -L1) tumor proportion score (TPS) ≥1% ,including patient swith 
EGFR mutation who have failed both prior EGFR TKI and platinum doublet chemotherapy. 
This is based on data from KEYNOTE -010[IB Edition 15 2017] . KEYNOTE -[ADDRESS_321892] second -line docetaxel therapy in 1034 previously treated participants with advanced 
NSCLC and a PD -L1 TPS ≥1%, including patient swith EGFR mutation who have failed 
both TKI and platinum doublet chemotherapy. Results from KEYNOTE -010 indicated a 
significant overall survival (OS) benefit for pembrolizuma b over docetaxel therapy with an 
HR of 0. 71(p=0.[ZIP_CODE]) and 0.61 (p<0.[ZIP_CODE]) for pembrolizumab 2 mg/kg every 3 weeks 
(Q3W )and 10 mg/kg Q3W, respectively ,compared to docetaxel. Pembrolizumab was 
superi or to docetaxel in the strongly positive TPS ≥50% stratum with regard to PFS, with an 
HR of 0. 58(p=0.[ZIP_CODE]) and 0.59 (p=0.[ZIP_CODE]) for pembrolizumab 2 mg/kg Q3W and 
08FZ0N
Product:   MK-3475 53
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential10mg/kg Q3W, respectively, compared to docetaxel. Although KEYNOTE -[ADDRESS_321893] improved OS 
favoring pembrolizumab 2mg /kg over standard of care docetaxel, with OS [HR] was 0.78 
(95% CI :0.39, 1.60).
In addition, the Phase 3study I Mpower150, has shown that chemotherapy in combination 
with checkpoint inhibitor anti -PD-L1 (atezolizumab) with the addition of bevacizumab, 
reduces the risk of disease progression in advanced non -squamous NSCLC with an 
investigator assessed PFS [HR]=0.62 ; p<0.0001 ;95 % CI: 0.52 , 0.74 (patients with ALK and 
EGFR tumor mutations were excluded from the primary intent -to-treat [ ITT]analysis ). When 
the analysis was performed on the ITT population that included patients with mutant EGFR 
[108/800 (1 4%)] or ALK, the PFS [HR] was 0.59 (95 % CI: 0.37 , 0.94), confirming the trend 
in improvement in PFS when a checkpoint inhibitors is added to chemotherapy in patients 
with EGFR mutations who has failed prior EGFR TKIs therapy [Reck, M., et al 2017] [Reck, 
M., et al 2017] .  
Based on the potential beneficial role of pembrolizumab in previously treated (with EGFR
TKIs treatment followed by [CONTACT_11553]) patients with EGFR mutant metastatic NSCLC, 
and since chemotherapy combination with pembrolizu mab or atezolizumab demonstrated
promising ORR and /orPFS in the first -line setting in non -squamous NSCLC as seen in 
KEYNOTE -021G andIMpower150 , the combination of chemotherapy with pembrolizumab 
in patients who have failed EGFR TKIs previously warrants further exploration .
Background
Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody 
(mAb) with high specificity of binding to the programmed cell death 1 ( PD-1) receptor, thus 
inhibiting its interaction with programmed cell death ligand 1 (PD -L1) and programmed cell 
death ligand 2 (PD -L2). Based on preclinical in vitro data, pembrolizumab has high affinity 
and potent receptor blocking activity for PD -1. Pembrolizumab has an acceptable preclinical 
safety profile and is in clinical development as an IV immunotherapy for adva nced 
malignancies. Keytruda®(pembrolizumab) is indicated for the treatment of patients across a 
number of indications. For more details on specific indications refer to the I B.
Refer to the IB/approved labeling for detailed background information on pembrolizumab .
Pharmaceutical and Therapeutic Background
The importance of intact immune surveillance function in controlling outgrowth of neoplastic 
transformations has been known for decades [Disis, M. L. 2010] . Accumulating evidence 
shows a correlation between tumor -infiltrating lymphocytes in cancer tissue and favorable 
prognosis in various malignancies. In particular, the presence of CD8+ T -cells an d the ratio 
of CD8+ effector T -cells/FoxP3+ regulatory T -cells (T -regs) correlates with improved 
prognosis and long -term survival in solid malignancies, such as ovarian, colorectal, and 
pancreatic cancer; hepatocellular carcinoma; malignant melanoma; and r enal cell carcinoma. 
Tumor -infiltrating lymphocytes can be expanded ex vivo and reinfused, inducing durable 
08FZ0N
Product:   MK-3475 54
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialobjective tumor responses in cancers such as melanoma [Dudley, M. E., et al 2005] [Hunder, 
N. N. , et al 2008] .
The PD -[ADDRESS_321894] hijacked by [CONTACT_55548]. The normal function of PD -1, expressed on the cell surface of activated 
T-cells under healthy conditions, is to down -modulate unwanted or excessive immune 
responses, including autoimmune reactions. PD -1 (encoded by [CONTACT_13228]1 ) is an 
immunoglobulin (Ig) superfamily member related to cluster of differentiation 28 (CD28) and 
cytotoxic T -lymphocyte -associated protein 4 (CTLA -4) that has been shown to negatively 
regulate antigen receptor signaling upon engagement of it s ligands (PD -L1 and/or PD -L2) 
[Greenwald, R. J., et al 2005] [Okazaki, T., et al 2001] .
The structure of murine PD -1 has been resolved [Zhang, X., et al 2004] .PD-1 and its family 
members are type I transmembrane glycoproteins containing an Ig -variable –type (IgV -type) 
domain responsible for ligand binding and a cytoplasmic tail responsible for the binding of 
signaling molecules. The cytoplasmic tail of PD -1 contains 2 tyrosine -based signaling motifs, 
an immunoreceptor tyrosine -based inhibition motif, and an immunorecept or tyrosine -based 
switch motif. Following T -cell stimula tion, PD -1 recruits the tyrosine phosphatases, 
SHP-1and SHP -2, to the immunoreceptor tyrosine -based switch motif within its cytoplasmic 
tail, leading to the dephosphorylation of effector molecules such as CD3 zeta (CD3ζ), protein 
kinase C -theta (PKCθ), an d zeta -chain -associated protein kinase (ZAP70), which are 
involved in t he CD3 T -cell signaling cascade [Okazaki, T., et al 2001] [Chemnitz, J. M., et al 
2004] [Sheppard, K -A, et al 2004] [Riley , J. L. 2009] .Themechanism by [CONTACT_13209] -[ADDRESS_321895] from, that of CTLA -4, because both 
molecules regulate an overlappi[INVESTIGATOR_77971] [Parry , R. V., et al 2005] 
[Francisco, L. M., et al 2010] .As a consequence, the PD -1/PD -L1 pathway is an attractive 
target for therapeutic intervention in NSCLC.
Benefit/Risk Assessment
It cannot be guaranteed that participants in clinical studies will dire ctly benefit from 
treatment during participation, as clinical studies are designed to provide information about 
the safety and efficacy of an investigational medicine.
The b eneficial effects of pembrolizumab have been observed in several NSCLC studies to 
date. A significantly positive benefit/risk ratio has been demonstrated for pembrolizumab in 
multiple randomized studies for NSCLC, both as a monotherapy (KEYNOTE -010, 
KEYNOTE -024) and in combination with chemotherapy (KEYNOTE -021G, KEYNOTE -
189).
KEYNOTE -010 included patients with PD -L1 TPS ≥1% and an EGFR mutation ,who have
failed both a TKI and platinum doublet chemotherapy. Although KEYNOTE -[ADDRESS_321896] improved OS favoring pembrolizumab 2 mg/kg over standard of care docetaxel
(HR=0.78; 95% CI: 0.39 , 1.60). In addition, the Phase 3 stud y IMpower150 has shown that 
chemotherapy in combination with atezolizumab (a PD -L1 inhibitor) and bevacizumab 
reduced the risk of disease progression or death in advanced non -squamous NSCLC
[Reck, M., et al 2017] [Reck, M., et al 2017] . When the analysis was performed to include 
08FZ0N
Product:   MK-3475 55
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialpatients with mutant EGFR (108/800 [14%) ])or rearranged ALK, an improved PFS was 
observed ( HR=0.59; 95% CI: 0.37, 0.94). These data suggested that checkpoint inhibitors, 
either a lone or in combination with chemotherapy, have clinical activity in patients with 
EGFR mutation after TKI failure. The most frequently reported AEs for patients treated with 
pembrolizumab (reported in ≥20% of patients) included fatigue, cough, nausea, pruritus, 
rash, decreased appetite, constipation, arthralgia and diarrhea. These were predominantly 
Grade 1 to 2, with fatigue being the only AE that occurred with a severity of Grade 3 or 
above in 5% of patients. Immune -related pneumonitis, coliti s,hepatitis, hypophysitis, 
nephritis and thyroid abnormalities were seen at low frequency and were managed by 
[CONTACT_264812]. 
Based on data from KEYNOTE -021G and KEYNOTE -189, the addition of pembrolizumab 
did not increase the frequency of AEs beyond what was expected with regimens involving 
peme trexed and platinum doublet chemotherapy . Moreover, the incidence of most immune -
mediated AEs was not higher with pembrolizumab combination therapy than that previously 
observed with pembrolizumab monotherapy.
Despi[INVESTIGATOR_264785], most patients eventually have progressive disease. The current SOC 
chemotherapy does not improve outcomes. There remai ns a need to investigate new 
treatments which offer the prospect of added benefit for this patient population. The 
preliminary data showing potential benefits for patients with an EGFR mutation who 
progressed on a TKI, argues strongly for a comparison of t he addition of pembrolizumab
with chemotherapy to the currently accepted standard of care, platinum doublet 
chemotherapy. Additional details regarding specific benefits and risks for participants 
participating in this clinical study may be found in the accompanying IB and Informed 
Consent documents.
08FZ0N
Product:   MK-3475 56
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential3.Objectives/Hypotheses and Endpoints
In adult participants with TKI -resistant EGFR -mutated tumors in metastatic non -squamous 
NSCLC:
Objective/Hypothesis Endpoint
Primary
Objective: To compare PFS per Response 
Evaluation Criteria in Solid Tumors 1.1 
(RECIST 1.1) based on blinded 
independent central review (BICR) of the 
combinations of pembrolizumab + 
chemotherapy versus saline placebo + 
chemotherapy.
Hypothesis (H1): The combination of 
pembrolizumab + chemotherapy has 
superior PFS per RECIST 1.1 based on 
BICR compared to saline placebo + 
chemotherapyProgression -free survival (PFS) is the time 
from randomization to the first 
documented progressive disease (PD) or 
death due to any cause, whichever occurs 
first.
Objective: To compare OS of the 
combinations of pembrolizumab + 
chemotherapy versus saline placebo + 
chemotherapy.
Hypothesis (H 2): The combination of 
pembrolizumab +chemotherapy has 
superior OScompared to saline placebo +
chemotherapy.OSis defined as the time from 
randomization to death due to any cause.
This study will be considered to have met its success criteria if the combination of 
pembrolizumab + chemotherapy is superior to saline placebo + chemotherapy in PFS or OS.
08FZ0N
Product:   MK-3475 57
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialObjective/Hypothesis Endpoint
Secondary
Objective: To compare objective response 
rate (ORR) per RECIST 1.1 based on 
BICR of the combinations of 
pembrolizumab + chemotherapy versus 
saline placebo + chemotherapy.
Hypothesis (H 3): The combination of 
pembrolizumab + chemotherapy has 
super ior ORR per RECIST 1.1 based on 
BICR compared to saline placebo + 
chemotherapy.Objective response is a confirmed 
complete response (CR) or partial 
response (PR).
Objective: To evaluate DOR of the 
combinations of pembrolizumab + 
chemotherapy versus saline placebo + 
chemotherapy.DOR is defined as the time from the 
earliest date of qualifying response until 
earliest date of disease progression or 
death from any cause, whichever comes 
first, per RECIST 1.1 based on BICR.
Objectiv e: Toevaluate the patient 
reported outcomes (PROs) mean score 
changes from baseline in global health 
status and quality of life scale between 
pembrolizumab + chemotherapy versus 
saline placebo + chemotherapy.European Organization for Research and 
Treatme nt of Cancer (EORTC) Quality of 
Life Questionnaire -Core 30 items (QLQ -
C30) global health status (item 2 9) and 
quality of life scale (item 30).
Objective: To evaluate the PROs time to 
true deterioration (TTD) in the composite 
endpoint of cough, ch est pain ordyspnea 
between pembrolizumab + chemotherapy 
versus saline placebo + chemotherapy.TTD is the time from baseline to first 
onset of 10 points or more deterioration
from baseline with confirmation by [CONTACT_19378] 10 points or more 
deterioration from baseline of the 
composite endpoint of cough [EORTC 
QLQ -Lung Cancer Module 13 (LC13) 
item 1], chest pa in [EORTC QLQ -LC13 
item 10], or dyspnea [EORTC QLQ -C30 
item 8] .
Objective: To evaluate the safety and 
tolerability o f the combination of 
pembrolizumab + chemotherapy and 
saline placebo + chemotherapy.Adverse events (AEs) and study drug 
discontinuation due to AEs.
08FZ0N
Product:   MK-3475 58
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialObjective/Hypothesis Endpoint
Tertiary/Exploratory
Objective: To compare the PFS and ORR 
perModified RECIST 1.1 for Immune -
based Therapeutics (iRECIST) of the 
combinations of p embrolizumab + 
chemotherapy versus saline placebo + 
chemotherapy.PFS isdefined as the time from 
randomization to the first documented PD 
per iRECIST as assessed by [CONTACT_264813], 
whichever occurs first. 
ORR is defined as the proportion of 
participants who have a confirmed CR or 
PR per iRECIST as assessed by [CONTACT_3786].
Objective: To evaluate changes in health-
related quality of life assessments from 
baseline in the overall study population 
using the EORTC QLQ -C30 and EORTC
QLQ- LC13Change from baseline in health -related 
quality of life evaluated using the multi -
item and single -item scales of EORTC 
QLQ- C30 and EORTC QLQ -LC13.
Objective : To characterize utilities using 
the European Quality of Life Five -
dimension Five -level Scale Questionnaire 
(EQ- 5D-5L).Health utilities assessed using the EQ -
5D-5L.
4.Study Design 
Overall Design 
This is a worldwide, randomized , active -control with placebo, parallel -group, multi- site, 
double -blind study of IV pembrolizumab (also known as MK -3475) combined with 
pemetrexed plus platinum chemotherapy versus saline placebo c ombined with pemetrexed 
plus platinum chemotherapy in participants with TKI-resistant EGFR- mutat edtumors in 
metastatic non-squamous NSCLC. Approximately 492 participant s will be enrolled in this 
trial to examine the efficacy of pembrolizumab combined with chemotherapy compared to 
chemotherapy alone. Participant swill be randomized 1:1 to either receive pembroliz umab 
200 mg combined with pemetrexed and platinum chemotherapy (investigator ’s choice of 
carboplatin or cisplatin), or saline placebo plus pemetrexed and platinum chemotherapy
(investigator ’s choice of carboplatin or cisplatin ) as indicated below:
CCI
08FZ0N
Product:   MK-3475 59
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialArm 1 : Pembrolizumab 200 mg + pemetrexed 500 mg/m2(with vitamin 
supplementation) + carboplatin AUC 5 mg/mL •min OR cisplatin 75 mg/m2, all on 
Day 1 every 3 weeks (Q3W) for 4 cycles followed by [CONTACT_79911] 200 mg + 
pemetrexed 500 mg/m2Q3W for up to an additional 31 cycles ( up to 35 total 
cycles ), followed by [CONTACT_13438] 500 mg/m2Q3W maintenance until progression 
or unacceptable toxicity.
Arm 2 : Saline placebo + pemetrexed 500 mg/m2(with vitamin supplementation) 
+ carboplatin AUC 5 mg/mL •min OR cisplatin 75 mg/m2, all on Day 1 Q3W for 4 
cycles followed by [CONTACT_264814] + pemetrexed 500 mg/m2Q3W for up to an 
additional 31 cycles (up to 35 total cycles ), followed by [CONTACT_13438] 500 mg/m2
Q3W maintenance until progression or unacceptable toxicity.
Participant s who received adjuvant or neoadjuvant therapy are permitted onto the study if the
therapy was completed at least 6 months prior to the development of metastatic disease .
Participant s will be stratified by [CONTACT_4002] -L1 expression: TPS ≥50% v ersus <50%;treatment 
history :osimertinib v ersus no osimertinib ;and geographic region of the enrolling site: East 
Asia v ersus Non -East Asia, prior to randomization.
Treatment with pembrolizumab or saline placebo will continue until reaching a 
discontinuation c riteri on(Section 7.1), examples of which include: administration of 
35study treatment s, documented disease progression, unacceptable adverse event(s), 
intercurrent illness that prevents further administration of treatment, investigator’s decision 
to withdraw the participant , participant withdraws consent, pregnancy of the participant , 
nonco mpliance with study treatment or procedure requirements, or administrative reasons.
Maintenance pemetrexed may continue for participants past 35 cycles until reaching a 
discontinuation criterion (Section 7.1), as long as the participant is receiving benefi t and per 
local regulations, whereas pembrolizumab/saline placebo are limited to 35 cycles.
Participant s will be evaluated at 6 weeks (42 +7 days) and then every 9 weeks (63 ±7 days) 
with radiographic imaging to assess response to treatment for the first 51weeks and every 
12weeks (84 ±7 days) subsequently; treatment -based decisions should be based on the
iRECIST criteria . All imaging obtained on study during the initial treatment phase will be 
submitted without indication of treatment assignment to a central imaging review vendor, ie, 
blinded independent central review (BICR), who will assess the images using RECIST 1.1
for determination of PFS and ORR(Section 8.2.1 ).
AE monitoring will be ongoing throughout the trial and graded in sev erity according to the 
guidelines outlined in the National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0 (Section 10.11 ).
At the time of documented disease progression as confirmed by [CONTACT_54618] 1.1
(Sect ion 8.2.1 ),participant s may have treatment assignment unblinded (Figure 3). 
Participant s who received saline placebo in combi nation with chemotherapy may be eligible 
to receive pembrolizumab monotherapy for a total of 35 administrations in the Crossover 
Treatment Phase (Section 8.11.3 ).Tumor imaging is to be re -baselined and RECIST 1.1 
criteria used forparticipant assessments (Sections [IP_ADDRESS] and [IP_ADDRESS] ).
08FZ0N
Product:   MK-3475 60
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialParticipant s who received pembrolizumab in combination with chemotherapy, but are 
deemed to be benefiting clinically despi[INVESTIGATOR_264786], may continue study treatment
beyond progression and receive pembrolizumab monotherapy in the Crossover Treatm ent 
Phase (Section 8.11.3 )to complete a total of up to35 pembrolizumab administrations. Repeat 
imaging should occur at appropriate intervals per iRECIST criteria (Sections 8.2.1 and 10.10 ) 
until iCPD is established.
Study treatment may continue until participant reaches a discontinuation criterion (Section 
7.1), examples of which include subsequent documented progression, unacceptable adverse 
event(s), intercurrent illness that prevents further administration of treatment, investigator ’s 
decision to withd raw the participant , participant withdraws consent, pregnancy of the
participant , noncompliance with study treatment or procedure requirements, or for 
administrative reasons .
Alternatively, participants may have treatment assignment remain b linded at the time of 
BICR -verified progression and may continue receiving the study treatment per their 
randomized treatment assignment as long as they continue to be clinically stable (Figure 3).
Clinical Stability is defined in Section 7.1. 
Blinded study treatment can continue beyond verified progression at the Investigator’s 
discretion . Repeat imaging should occur at appropriate intervals per iRECIST criteri a 
(Sections 8.2.1 and 10.10 ) until iCPD is established. Once iCPD is established, the 
participant may then have treatment assignment unblinded , but may not continue study 
treatment in the Crossover Treatment Phase (Section 8.11.3 ) as described above.
Participant s who attain a confirmed complete response (CR) per RECIST 1.1 criteria may 
consider stoppi[INVESTIGATOR_262] . These participant s, as well as participant srandomized to 
the pembrolizumab plus chemotherapy arm that stop study treatment after 35 treatment 
administrations may be eligible for the Second Course Phase (Figure 4). 
Participants randomized to the saline placebo plus chemotherapy arm who complete 35 
treatment administrations and subsequently experience progressive disease will not be 
eligible for Secon d Course Phase but may continue into the Crossover Treatment Phase 
instead (Section 8.11.3 ). 
The Second Course Phase is re -treatment with open -label pembrolizumab monotherapy after 
Initial Treatment Phase completion or the attainment of a CR and upon subsequent 
radiographic disease progression. Second Course Phase is only available to participants 
randomized to the pembrolizumab plus chemotherapy arm. Participation is at the discretion 
of the investigator according to defined criteria in Section 8.11.[ADDRESS_321897]:   MK-3475 61
Protocol/Amendment No.: 789-[ADDRESS_321898] survival status to be assessed at additional time points and entered 
into the database during the course of the study. For example, survival status may be 
requested prior to, but not limited to, an external Data Monitoring Committee ( eDMC) 
review.
All participants will be followed for overall survival until death, withdrawal of consent, or 
the end of the study. Survival status can be done in a variety of ways including phone, email, 
chart review, or review of public records. Survival s tatus information (whether by [CONTACT_756], 
review of public records, etc.) should be officially documented by [CONTACT_779].
Specific procedures to be performed during the study , as well as their prescribed times and 
associated visit windows, are outlined in the Schedule of Activities ( SoA),Section 1.3. 
Details of each procedure are provided in Section 8.
Scientific Rationale for Study Design 
Rationale for Endpoints
Efficacy Endpoints
This study will use PFS based on RECIST 1.1 criteria as assessed by [CONTACT_264815] ( OS)asthe co-primary endpoint s. 
Progression -free survival is an acceptable measure of clinical benefit for a late stage study
that demonstra tes superiority of a new antineoplastic therapy, especially if the magnitude of 
the effect is large and the therapy has an acceptable risk/benefit profile. The use of BICRand 
RECIST 1.1 to assess PFS is typi[INVESTIGATOR_264787]. 
Images will be read by a central imaging vendor blinded to treatment assignment to minimize 
bias in the response assessments . Inaddition, the final determination of radiologic 
progression will be based on the central assessment of progression, rather than a local site 
investigator/radiology assessment. Real time verification of radiologic progression when 
requested by [CONTACT_121159]/radiology assessment as assessed by [CONTACT_264816] .
Overall survival (OS) has been recognized as the gold standard for the demonstration of 
superiority of a new antineoplastic therapy in randomized clinical studies.
ORR by [CONTACT_393] 1.[ADDRESS_321899]:   MK-3475 62
Protocol/Amendment No.: 789-[ADDRESS_321900] 1.1 throughout the protocol. Further details are found in
Section [IP_ADDRESS] .
Modified RECIST for Immune -based Therapeutics (iRECIST)
RECIST 1.1 will be adapted to account for the unique tumor response characteristics seen 
following treatment with pembrolizumab (Section [IP_ADDRESS] ). Immunotherapeutic agents such 
as pembrolizumab may produce antitumor effects by [CONTACT_264817] r-specific 
immune responses. The response patterns seen with such an approach may extend beyond the 
typi[INVESTIGATOR_264788], and participant s treated with 
pembrolizumab may manifest a clinical response after an initial i ncrease in tumor burden or 
even the appearance of new lesions. Thus, standard RECIST 1.1 may, not provide an 
accurate response assessment of immunotherapeutic agents such as pembrolizumab. Based 
on an analysis of participants with melanoma enrolled in KEYN OTE -001 (KN001), 7% of 
evaluable participants experienced delayed or early tumor pseudo -progression. Of note, 
participants who had progressive disease (PD) by [CONTACT_393] 1.1 but not by [CONTACT_246750] -related 
response criteria [Wolchok, J. D., et al 2009] had longer overall survival than participants 
with PD by [CONTACT_119580] [Hodi, F. S., et al 2014] . Additionally, the data suggest that RECIST 
1.1 may underestimate the benefit of pembrolizumab in approximately 15% of participants. 
These findings support the need to apply a modification to RECIST 1.[ADDRESS_321901] 1.1 for immune -based therapeutics (iRECIST) assessment has been 
developed and published by [CONTACT_264818], with input from leading experts 
from industry and academia, along with participation from the US Food and Drug 
Administration and the European Medicines Agency [Seymour, L., et al 2017] . The 
unidimensional measurement of target lesions, qualitative assessment of non -target les ions, 
and response categories are identical to RECIST 1.1, until progression is seen by [CONTACT_393] 
1.1. However, if a participant is clinically stable, additional imaging may be performed to 
confirm radiographic progression. iRECIST will be used by [CONTACT_264819] d.
Safety Endpoints
The incidence of AE/ serious AEs ( SAEs )(including fatal SAEs), immune -related AEs, 
laboratory abnormalit ies, and rates of dose interruption and discontinuation due to AEs are 
important endpoints for safety and tolerability evaluations.
Refer to Section 10. [ADDRESS_321902]:   MK-3475 63
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Rationale for Patient Reported Outcomes
Symptomatic improvement is considered a clinical benefit and accepted by [CONTACT_21652]. 
As part of the analyses for this study , participant s will provide information regarding their 
health -related quality of life (HRQoL) via the following assessment t ools: European 
Organisation for Research and Treatment of Cancer ( EORTC )QLQ -C30, EORTC 
QLQ -LC13 , and EQ -5D-5Lquestionnaires. 
EORTC QLQ -C30 and EORTC QLQ -LC13
EORTC QLQ -C30 is the most widely used cancer specific health related quality of life 
(QoL) instrument, which contains 30 items and measures 5 functional dimensions (physical, 
role, emotional, cognitive, and social), 3 symptom items (fatigue, nausea/vomitin g, and pain), 
6 single items (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial 
impact), and a global health and QoL scale [Aaronson, N. K., et al 1993] . The EORTC QLQ -
C30 is a psy chometrically and clinically validated instrument appropriate for assessing QoL 
in oncology studies [Aaronson, N. K., et al 1993] .
The EORTC Quality of Life Questionnaire and Lung Cancer Module 13 (QLQ -LC13), a 
supplemental lung cancer -specific module used in combination with QLQ -C30, comprises 
multi -item and single -item measures of lung cancer -associated symptoms (cough, 
hemoptysis, dyspnea, and site specific pain) and treatment -related symptoms (sore mouth, 
dysphagia, peripheral neuropathy and alopecia) [Bergman, B., et al 1994] . It is scored on a 4 
point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) and has been translated and 
validated into more than 60 languages. 
EQ-5D-5L
The EuroQol 5 -dimension, 5 -level questionnaire ( EQ-5D-5L)is a standardized instrument 
for use as a measure of health outcome and will provide data to develop health utilities or 
quality -adjusted life -years for use in health economi c analyses [Rabin, R. and de Charro, F. 
2001] . The 5 health state dimensions in the EQ -5D-5Linclude the following: mobility, self -
care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5 
point scale from 1 (no problem) to 5 (unable to/extreme problems). The EQ -5D-5Lalso 
includes a graded (0 to 100) vertical visual analog scale on which the participant rates his or 
her general state of hea lth at the time of the assessment. This instrument has been used 
extensively in cancer studies and published results from these studies support its validity and 
reliability [Pi[INVESTIGATOR_19323], A. S., et al 2007] .
Planned Exploratory Biomarker Research
Cancer immunotherapi[INVESTIGATOR_19325]. 
However, the mechanism of action of these exciting new therapi[INVESTIGATOR_264789] t to leverage these new drugs 
in treating patients. Thus, to aid future patients, it is important to investigate the determinants 
of response or resistance to cancer immunotherapy and other treatments administered, as well 
as determinants of AEs in the cou rse of our clinical studies. These efforts may identify novel 
predictive/PD biomarkers and generate information that may better guide single -agent and 
combination therapy with immuno -oncology drugs. To identify novel biomarkers, 
08FZ0N
Product:   MK-3475 64
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialbiospecimens (ie, blood com ponents, tumor material) will be collected to support analyses of 
cellular components (eg, protein, DNA, RNA, metabolites) and other circulating molecules. 
Investigations may include but are not limited to:
Germline (blood) genetic analyses (eg, SNP analys es, whole exome sequencing, whole 
genome sequencing)
This research may evaluate whether genetic variation within a clinical study population 
correlates with response to the treatment(s) under evaluation. If genetic variation is found to 
predict efficacy or adverse events, the data might inform optimal use of therapi[INVESTIGATOR_264790]. Furthermore, it is important to evaluate germline DNA variation across 
the genome in order to interpret tumor -specific DNA mutations. Finally, microsatellite 
instabi lity (MSI) may be evaluated as this is an important biomarker for some cancers (ie, 
colorectal cancer).
Genetic (DNA) analyses from tumor
The application of new technologies, such as next generation sequencing, has provided 
scientists the opportunity to id entify tumor -specific DNA changes (ie, mutations, methylation 
status, microsatellite instability). Key molecular changes of interest to immuno -oncology 
drug development include the mutational burden of tumors and the clonality of T -cells in the 
tumor micro environment. Increased mutational burden (sometimes referred to as a ‘hyper -
mutated’ state) may generate neo -antigen presentation in the tumor microenvironment. To 
conduct this type of research, it is important to identify tumor -specific mutations that occ ur 
across all genes in the tumor genome. Thus, genome -wide approaches may be used for this 
effort. Note that in order to understand tumor -specific mutations, it is necessary to compare 
the tumor genome with the germline genome. Microsatellite instability m ay also be evaluated 
as this is an important biomarker for some cancers (ie, colorectal cancer). Circulating tumor 
DNA and/or RNA may also be evaluated from blood samples.
Tumor and /orblood RNA analyses
Both genome -wide and targeted messenger RNA (mRNA) e xpression profiling and 
sequencing in tumor tissue and /orin blood may be performed to define gene signatures that 
correlate to clinical response to treatment with immunotherapi[INVESTIGATOR_13265]/or other treatments 
administered. Immunotherapi[INVESTIGATOR_264791] a response in t umors that likely reflects an 
inflamed/immune phenotype. Specific immune -related gene sets (ie, those capturing 
interferon -gamma transcriptional pathways) may be evaluated and new signatures may be 
identified. Individual genes related to the immune system may also be evaluated (eg, IL -10). 
MicroRNA profiling may also be pursued as well as exosomal profiling.
Proteomics and immunohistochemistry (IHC) using blood and/or tumor
Tumor and /orblood samples from this study may undergo proteomic analyses (eg, PD -L1 
IHC). PD L1 protein level in tumor sections, assessed by [CONTACT_4658], has been shown to correlate 
with response to immunotherapy in patients with NSCLC, and an in vitro diagnostic (IVD) 
device has been deve loped for use with immunotherapy in NSCLC. Preliminary data 
indicates that this association may also be true in additional cancer types (ie, triple negative 
breast cancer, head and neck, and gastric). Additional tumor or blood -derived proteins may 
also cor relate with response to immunotherapy. Therefore, tumor tissue may be subjected to 
08FZ0N
Product:   MK-3475 65
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialproteomic analyses using a variety of platforms that could include but are not limited to 
immunoassays and liquid chromatography/mass spectrometry. This approach could ident ify 
novel protein biomarkers that could aid in patient selection for immunotherapy and/or 
treatments .
Other biomarkers
In addition to expression on the tumor tissue, PD -L1 and other tumor derived proteins can be 
shed from tumor and released into the blood. Assays such as enzyme -linked immunosorbent 
assay (ELISA) that measure proteins may also be evaluated from blood samples. Correlation 
of these biomarkers with response to immunotherapy and/or treatments may identify new 
approaches for predictive biomarkers in blood, representing a major advance from today’s 
reliance on assessing tumor biomarkers. This research would serve to develop such assays for 
future clinical use. 
Other molecular changes of interest include the subtype of T -cells in the tumor 
microenv ironment. The T -cell repertoire from tumor tissue and blood components may be 
evaluated.
Future Biomedical Research
The Sponsor will conduct future biomedical research on specimens for which consent was 
provided during this study . This research may include genetic analyses (DNA), gene 
expression profiling ( ribonucleic acid [ RNA ]), proteomics, metabolomics (serum, plasma) 
and/or the measurement of other analytes, depending on which specimens are consented for 
future biomedical research.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only be conducted on specimens from 
appropriately consented participants. The objective of collecting/retaining specimens for 
future biomedical research is to explore and identify biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
particip ants receive the correct dose of the correct drug/vaccine at the correct time. The 
details of future biomedical research are presented in Section 10.2.
Rationale for the Use of Comparator/Placebo
Platinum doublet chemotherapy remains the most widely accept ed approach, and currently 
considered the standard of care fortreating Stage IVNSCLC in patients with EGFR mutation 
who has failed either 1stor 2nd generation EGFR TKI (eg,erlotinib/afatinib/gefitinib) , and has 
not develop T790M mutation as a TKIs -resistant mechanism . Platinum doublet 
chemotherapy is also considered the standard of care for patient who has developed T790M 
mutation and has failed 3rdgeneration EGFR TKI osimertinib. The most commonly used 
platinum doublet is pemetrexed in combination with cisplatin or carboplatin . In a non -
inferiority, Phase 3trial, overall survival in 1725 subjects with previously untreated NSCLC 
was found to be non -inferior after treatment with cisplatin and pemetrexed compared to 
cisplatin combined with gemcitabine (median survival 10.3 months versus 10.3 months; HR, 
0.94; 95% CI :0.84%,1.05%) [Scagliotti, G. V., et al 2008] . However, in a planned subgroup 
08FZ0N
Product:   MK-3475 66
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialanalysis, cisplatin and pemetrexed was found to be sup erior in subjects with non -squamous
NSCLC (n=1000; HR 0.81; 95% CI :0.7, 0.94; p = 0.005). Pemetrexed and platinum therapy 
has become a significant treatment of choice for advanced non -squamous NSCLC. 
Continuation of pemetrexed after initial 4cycles of pe metrexed cisplatin demonstrated a 
survival benefit in a randomized double -blind, placebo -controlled study: median overall 
survival 13.9 months (95% CI:12.8, 16.0) for pemetrexed compared to 11.0 months ( 95%
CI:10.0, 12.5) for placebo and a HRof 0.78 ( 95% CI:0.64, 0.96) [Paz-Ares, L. G., et al 
2013] .Pemetrexed in combination with either cisplatin or carboplatin is therefore an 
appropriate control arm treatment in this Phase 3trial.  
The use of pembrolizumab matching placebo in combination with platinum doublet 
chemotherapy will ensure the objectivity of the local investigators’ treatment decision and 
AE causality assessments, while still providing participants the SOC treatment.
Justification for Dose 
Rationale for Pembrolizumab Dosing Regimen
The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based 
on the totality of data generated in the Keytruda development program, 200 mg Q3W is the 
appropriate do se of pembrolizumab for adults across all indications and regardless of tumor 
type. As outlined below, this dose is justified by:
Clinical data from 8 randomized studies demonstrating flat dose -and exposure -
efficacy relationships from 2 mg/kg Q3W to 10 mg /kg every 2 weeks (Q2W), 
Clinical data showing meaningful improvement in benefit -risk including overall 
survival at 200 mg Q3W across multiple indications, and
Pharmacology data showing full target saturation in both systemic circulation 
(inferred from ph armacokinetic [PK] data) and tumor (inferred from physiologically -
based PK [ Physiological Based Pharmacokinetics ( PBPK )] analysis) at 200 mg Q3W
Among the 8 randomized dose -comparison studies, a total of 2262 participants were enrolled 
with melanoma and no n-small cell lung cancer (NSCLC), covering different disease settings 
(treatment naïve, previously treated, PD -L1 enriched, and all -comers) and different treatment 
settings (monotherapy and in combination with chemotherapy). Five studies compared 
2mg/kg Q 3W versus 10 mg/kg Q3W (KN001 Cohort B2, KN001 Cohort D, KN002, 
KN010, and KN021), and 3 studies compared 10 mg/kg Q3W versus 10 mg/kg Q2W 
(KN001 Cohort B3, KN001 Cohort F2 and KN006). All of these studies demonstrated flat 
dose-and exposure -response rela tionships across the doses studied representing an 
approximate 5 -to 7.5 -fold difference in exposure. The 2 mg/kg (or 200 mg fixed -dose) Q3W 
provided similar responses to the highest doses studied. Subsequently, flat dose -exposure -
response relationships we re also observed in other tumor types including head and neck 
cancer, bladder cancer, gastric cancer and classical Hodgkin Lymphoma, confirming [ADDRESS_321903]:   MK-3475 67
Protocol/Amendment No.: 789-[ADDRESS_321904], PK 
data in KN001 evaluating target -mediated drug di sposition (TMDD) conclusively 
demonstrated saturation of PD -[ADDRESS_321905] tumor PD -1 saturation over a wide 
range of tumor penetration and PD -1 expression. Th is evaluation concluded that 
pembrolizumab at 200 mg Q3W achieves full PD -1 saturation in both blood and tumor.
Finally, population PK analysis of pembrolizumab, which characterized the influence of 
body weight and other participant covariates on exposure, has shown that the fixed -dosing 
provides similar control of PK variability as weight based dosing, with considerable overlap 
in the distribution of exposures from the 200 mg Q3W fixed dose and 2 mg/kg Q3W dose. 
Supported by [CONTACT_131877], and g iven that fixed -dose has advantages of reduced 
dosing complexity and reduced potential of dosing errors, the [ADDRESS_321906] labels. 
Chemotherapy may be reduced, interrupted, or discontinued at the Investigator’s discretion 
using the guidance provided in Section 6.6. (Note: Guidance in Section 6.6should serve as a 
guide and do not replace investigator judgment and applicable local label recommendations if 
more stringent .)
Beginning and End of Study Definition
The overall study begins when the first participant provides documented informed consent.
The overall study ends when the last participant completes the last study -related contact , 
withdraws consent or is lost to follow -up (ie, the participant is unable to be contact[CONTACT_24992]).
Upon study completion, participants are discontinued and may be enrolled in a 
pembrolizumab extension study, if available. 
Clinical Criteria for Early Study Termination
The clinical trial may be terminated early if the extent (incidence and/or severity) of 
emerging effects/clinical endpoints is such that the risk/benefit rati o to the trial population as 
a whole is unacceptable. In addition, further recruitment in the trial or at (a) particular trial 
site(s) may be stopped due to insufficient compliance with the protocol, G ood Clinical 
Practice (GCP) and/or other applicable reg ulatory requirements, procedure -related problems 
or the number of discontinuations for administrative reasons is too high.
5.Study Population
As stated in the Code of Conduct for Clinical Trials (Appendix 1), this study includes 
participants of varying age (as applicable) , race, ethnicity, and sex (as applicable) . The 
collection and use of these demographic data willfollow all local laws and participant 
confidentiality guidelines while supporting the study of the disease, its related factors, and 
the Investigational Medical Product ( IMP)under investigation.
08FZ0N
Product:   MK-3475 68
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialMale/ female participants with TKI-resistant EGFR -mutat edtumors in metastatic NSCLC
who are at least 18years of age will be enrolled in this study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Type of Participant and Disease Characteristics
1.Have histologically or cytologically confirmed diagnosis of Stage IV (AJCC Version 
8 or current version as applicable) non-squamous NSCLC.
2.Have documenta tion of tumor activating EGFR mutation , specifically either DEL [ADDRESS_321907] 1.1 after 
treatment with anEGFR TKI therapy:
a)Participant spreviously treated with 1stor 2ndgeneration EGFR TKI (eg ,
erlotinib/afatinib/gefitinib) are required to have confirmed documented 
absence of EGFR T790M mutation .Note: Participants with negative EGFR
T790M mutation using plasma specime nswill be required to have tissue 
biopsy confirmation of negative T790M mutation prior to 
enrollment /confirmation of eligibility.
b)Participant swith confirmed acquired T790M mutation after 1stor 2nd
generation EGFR TKI ( eg,erlotinib/afatinib/gefitinib) are required to have 
osimertinib TKI treatment failure prior to enro llment .Note: Participants must 
have documenta tionof acquired T790M mutation (using plasma or tissue 
biopsy specimens) after 1stdisease progression prior to osimertinib treatment. 
c)Participant spreviously failed osimertinib TKI treatment as 1stlinetherapy are 
eligible regardless of their EGFR T790M mutation status.
Note: TKI washout period for all participants is [ADDRESS_321908] dose of study medication.
Note: The site’s study team must have reviewed pre -trial images that are of 
diagnostic quality from at least [ADDRESS_321909] 1.1 as assessed by [CONTACT_219526]/radiology. Lesions situated in a previously irradiated area are considered 
measurable if progression has been demonstrated in such lesions.
08FZ0N
Product:   MK-3475 69
Protocol/Amendment No.: 789-[ADDRESS_321910] provided archival tumor tissue sample or newly obtained (no anti -neoplastic 
therapy since biopsy) core or excisional biopsy of a tumor lesion not previously 
irradiated. Formal in-fixed, paraffin embedded (FFPE) tissue blocks are preferred to 
slides. Newly obtained biopsies are preferred to archiv altissue.
Note: If site is sending unstained slides, we strongly recommend that sites freshly cut 
sections and send out to the pathol ogylaboratory within 7 days from sectioning in 
order for samples to be received within 14 days of site slide -cutting date.
Demographics
6.Be ≥[ADDRESS_321911] dose of 
study treatment but before randomization.
Male participants:
9.A male participant must agree to use contraception as detailed in Section 10.[ADDRESS_321912] dose of chemotherapeutic agents .
Female participants:
10.A female participant is eligible to participate if she is not pregnant (see Section 10.3), 
not breastfeeding, and at least one of the following conditions applies:
a.Not a woman of childbearing potential (WOCBP) as defined in Appendix [ADDRESS_321913] adequate organ function as defined in the following table ( Table 1). Specimens 
must be collected within 10days prior to the start of study treatment.
08FZ0N
Product:   MK-3475 70
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialTable 1 Adequate Organ Function Laboratory Values
System Laboratory Value
Hematological
Absolute neutrophil count (ANC) ≥1500/µL
Platelets ≥100 000/µL
Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/L1
Renal
Creatinine OR
Measured or calculated2creatinine clearance
(GFR can also be used in place of creatinine or 
CrCl)≤1.5 × ULN OR
≥50 mL/min for participant with creatinine 
levels >1.5 ×institutional ULN
Hepatic
Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for 
participants with total bilirubin levels 
>1.5 ×ULN
AST (SGOT) and ALT (SGPT) ≤2.5×ULN 
Coagulation
International normalized ratio (INR) OR 
prothrombin time (PT)
Activated partial thromboplastin time (aPTT)≤1.5 ×ULN unless participant is receiving 
anticoagulant therapy as long as PT or aPTT is 
within therapeutic range of intended use of 
anticoagulants
ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate 
aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit 
of normal.
1Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion 
within last 2 weeks.
2Creatinine Clearance should be calculated using the Cockcroft -Gault Method: Refer to Section 10.8 for the 
appropriate calculation .
Note: This table includes eligibility -defining laboratory value requirements for treatment; laboratory value 
requirements sho uld be adapted according to local regulations and guidelines for the administration of specific 
chemotherapi[INVESTIGATOR_014].
Exclusion Criteria 
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
1.Has predominantly squamous cell histology NSCLC. Mixed tumors will be 
categorized by [CONTACT_19400]; if small cell elements are present, the 
participant is ineligible.
08FZ0N
Product:   MK-3475 71
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential2.Has symptomatic ascites or pleural effusion. A participant who is clinically stable 
following treatment for these conditions (including therapeutic thoraco -or 
paracentesis) is eligible.
3.A WOCBP who has a positive urine pregnancy test within 72 hours prior to 
randomization (see Section 10.3). If the urine test is positiv e or cannot be confirmed 
as negative, a serum pregnancy test will be required. 
Note:   In the event that [ADDRESS_321914] (urine or serum) must be 
perfo rmed and must be negative in order for participant to start receiving study 
medicatio n
Prior/Concomitant Therapy
4.Has received prior therapy with an anti -PD-1, anti -PD-L1, or anti -PD-L2 agent or 
with an agent directed to another stimulatory or co -inhibitory T-cell receptor 
(eg,CTLA -4, OX -40, CD137).
5.Has received prior systemic cytotoxic chemotherapy or investigational agent(s) , 
excluding EGFR TKIs, for metastatic NSCLC.
Note: Prior treatment with chemotherapy and/or radiation as part of
neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 
6months prior to the diagnosis of metastatic NSCLC.
Note: If participant received major surgery, they must have recovered adequately 
from the toxicity and/or complications f rom the intervention prior to starting study
treatment.
Note: Prior exposure to traditional medicine(s) is allo wed as long as therapy was 
discontinu ed at least [ADDRESS_321915] dose of study treatment.
6.Has received prior radiotherapy within 2 weeks of start of study treatment or has 
received lung radiation therapy of >[ADDRESS_321916] had radiation pneumonitis. A 1-week 
washout is permitted for palliative radiation ( ≤2 weeks of radiotherapy) to non -central 
nervous system ( CNS )disease.
7.Has received a live vaccine within [ADDRESS_321917] dose of study treatment . 
Examples of live vaccines include, but are not limited to, the following:  measles, 
mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, bacillus 
Calmet te–Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for 
injection are generally killed virus vaccines and are allowed; however, intranasal 
influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
Prior/Concurrent Cl inical Study Experience
8.Is currently participating in or has participated in a study of an investigational agent 
or has used an investigational device within [ADDRESS_321918]:   MK-3475 72
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialNote:  Participants who have entered the follo w-up phase of an investigational study 
may participate as long as it has been [ADDRESS_321919] dose of the previous 
investigational agent.
Diagnostic Assessments
9.Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy 
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of 
immunosuppressive therapy within [ADDRESS_321920] 5years.  
Note:  Participants with basal cell carcinoma of the skin, squamous cell carcinoma of 
the skin, superficial bladder cancer , or carcinoma in situ (eg, br east carcinoma, 
cervical cancer in situ) that have undergone potentially curative therapy are not 
excluded.
11.Has known active untreated CNS metastases and/or carcinomatous meningitis. 
Participant s with previously treated brain metastases may participate pro vided they 
are radiologically stable, ie, without evidence of progression for at least 4 weeks by 
[CONTACT_19406] (note that the repeat imaging should be performed during study 
screening),  clinically stable and without requirement of steroid treatment for at least 
[ADDRESS_321921] dose of study treatment. 
12.Has severe hypersensitivity ( ≥Grade 3) to pembrolizumab and/or any of its 
excipi[INVESTIGATOR_840].
13.Has a known sensitivity to any component of cisplatin, carboplatin ,or pemetrexed .
14.Has an active autoimmune dise ase that has required systemic treatment in past 2 years 
(ie, with use of disease modifying agents, corticosteroids or immunosuppressive 
drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid 
replacement therapy for adrenal or p ituitary insufficiency) is not considered a form of 
systemic treatment and is allowed.
15.Has a history of (non -infectious) pneumonitis that required steroids or has current 
pneumonitis.
16.Has an active infection requiring systemic therapy.
17.Has a known history of human immunodeficiency virus (HIV) infection. No HIV 
testing is required unless mandated by [CONTACT_14306].
18.Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] 
reactive or HBV -DNA detected ) or known active Hepatitis C virus (defined as HCV 
RNA [qualitative] is detected or HCV antibody reactive, if HCV -RNA is not the local 
SOC ) infection.
Note: No testing for Hepatitis B and Hepatitis C is required unless mandated by [CONTACT_19384].
19.Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
08FZ0N
Product:   MK-3475 73
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential20.Has a history or current evidence of any condition, therapy, or laboratory abnormality 
that might confound the results of the study , interfere with the participant 's 
participation for the fu ll duration of the study , or is not in the best interest of the 
participant to participate, in the opi[INVESTIGATOR_80021].
21.Has known psychiat ric or substance abuse disorder that would interfere with 
cooperating with the requirements of the study.
Other Exclusions
22.Is pregnant or breastfeeding or expecting to conceive or father children within the 
projected duration of the study, starting with the screening visit through [ADDRESS_321922] adverse effects on a fetus in utero. Refer to Section 10.3 for 
approved methods of contraception.
Participants should be informed that ta king the study medication may involve unknown risks 
to the fetus (unborn baby) if pregnancy were to occur during the study. In order to participate 
in the study, participants of childbearing potential must adhere to the contraception 
requirement ( Section 10.3)from the day of study medication initiation (or 14days prior to 
the initiation of study medication for oral contraception) throughout the study period up to 
120days after the last dose of pembrolizumab and up to [ADDRESS_321923] monthly and document the participant’s status until the pregnancy has 
been completed or terminated. The outcome of the pregnancy will be reported to the Sponsor 
without delay and within 24 hours if the outcome is a serious adverse experience (eg, death, 
abortion, congenital anomaly, or other disabling or l ife-threatening complication to the 
mother or newborn). The study Investigator will make every effort to obtain permission to 
follow the outcome of the pregnancy and report the condition of the fetus or newborn to the 
08FZ0N
Product:   MK-3475 74
Protocol/Amendment No.: 789-[ADDRESS_321924] be reported to the Sponsor and 
followed as described in Section 10.3.
Use in Nursing Women
It is unknown whether pembrolizumab is excreted in human milk.  Since many drugs are 
excreted in human milk, and because of the potential for serious adverse reactions in the 
nursing infant, participant s who are breastfeeding are not eligible for enrollment.
Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomized . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participants to meet the Consolidated Standards 
of Reporting Trials (CONSORT) publishing requirements and to respond to queries from 
regulatory authorities. Minimal information includes demography, screen failure details, 
eligibility criteria, and any AEs or serious adverse e vents (SAE s) meeting reporting 
requirements as outlined in the data entry guidelines.
Participant Replacement Strategy
A participant who discontinues from study treatment or withdraws consent will not be 
replaced.
6.Treatments
Study treatment is defined as a ny investigational treatment(s), marketed product(s), placebo ,
or medical device (s)intended to be administered to a study participant according to the study 
protocol.
Clinical supplies [study treatment(s) provided by [CONTACT_1034]] will be packaged to support 
enrollment. Clinical supplies will be affixed with a clinical label in accordance with 
regulatory requirements.
Treatments Administered
The treatments to be used in this study areoutlined below in Table 2.
08FZ0N
Product:   MK-3475 75
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialTable 2 Study Treatment(s)
Arm 
NameArm 
TypeIntervention 
NameIntervention 
TypeDose 
FormulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adminis -
trationRegimen/ 
Treatment 
Period UseIMP or 
NIMP/
AxMP Sourcing
Arm 1 Experi -
mentalPembrolizumab 
(MK -3475)Biological/ 
VaccineSolution for 
Infusion100 mg/ 
vial200 mg IV Infusion Q3W Test Product IMP Provided centrally 
by [CONTACT_264820] 1 Experi -
mentalPemetrexed Drug Lyophilized 
Powder500 mg / 
vial500 
mg/m2IV Infusion Q3W Background 
TreatmentNIMP/ 
AxMPProvided locally by 
[CONTACT_3452], 
subsidiary, or 
designee. OR 
Provided centrally 
by [CONTACT_264820] 1 Experi -
mentalCarboplatin Drug Solution for 
Infusion10 mg/mL 
vialAUC 5 
mg/mL •
minIV Infusion Q3W for 
4 cycles 
(Cycles 1 -
4)Background 
TreatmentNIMP/ 
AxMPProvided locally by 
[CONTACT_3452], 
subsidiary, or 
designee. OR 
Provided centrally 
by [CONTACT_264820] 1 Experi -
mentalCisplatin Drug Solution for 
Infusion1 mg/mL 
vial75 
mg/m2IV Infusion Q3W for 
4 cycles 
(Cycles 1 -
4)Background 
TreatmentNIMP/ 
AxMPProvided locally by 
[CONTACT_3452], 
subsidiary, or 
designee. OR 
Provided centrally 
by [CONTACT_264820] 2 Placebo 
Com -
paratorSaline Placebo Drug Solution for 
InfusionNA NA IV Infusion Q3W Placebo IMP Provided locally by 
[CONTACT_3452], 
subsidiary, or 
designee
Arm 2 Placebo 
Com -
paratorPemetrexed Drug Lyophilized 
Powder500 mg / 
vial500 
mg/m2IV Infusion Q3W Background 
TreatmentNIMP/ 
AxMPProvided locally by 
[CONTACT_3452], 
subsidiary, or 
designee. OR 
Provided centrally 
by [CONTACT_1034]
08FZ0N
Product:   MK-3475 76
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialArm 
NameArm 
TypeIntervention 
NameIntervention 
TypeDose 
FormulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adminis -
trationRegimen/ 
Treatment 
Period UseIMP or 
NIMP/
AxMP Sourcing
Arm 2 Placebo 
Com -
paratorCarboplatin Drug Solution for 
Infusion10 mg/mL 
vialAUC 5
mg/mL •
minIV Infusion Q3W for 
4 cycles 
(Cycles 1 -
4)Background 
TreatmentNIMP/ 
AxMPProvided locally by 
[CONTACT_3452], 
subsidiary, or 
designee. OR 
Provided centrally 
by [CONTACT_264820] 2 Placebo 
Com -
paratorCisplatin Drug Solution for 
Infusion1 mg/mL 
vial75 
mg/m2IV Infusion Q3W for 
4 cycles 
(Cycles 1 -
4)Background 
TreatmentNIMP/ 
AxMPProvided locally by 
[CONTACT_3452], 
subsidiary, or 
designee. OR 
Provided centrally 
by [CONTACT_264821]=area under the curve; EEA=European Economic Area; IMP=investigational medicinal product; IV=intravenous; NA=not applicable; NIMP/AxMP=noninvestigational/
auxiliary medicinal product ; Q3W=every 3 weeks .
The classification of IMP and NIMP/AxMP in this table is based on guidance issued by [CONTACT_264822]. Country differences with 
respect to the definition/classification of IMP and NIMP/AxMP may exist. In these circu mstances, local legislation is followed.
In this protocol, placebo for pembrolizumab is diluent alone (normal saline and/or dextrose); diluent is used for blinding pu rposes and does not contain active ingredients.
08FZ0N
Product:   MK-3475 77
Protocol/Amendment No.: 789-[ADDRESS_321925] one of the following 
regimens prior to randomization:
Pemetrexed 500 mg/m2+ carboplatin AUC 5mg/mL •min Q3W for 4 cycles followed 
by [CONTACT_13438] 500 mg/m2Q3W
Pemetrexed 500 mg/m2+ cisplatin 75 mg/m2for 4 cycles followed by [CONTACT_13438] 
500 mg/m2Q3W
Maintenance pemetrexed may continue for participants past 35 administrati onsuntil reaching 
a discontinuation criterion (Section 7.1), as long as the participant is receiving benefit and per 
local regulations, whereas pembrolizumab/saline placebo are limited to [ADDRESS_321926] that is provided by [CONTACT_3452], subsidiary, or 
designee, every attempt will be made to source these supplies from a single lot/bat ch number.  
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_113743].
All supplies indicated in Table 2will be provided per the ‘Sourcing’ row depending upon 
local country operational requirements. Every attempt should be made to source these 
supplies from a single lot/batch number where possible (eg, not applicable in the case where 
multiple lots or batches may be required due t o the length of the study ,etc.).
Refer to Section 8.1.8 for details regarding administration of the study treatment.
Preparation/Handling/Storage/Accountabi lity
Dose Preparation
Pembrolizumab: the dose amount required to prepare the pembrolizumab infusion solution 
will be based on a fixed dose of [ADDRESS_321927] 
label at the doses indicated below:
Pemetrexed: 500mg/m2
Cisplatin: 75mg/m2
08FZ0N
Product:   MK-3475 78
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialCarboplatin: AUC 5 mg/mL •min (using Calvert formula). Carboplatin dose not to 
exceed 750 mg
Calvert Formul a
Total Dose (mg) = (target AUC) x (CrCl *+25)
The estimated GFR used in the Calvert formula should not exceed 125 mL/min
Maximum carboplatin dose (mg) = target AUC 5 (mg/mL •min )x (125+25) = 
5x150 mL/min = 750 mg
*CrCl should be calculated using the Cockcroft -Gault Method: Refer to Section 10.[ADDRESS_321928] be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in accordance 
with the labeled storage conditions with access limited to the investigator and authorized site 
staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local c ountry Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_19333] (if applicable) as per local guidelines unless ot herwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution and usage of study 
treatments in accordance with the p rotocol and any applicable laws and regulations.
Measures to Minimize Bias: Randomization and Blinding
Method of Treatment Assignment 
Treatment allocation/randomization will occur centrally using an interactive response 
technology (IRT) system. There are 2study treatment arms. Participants will be assigned 
randomly in a 1:1ratio to pembrolizumab plus pemetrexed plus platinum chemothera py or 
saline placebo plus pemetrexed plus platinum chemotherapy , respectively.
08FZ0N
Product:   MK-3475 79
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Stratification
Treatment allocation/randomization will be stratified according to the following factors:
1.PD-L1 expression: Tumor Proportion Score (TPS) ≥50% or TPS <50%;
2.Treatme nt history: osimertinib or no osimertinib ;
3.Geographic region of the enrolling site: East Asia v ersus Non -East Asia
Blinding 
This is a double -blinded trial; therefore, the participant , the Investigator and Sponsor 
personnel or delegate(s) who are involved in the treatment administration or clinical 
evaluation of the participant s are unaware of the group assignments. The chemotherapy 
agents will be open -label. The Sponsor, investigator and participant will not know whether 
the treatment administered contains pembrolizumab or saline placebo. The study site’s 
unblinded pharmacist will obtain each participant ’s study identification number and study 
treatment assignment from the interactive voice response system (IVRS)/interactive web 
response system (IWRS) and prepare the solutions for infusion. The unblinded pharmacist 
will provide the investigative staff with ready -to-use blinded pembrolizumab/saline placebo 
infusion solutions, packaged id entically in order to maintain the blinding, for administration 
at scheduled infusion . The unblinded pharmacist should have no involvement in study 
assessments.
SeeSection 8.1.10 for a description of the method of unblinding a participant during the 
study , should such action be warranted.
Treatment Compliance
Administration of study medication(s) will be monitored by [CONTACT_11219]/or study
staff. The total volume of study medication infused will be compared with the total volume 
prepared to determin e compliance with each dose administered.
Interruptions from the protocol -specified treatment plan for more than [ADDRESS_321929]:   MK-3475 80
Protocol/Amendment No.: 789-[ADDRESS_321930] all medications taken for 
SAEs and ECIs as defined in Section 10.4.
Prohibited Concomitant Medications
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during the ongoing study .If there is a clinical indication for any medication or vaccination
specifically prohibited, discontinuation from study intervention may be required. The 
investigator is to discuss prohibited medication /vaccination with the Sponsor ’sClinical 
Director. The final decision on any supportive therapy or vaccination rests with the 
investigator and/or the participant's primary physician. Howe ver, the decision to continue the 
participant on study treatment requires the mutual agreement of the investigator, the Sponsor 
and the participant.
Listed below are specific restrictions for concomitant therapy or vaccination during the 
course of the study:
Antineoplastic systemic chemotherapy or biological therapy 
Immunotherapy not specified in this protocol
Chemotherapy not specified in this protocol
Investigational agents other than pembrolizumab /saline placebo
Radiation therapy 
Note:  Radiation therapy to a symptomatic solitary lesion or to the brain may be 
allowed at the Investigator’s discretion. 
Live vaccines within [ADDRESS_321931] dose of study treatment and while 
participating in the study .Examples of live vacc ines include, but are not limited to, 
the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, 
and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed 
virus vaccines and are allowed; however, intranas al influenza vaccines (eg, 
FluMist®) are live attenuated vaccines and are not allowed. 
Note: Any licensed COVID -19 vaccine (including for Emergency Use) in a particular 
country is allowed in the study as long as they are mRNA vaccines, replication -
incompe tent adenoviral vaccines, or inactivated vaccines. These vaccines will be 
treated just as any other concomitant therapy.
Investigational vaccines (ie, those not licensed or approved for Emergency Use) are 
not allowed.
08FZ0N
Product:   MK-3475 81
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialSystemic glucocorticoids for any purpo se other than those described in Section 
[IP_ADDRESS] are prohibited .The use of physiologic doses of corticosteroids may be 
approved after consultation with the Sponsor.
Replacement doses of steroid s (for example, prednisone 10 mg daily) are permitted 
while on study, as is the use of local steroid injections and topi[INVESTIGATOR_8826].
Phenytoin during therapy with cisplatin/carboplatin .
Participant s who, in the assessment of the Investigator, require the use of any of the 
aforementioned treatments for clinical management should be discontinued from study
treatment .  
All treatments that the Investigator considers necessary for a participant ’s welfar e may be 
administered at the discretion of the Investigator in keepi[INVESTIGATOR_12983]. All concomitant medication will be recorded on the eCRF including all 
prescription, over -the-counter (OTC) products, herbal supplements, an d IV medications and 
fluids. If changes occur during the study period, documentation of drug dosage, frequency, 
route, and date should also be included on the eCRF.
All concomitant medications received within [ADDRESS_321932] (ECIs) as defined in Section 10.4.
If a participant enters into second course therapy, all concomitant medications received 
within [ADDRESS_321933] all medications take n for 
SAEs and ECIs as defined in Section 10.4.
Rescue Medications and Supportive Care
Participants should receive appropriate supportive care measures as deemed necessary by [CONTACT_78017]. Suggested supportive care measures for the management of AEs with 
potential immunologic etiology are outlined along with the dose modifi cation guidelines in 
Section 6.6.
Note: If after the evaluation of the event, it is determined not to be related to pembrolizumab, 
the Investigator does not need to follow the treatment guidance. Refer to Table 4in Section 
6.6for guidelines regarding dose modification and supportive care. 
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or 
skin photography as part of evaluation of the event. 
Forsupportive care guidelines for chemotherapy agents, please r efer to current version of the 
SmPC for cisplatin, carboplatin, and pemetrexed for details .
08FZ0N
Product:   MK-3475 82
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Systemic Corticosteroid Use
Systemic corticosteroids are permitted in the following situations:
To modu late symptoms of an AE that is suspected to have an immunologic etiology
as guided in Table 4.
For the prevention of emesis and other chemotherapy -related AEs.
To premedicate for IV contrast allergies .
To treat asthma or chronic obstructive pulmonary disease (COPD) exacerbations 
(only short -term oral or IV use in doses >10 mg/day prednisone equivalent) .
For chronic systemic replacement not to exceed 10 mg/day prednisone equivalent .
In addition, the following corticosteroid use is allowed :
Topi[INVESTIGATOR_113744]
Intraarticular joint use
Inhalation in the management of asthma or COPD
Antiemetic Use
For participants receiving chemotherapy, antiemetic therapy should follow Multinational 
Association of Supportive Care in Cancer (MASCC) or appropriate local guidelines 
(Section 10.7) and should, for the first [ADDRESS_321934], 
dexamethasone (or equivalent), and aprepi[INVESTIGATOR_053] (or equivalent NK -[ADDRESS_321935]) as 
per the guideline followed.
Colony -Stimulating Factors
For participants receiv ing chemotherapy, the American Society of Clinical Oncology 
(ASCO) guidelines for use of colony -stimulating factors (CSFs), or local equivalent, should 
be used for patient management [Smith, T. J., et al 2015] .
Pemetrexed Pre medication
All participants must receive the appropriate supplementation of vitamin B12 and folic acid 
and corticostero id prophylaxis as listed below or as per local label:
Folic acid 350 to 1000 μg oral: at least [ADDRESS_321936] dose of pemetrexed.
Vitamin B12 [ADDRESS_321937] dose of pemetrexed 
and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given 
the same day as pemetrexed administration.
Dexamethasone prophylaxis 4 mg, orally twice per day (or equivalent). Taken the day 
before, day of, and day after p emetrexed administration. Higher or additional doses 
are permitted for antiemetic prophylaxis during Cycles 1through 4 but not to exceed 
doses in MASCC guidelines (or local equivalent).
08FZ0N
Product:   MK-3475 83
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Cisplatin Premedication
Hydration is necessary to cause sufficient di uresis during and after treatment with cisplatin. 
All participants should receive adequate hydration from 2 to 12 hours prior to administration 
until minimum 6 hours after the administration of c isplatin per the local label . 
Dose Modification (Escalation/ Titration/Other)
If appropriate, the investig ator may attribute each toxicity event to cisplatin/carboplatin, 
pemetrexed or pembrolizumab alone or to the combination and use a stepwise dose reduction 
according to Table 3to Table 7. Dose modifications must be based on the maximum toxicity 
experienced during a cycle. Toxicity needs to resolve to Grade ≤1 or baseline prior to 
resuming subsequent cycle. For individual participants requiring a dose modification, 
treatment for each new cycle may be delayed if the scheduled off -drug periods are not 
adequate to allow for recovery to Grade ≤[ADDRESS_321938] a maximum of 2 do se 
modifications (if applicable) to each of the components of study therapy throughout the 
course of the stu dy for toxicities. If a participant experiences several toxicities and there are 
conflicting recommendations, the most conservative dose adjustment recommended should 
be followed (dose reduction appropriate to the most severe toxicity). Participants who require 
a 3rd dose modification to an y particular component will have that agent discontinued.
Reduction of 1chemotherapy agent and not the other agent is appropriate if, in the opi[INVESTIGATOR_13046] , the toxicity is clearly related to one of the treatments. If, in the opi[INVESTIGATOR_13046] , the toxicity is related to the combination of both chemotherapy agents, both 
drugs should be reduced according to recommended dose modifications. If the toxicity is 
related to the combination of 3agents, all 3agents should be reduced (if app licable), 
interrupted or discontinued according to the recomm ended dose modifications. 
Participants may have chemotherapy discontinued and continue on pembrolizumab/saline 
placebo alone. Similarly participant s may discontinue pembrolizumab/saline placebo and 
continue on chemotherapy alone if appropriate.
Chemotherapy may be interrupted for a maximum of [ADDRESS_321939] dose; pembrolizumab 
may be interrupted for a maximum of [ADDRESS_321940] dose.
The Common Terminology Criteria for Adverse Events versio n 4.0 (CTCAE 4.0) must be 
used to grade the severity of adverse events. All dose modifications should be based on the 
AE requiring the greatest dose modification. Dose modifications are detailed in Table [ADDRESS_321941]:   MK-3475 84
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialTable 3 Dose Modifications for Study Medications
Dose Level 0 Dose Level -1 Dose Level -2 Dose Level -3
Cisplatin 75 mg/m256 mg/ m238 mg/ m2Discontinue
CarboplatinArea under curve ( AUC )5
Maximum dose 750mgAUC 3.75
Maximum dose 
562.5mgAUC 2.5
Maximum dose 
375mgDiscontinue
Pemetrexed 500mg/m2 375 mg/m2 250 mg/m2 Discontinue
Pembrolizumab/
Saline placebo200 mg fixed doseDose reductions 
are not permittedDose reductions 
are not permittedDose reductions 
are not permitted
Dose Modification for Pembrolizumab
Immune -Related Events and Dose Modification (Withhold, Treat, Discontinue)
Dose Modification and Toxicity Management for Immune -related AEs Associated with 
Pembrolizumab
AEs associated with pembrolizumab exposure may represent an immune -related response. 
These irAEs may occur shortly af ter the first dose or several months after the last dose of 
pembrolizumab treatment and may affect more than one body system simultaneously. 
Therefore, early recognition and initiation of treatment is critical to reduce complications. 
Based on existing cli nical study data, most irAEs were reversible and could be managed with 
interruptions of pembrolizumab, administration of corticosteroids and/or other supportive 
care. For suspected irAEs, ensure adequate evaluation to confirm etiology or exclude other 
causes. Additional procedures or tests such as bronchoscopy, endoscopy, skin biopsy may be 
included as part of the evaluation. Based on the severity of irAEs, withhold or permanently 
discontinue pembrolizumab and administer corticosteroids.
Dose Modification a nd Toxicity Management Guidelines for irAEs associated with 
pembrolizumab monotherapy, coformulations, or IO combinations are provided in Table 4. 
08FZ0N
Product:   MK-3475 85
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialTable 4 Dose Modification and Toxicity Management Guidelines for Immune -related Adverse Events Associated with 
Pembrolizumab Monotherapy, Coformulations or IO Combinations
General instructions:
1.Severe and life -threatening irAEs should be treated with IV corticosteroids followed by [CONTACT_13215]. Other immunosuppressive treatment shou ld begin 
if the irAEs are not controlled by [CONTACT_13216].
2.Pembrolizumab monotherapy, coformulations or IO combinations must be permanently discontinued if the irAE does not resolve or the corticosteroid 
dose is not ≤10mg/day within [ADDRESS_321942] tre atment. 
3.The corticosteroid taper should begin when the irAE is ≤ Grade [ADDRESS_321943] been withheld, treatment may resume after the irAE decre ased to ≤Grad e1 
after corticosteroid taper.
irAEsToxicity Grade 
(CTCAEv4.0)Action With 
Pembrolizumab 
Monotherapy, 
Coformulations or 
IO CombinationsCorticosteroid and/or Other 
Therapi[INVESTIGATOR_19340] -up
Pneumonitis Grade 2 Withhold Administer corticosteroids 
(initial dose of 1 -2 mg/kg 
prednisone or equivalent) 
followed by [CONTACT_13217]Monitor participants for signs and symptoms of 
pneumonitis
Evaluate participants with suspected pneumonitis 
with radiographic imaging and initiate corticosteroid 
treatment
Add prophylactic antibiotics for opportunistic 
infectionsRecurrent Grade 2 
or Grade 3 or 4 Permanently 
discontinue
Diarrhea / Colitis Grade 2 or 3 Withhold Administer corticosteroids 
(initial dose of 1 -2 mg/kg 
prednisone or equivalent) 
followed by [CONTACT_13217]Monitor participants for signs and symptoms of 
enterocolitis (ie, diarrhea, abdominal pain, blood or 
mucus in stool with or without fever) and of bowel 
perforation (ie, peritoneal signs and ileus)
Partici pants with ≥Grade 2 diarrhea suspecting colitis 
should consider GI consultation and performing 
endoscopy to rule out colitis
Participants with diarrhea/colitis should be advised to 
drink liberal quantities of clear fluids. If sufficient 
oral fluid inta ke is not feasible, fluid and electrolytes 
should be substituted via IV infusion.Recurrent Grade [ADDRESS_321944]:   MK-3475 86
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialirAEsToxicity Grade 
(CTCAEv4.0)Action With 
Pembrolizumab 
Monotherapy, 
Coformulations or 
IO CombinationsCorticosteroid and/or Other 
Therapi[INVESTIGATOR_19340] -up
AST / ALT 
Elevation or 
Increased 
BilirubinGrade 2 Withhold Administer corticosteroids 
(initial dose of 0.5-1 mg/kg 
prednisone or equivalent) 
followed by [CONTACT_13217]Monitor with liver function tests (consider weekly or 
more frequently until liver enzyme value returned to 
baseline or is stable)
Grade 3 or 4 Permanently 
discontinueAdminister corticosteroids 
(initial dose of 1 -2 mg/kg 
prednisone or equivalent) 
followed by [CONTACT_13217]
T1DM or 
HyperglycemiaNew onset T1DM 
or 
Grade 3 or 4 
hyperglycemia 
associated with 
evidence of β -cell 
failureWithhold aInitiate insulin replacement 
therapy for participants with 
T1DM
Administer anti -
hyperglycemic in participants 
with hyperglycemiaMonitor participants for hyperglycemia or other signs 
and symptoms of diabetes
Hypophysitis Grade 2 Withhold Administer corticosteroids 
and initiate hormonal 
replacements as clinically 
indicatedMonitor for signs and symptoms of hypophysitis 
(including hypopi[INVESTIGATOR_44791])
Grade 3 or 4 Withhold or 
permanently 
discontinue a
Hyperthyroidism Grade 2 Continue Treat with non -selective 
beta-blockers (eg, 
propranolol) or thionamides 
as appropriateMonitor for signs and symptoms of thyroid disorders
Grade [ADDRESS_321945]:   MK-3475 87
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialirAEsToxicity Grade 
(CTCAEv4.0)Action With 
Pembrolizumab 
Monotherapy, 
Coformulations or 
IO CombinationsCorticosteroid and/or Other 
Therapi[INVESTIGATOR_19340] -up
Hypothyroidism Grade 2 -4 Continue Initiate thyroid replacement 
hormones (eg, levothyroxine 
or liothyronine) per standard 
of careMonitor for signs and symptoms of thyroid disorders
Nephritis and 
renal dysfunctionGrade 2 Withhold Administer corticosteroids 
(prednisone 1 -2 mg/kg or 
equivalent) followed by [CONTACT_13217]Monitor changes of renal function
Grade 3 or 4 Permanently 
discontinue
Myocarditis Grade 1 Withhold Based on severity of AE 
administer corticosteroidsEnsure adequate evaluation to confirm etiology 
and/or exclude other causes
Grade 2, 3 or 4 Permanently 
discontinue
All Other irAEs Persistent Grade 2 Withhold Based on severity of AE 
administer corticosteroidsEnsure adequate evaluation to confirm etiology or 
exclude other causes
Grade 3 Withhold or 
discontinue b
Recurrent Grade 3 
or Grade 4 Permanently 
discontinue
AE(s)=adverse event(s); ALT= alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common Terminology Criteria for Adverse Events; DRESS=Drug Rash 
with Eosinophilia and Systemic Symptom; GI=gastrointestinal; IO=immuno -oncology; ir=immune related; IV=intravenous; SJS=Stevens -Johnson Syndrome; T1DM=type 1 
diabetes mellitus; TEN=Toxic Epi[INVESTIGATOR_19342]; ULN=upper limit of normal.
Note: Non -irAE will be managed as appropriate, following clinical practice recommendations.
aThe decision to withhold or permanently discontinue pembrolizumab monotherapy, coformulations or IO combinations is at the discretion of the investigator or treating
physician. If control achieved or ≤ Grade 2, pembrolizumab monotherapy, coformulations or IO combinations may be resumed.
bEvents that require discontinuation include, but are not limited to: Guillain -Barre Syndrome, encephalitis, myelitis, DRESS, SJS, TEN and other clinically important irAEs (eg, 
vasculitis and sclerosing cholangitis).
08FZ0N
Product:   MK-3475 88
Protocol/Amendment No.: 789-[ADDRESS_321946]:   MK-3475 89
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialTable 5 Pembrolizumab Infusion Reaction Dose modification and Treatment Guidelines
NCI CTCAE Grade Treatment Premedication at Subsequent Dosing
Grade 1
Mild reaction; infusion 
interruption not indicated; 
intervention not indicatedIncrease monitoring of vital signs as medically indicated until the participant is 
deemed medically stable in the opi[INVESTIGATOR_871].None
Grade 2
Requires therapy or infusion 
interruption but responds 
promptly to symptomatic 
treatment ( eg,antihistamines, 
NSAIDs, narcotics, IV fluids); 
prophylactic medications 
indicated for ≤24 hrsStop Infusion.
Additional appropriate medical therapy may include but is not limited to:
IV fluids
Antihistamines
NSAIDs
Acetaminophen
Narcotics
Increase monitoring of vital signs as medically indicated until the participant is 
deemed medically stable in the opi[INVESTIGATOR_871].
If symptoms resolve within 1 hour of stoppi[INVESTIGATOR_13056], the infusion may 
be restarted at 50% of the original infusion rate ( eg,from 100 mL/hr to 50 
mL/hr). Otherwise dosing will be held until symptoms resolve and the 
participant should be premedicated for the next scheduled dose.
Participants who develop Grade 2 toxicity despi[INVESTIGATOR_264792] 1.5h (± 
30 minu tes) prior to infusion of 
pembrolizumab with:
Diphenhydramine 50 mg po (or equivalent 
dose of antihistamine).
Acetaminophen 500 -1000 mg po (or 
equivalent dose of analgesic).
08FZ0N
Product:   MK-3475 90
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialNCI CTCAE Grade Treatment Premedication at Subsequent Dosing
Grades 3 or 4
Grade 3:
Prolonged (ie, not rapi[INVESTIGATOR_38194]/or brief 
interruption of infusion); 
recurrence of symptoms 
following initial improvement; 
hospi[INVESTIGATOR_12258] ( eg,renal 
impairment, pulmonary 
infiltrates)
Grade 4:
Life-threatening; pressor or 
ventilatory support indicatedStop Infusion.
Additional appropriate medical therapy may include but is not limited to:
Epi[INVESTIGATOR_238]**
IV fluids
Antihistamines
NSAID s
Acetaminophen
Narcotics
Oxygen
Pressors
Corticosteroids
Increase monitoring of vital signs as medically indicated until the participant is 
deemed medically stable in the opi[INVESTIGATOR_871].
Hospi[INVESTIGATOR_13021].
**In cases of anaphylaxis, epi[INVESTIGATOR_13079].
Participant is permanently discontinued from further study drug 
treatment.No subsequent dosing
Appropriate resuscitation equipment should be available at the bedside and a physician readily available d uring the period of drug administration.
For further information, please refer to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE) at http://ctep.cance r.gov
08FZ0N
Product:   MK-3475 91
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialOther allowed dose interruption for pembrolizumab 
Pembrolizumab may be interrupted for situations other than treatment -related AEs such as 
medical / surgical events or logistical reasons not related to study therapy. Participants should 
be placed back on study therapy within 12weeks of the scheduled inte rruption, unless 
otherwise discussed with the Sponsor. The reason for interruption should be documented in 
the participant 's study record.
Dose Modification for Chemotherapy
Recommended dose modifications for key chemother apy toxicities are outlined in Table [ADDRESS_321947] investigator judgment and applicable 
local label recommendations if more stringent.
Table 6 Recommended Dose Modifications for Chemotherapy Hematological Toxicity
Pemetrexed Cisplatin/Carboplatin
Platelets ANC Dose level (DL) from Table 3
≥50,000/mcL   AND ≥ 500/mcL DL 0 DL 0
≥50,000/mcL   AND < 500/mcL DL -1 DL -1
<50,000/ mcL without bleeding 
ANDANY DL -1 DL -1
<50,000/mcL with Grade ≥ 2 
bleeding ANDANY DL -2 DL -2
ANY AND< 1,000/mcL + fever ≥ 
38.5°C (101°F)DL -1 DL -1
Table 7 Recommended Dose Modifications for Chemotherapy Non-Hematological 
Toxicity
Pemetrexed Cisplatin Carboplatin
Event CTC Grade Dose level (DL) from Table [ADDRESS_321948]:   MK-3475 92
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialCreatinine clearance (CrCl):
CrCl will be based original weight -based Cockcroft and Gault formula in Section 10.8. CrCl 
must be ≥45mL/min prior to the administration on the day of chemotherapy. Pemetrexed 
and/or platinum may be delayed for up to 42 days to allow the participant time to recover 
from the toxicity. If a partic ipant ’sCrCl value has not returned to ≥45 mL/min within 
42days after the previous dose, platinum and/or pemetrexed must be discontinued.
Treatment After the End of the Study 
There is no study -specified treatment following the end of the study.
Clinical Supplies Disclosure
This study is blinded but supplies are provided open label; therefore, an unblinded 
pharmacist or qualified study site personnel will be used to blind supplies. Study treatment 
identity (name, strength or potency) is included i n the label text; random code/disclosure 
envelopes or lists are not provided.
The emergency unblinding call center will use the treatment/randomization schedule for the 
study to unblind participants and to unmask study treatment identity .The emergency 
unblinding call center should only be used in cases of emergency (see Section 8.1.10 ). In the 
event that the emergency unblinding call center is not available for a given site in this study , 
the central electronic treatment allocation/randomization system ( IRT) should be used in 
order to unblind participants and to unmask study treatment identity. The Sponsor will not 
provide random code/disclosure envelopes or lists with the clinical supplies.
See Section 8.1.[ADDRESS_321949] be collected through the participant’s last scheduled follow -up, even 
if the participant has discontinued study treatment. Therefore, all participants who 
discontinue study treatment prior to completion of the protocol -specified treatment period
will still continue to participate in the study as specified in Section 1.3and Section 8.11.5
unless the pa rticipan t has withdrawn from the study (Section 7.2) .
Participants may discontinue study treatment at any time for any reason or be discontinued
from the study treatment at the discretion of the investigator should any untoward effect 
occur. In addition, a participant may be discontinued from study treatment by [CONTACT_264823], the study plan is v iolated, or for 
administrative and/or other safety reasons. Specific details regarding procedures to be 
performed at study treatment discontinuation are provided in Section 8.1.[ADDRESS_321950]:   MK-3475 93
Protocol/Amendment No.: 789-[ADDRESS_321951] be discontinued from study treatment but continue to be m onitored in the 
study for any of the following reasons:
○The participant or participant’s legally acceptable representative requests to discontinue 
study treatment.
oThe participant’s treatment assignment has been unblin ded by [CONTACT_264824] -verified radiographic disease progression, by [CONTACT_264825] .
oAny prolonged interruption of study intervention beyond the permitted periods, for irAE 
management or other allowed dose interrupt ions, as noted in Sec tion6.6.[ADDRESS_321952].
oThe participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, placed the participant at unnecessary risk from continued 
administration of study treatment.
oThe participant has a confirmed positive serum pregnancy test.
oBICR -verified disease progression as outlined in Section 8.2.1 AND the participant is 
clinically unstable .
Clinical Stability is defined as:
1.Absence of symptoms and signs indicating clinical lysignificant progression of 
disease (in cluding worsening of laboratory values) indicating disease progression.
2.No decline in ECOG performance status.
3.Absence of rapid progression of disease or progressive tumor at critical 
anatomical sites ( eg,cord compression) requiring urgent alternative medical 
intervention.
oAny progression or recurrence of any malignancy, or occurrence of another malignancy 
that requires active treatment
oNoncompliance with study treatment or procedure requirements
oUnaccepta ble adverse experiences .
Completion of pembrolizumab Q3W monotherapy consists of 35 treatments (approximately 
2 years). Discontinuation of treatment may be considered for participants who have attained a 
confirmed CR and have been treated for at least 8 c ycles (at least 24 weeks), receiving [ADDRESS_321953]:   MK-3475 94
Protocol/Amendment No.: 789-[ADDRESS_321954] be withdrawn from the study if the participant or participant’s legally 
acceptable representative withdraws consent from the study.
If aparticipant decides not to continue receiving study intervention, the participant is to be 
encouraged to continue visits in the study for follow -up, imaging, and vital status assessment .
Participants who withdraw consent during the study
If the participant or participant’s legally acceptable representative withdraws consent, the 
participant must be withdrawn from the study.
Section 8.1.9 delineates the specific procedures performed at the time of withdrawal and
withdrawal from future biomedical research .Survival Follow -up Procedures are outlined in 
Section [IP_ADDRESS] .Any AEs that are present at the time of withdrawal should be followed in 
accordance with the safety requirements outlined in Section 8.4. The procedures to be 
performed sho uld a participant repeatedly fail to return for scheduled visits and/or if the 
study site is unable to contact [CONTACT_193419] 7.3.
Lost to Follow -up
If a participant fails to return to the clinic for a required study visit and/or i f the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
●The site must attempt to contact [CONTACT_19423]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
●The investigator or designee must make every effort to regain contact [CONTACT_126534] (eg, telephone calls and/or a certified letter to the 
participant’s last known mailing address or locally equivalent methods). These 
contact [CONTACT_13140]’s medical record.
●Note:  A participant is not considered lost to follow -up until the last scheduled visit 
for the individual participant. The missing data for the participant will be managed 
via the prespecified statistical data handling and analysis guidelines.
8.Study Assessments and Procedures
●Study procedures and their timing are summarized in the SoA. 
●Adherence to the study design r equirements, including those specified in the SoA, is 
essential and required for study conduct.
●The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_19426] (by [CONTACT_8640], training and experience) staff . Delegatio n of 
study site personnel responsibilities will be documented in the Investigator Trial File 
Binder (or equivalent).
●All study -related medical (or dental) decisions must be made by [CONTACT_75368] a qualified physician (or dentist when appropriate) .
08FZ0N
Product:   MK-3475 95
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential●All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log 
to record details of all participants screened a nd to confirm eligibility or record 
reasons for screening failure, as applicable. 
●Procedures conducted as part of the participant’s routine clinical management (eg, 
blood count) and obtained before signing of ICF may be utilized for screening or 
baselin e purposes provided the procedure met the protocol -specified criteria and were 
performed within the time frame defined in the SoA.
●Additional evaluations/testing may be deemed necessary by [CONTACT_264826]. In some cases, such 
evaluation/testing may be potentially sensitive in nature (eg, HIV, Hepatitis C, etc.), 
and thus local regulations may require that additional informed consent be obtained 
from the participant . In these cases, such evaluat ions/testing will be performed in 
accordance with those regulations.
The total amount of blood/tissue to be drawn/collected over the course of the trial (from pre -
trial to post -trial visits), including approximate blood/tissue volumes drawn/collected by [CONTACT_264827].
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
Administrative and General Procedures
Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent from each potential participant (or their legally 
acceptable representative )prior to participating in thisclinical study or future biomedical 
research . If there are changes to the participant’s status during the study (eg, health or age of 
majority requirements), the investigator or medically qualified designee must ensure the 
appropriate documented informed consent is in place. 
General Informed Consent
Informed consent given by [CONTACT_19429] a consent form. The form must include the trial protocol number, trial 
protocol title, dated signature, and agreement of the participant (or his/her legally acceptable 
representative) and of the person conducting the consent discussion .
A copy of the signed and dated informed consent form should be given to the participant 
before participation in the study .
The initial ICF, any subsequent revised ICF, and any written information provided to the 
participant must receive the IRB/IEC’s approval/favorable opi[INVESTIGATOR_19349]. The 
participant or his/her legally acceptable representative should be informed in a timely manner 
if new information becomes available that may be relevant to the participant's willingness to 
continue participation in the study. The communication of this information will be provided 
and documented via a revised consent form or addendum to the original con sent form that 
08FZ0N
Product:   MK-3475 96
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialcaptures the participant’s or the participant’s legally acceptable representative’s dated 
signature .
Specifics about the study and the study population are to be included in the study informed 
consent form . 
Informed consent will adhere to I RB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements .
Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically qualified designee will explain the future biomedical research 
consent to the participant, or the participant’s legally acceptable representative, answer all of 
his/her questions, and obtain documented informed consent before performing any procedure 
related to future biomedical research. A copy of the informe d consent will be given to the 
participant before performing any procedure related to future biomedical research .
Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_63522] a qualified 
physician to ensure that the participant qualifies for the study .
Participant Identification Card
All participants will be given a Participant Identification Card identifying them as 
participants in a research study . The card will contain study site contact [CONTACT_3031] 
(inclu ding direct telephone numbers) to be utilized in the event of an emergency. The 
investigator or qualified designee will provide the participant with a Participant Identification 
Card immediately after the participant provides documented informed consent. A t the time of 
treatment allocation/randomization, site personnel will add the treatment/randomization 
number to the Participant Identification Card.
The participant identification card also contains contact [CONTACT_264828] a health care provider can obtain information about study 
treatment in emergency situations where the investigator is not available.
Medical History
A medical history will be obtained by [CONTACT_27404].
Prior and Concomi tant Medications Review
Prior Medications
The investigator or qualified designee will review prior medication use, including any 
protocol -specified washout requirement, and record prior medication taken by [CONTACT_88688] 28days before first dose of study medication.
Prior anti -cancer treatment for NSCLC will be recorded separately and not listed as a prior 
medication. The investigator or qualified designee will review and record all prior anti -
cancer treatments including systemic treatm ents, radiation, and surgeries, regardless of the 
time prior to first dose of study treatment .
08FZ0N
Product:   MK-3475 97
Protocol/Amendment No.: 789-[ADDRESS_321955] not be re -used for 
different participants.
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial screening visit.
Specific details on the screening visit requirements (screening/rescreening) are provided in 
Section 8.11.1 . 
Treatment Eligibility Assessment (TEA) Form
A TEA form is included in this study to document the investigators’ choice of carboplatin or 
cisplatin and the rationale. These data may be required to support reimbursement efforts for 
pembrolizumab.  
The investigator must complete this form to document the rationale for the choice of 
carboplatin or cisplatin prior to randomization. 
Assignment of Treatm ent/Randomization Number
All eligible participants will be randomly allocated and will receive a 
treatment/randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomiza tion. Once a 
treatment/randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment/randomization number.
08FZ0N
Product:   MK-3475 98
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Treatment Administration
Administration of studymedication will be monitored by [CONTACT_1755]/or study staff.
Study interventions will be administered by [CONTACT_1755]/or study staff according to 
the specifications within the pharmacy manual . The total volume of pembrolizumab infused 
will be compared to the total volume prepared to determine compliance to each dose of 
pembrolizumab administered.
The instructions for preparing and administering pembrolizumab will be provided in the 
Pharmacy Manual .Premedication should also be dosed per the approved product labels and 
as described in Section 6.5.3 .
Study treatment should begin on the day of treatment allocation/randomization or as close as 
possible to the date on which the participant is allocated/assigned.
Timin g of Dose Administration
Participant s will receive blinded pembrolizumab 200 mg or saline placebo together with 
pemetrexed 500 mg/m2(with vitamin supplementation) + cisplatin 75 mg/m2OR carboplatin 
AUC 5 mg/mL•min all on Day 1 Q3W for 4 cycles followed b y blinded pembrolizumab 
200mg or saline placebo together with pemetrexed 500 mg/m2Q3W on Day 1 of each 
subsequent cycle until BICR -verified disease progression , study c ompletion , or any 
discontinuation criteria aremet per Sections 7.1 and 8.1.9 .
Study treatment should be administered on Day 1 of each cycle after all procedures / 
assessments have been completed (Section 1.3) . Study treatment can be administered 3 days
before or after of the targeted Day 1 for each cycle, except Cycle 1 Day 1 (C1D1) , where 
study treatment can only be administered + 3 days from randomization .
All study treatments will be administered on an out patient basis.
Timing of Dose Administration of Pembrolizumab /Saline Placebo
Pembrolizumab /saline placebo will be administered as a dose of 200 mg using a 30 -minute 
IV infusion prior to administration of chemotherapy agents . Sites should make every effort to 
target infusion timing to be as close to 30 minutes as possible. However, given the variability 
of inf usion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (ie, 
infusion time is 30 minutes -5 min/+10 min). 
The Pharmacy Manual contains specific instructions for pembrolizumab reconstitution, 
preparation of the infusion fluid, an d administration.
For participants who experience disease progression, investigators may elect to interrupt 
treatment by [CONTACT_264829]/discontinue treatment in the trial until 
confirmation of disease progression per RECIST 1.[ADDRESS_321956]:   MK-3475 99
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Pemetrexed
Pemetrexed 500 mg/m2will be administered as an IV infusion over 10 minutes Q3W until 
progression or unacceptable toxicity. All participants should receive the appropriate 
supplementation of vitamin B12 and folic acid and corticosteroid prophylaxis as described in 
Section 6.5and/or according to local practice and label s.
Cisplatin
Cisplatin 75 mg /m2willbe administered as an IV infusion over a recommended time of 60
minutes . However, cisplatin may be administered over 30 to 150 minutes to accommodate 
local SOC. Treatment will be administered after pemetrexed on Day 1 of the 21 day cycle, 
for a maximum of 4 administrations.
Cisplatin administration should be immediately preceded and followed by [CONTACT_264830] 6.6and administered according to local practice and labels. 
Carboplatin
Carboplatin AUC 5 mg/mL •min will be administered as an IV infusion over [ADDRESS_321957] 
of care chemotherapi[INVESTIGATOR_014].
Discontinuation and Withdrawal
Participants who withdraw consent from the study shoul dbe encouraged to complete all 
applicable activities scheduled for the final study visit at the time of withdrawal .
Once the participant moves to survival follow -up, he/she shall not be allowed to restart study 
treatment , but overall survival information will still be collected .
Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical research. Participants may 
withdraw consent at any time by [CONTACT_59554] [INVESTIGATOR_63472]. If 
medical records for the main study are still available, the investigator will contact [CONTACT_63527] (clinical.specimen.management@ MSD .com). 
Subsequently, the participant's consent for future biomedical research will be withdrawn. A 
letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the 
responsibility of the investigator to inform the participant of completion of withdrawal. Any 
analyses in progress at the time of request for withdrawal or already performed prior to the 
request being received by [CONTACT_264831]. No new analys es would be generated after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by [CONTACT_180631]) 
08FZ0N
Product:   MK-3475 100
Protocol/Amendment No.: 789-[ADDRESS_321958] been completely anonymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed.
Participant Blinding/Unblinding
STUDY TREATMEN T IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency situations where the investigator or medically qualified designee (consistent 
with local requirem ents) needs to identify the drug used by a participant and /orthe dosage 
administered ,he/she will contact [CONTACT_264832] a request for emergency unblinding. As requested by [CONTACT_264833] ,the emergency unblinding call center will provide the information to 
him/her promptly and report unblinding to the Sponsor .Prior to contact[CONTACT_88694] a participant’s treatment assignment, th e 
investigator who is a qualified physician should make reasonable attempts to enter the 
intensity/toxicity grade of the AEs observed, the relation to study drug, the reason thereof, 
etc., in the medical chart etc ., in the medical chart . If it is not possible to record this 
assessment in the chart prior to the unblinding, the unblinding should not be delayed .
For studies that require non-emergency unblinding as part of the study design (BICR -verified 
radiographic disease progression) to support treatme nt decisions, instructions in Section 8.11
should be followed. The emergency unblinding center should not be used for this purpose.
Participants whose treatment assignment has been unblinded by [CONTACT_93311]/or nonstudy treating physician should continue to be monitored in the 
study.
Additionally, the investigator or medically qualified designee must go into the IRTsystem 
and perform the unblind in the IRTsystem to update drug disposition. In the event that the 
emergency unblinding call center is not available for a given site in this study , the IRT
system should be used for emergency unblinding in the event that this is required for 
participant safety.
Study treatment identification information is to be unmasked ONLY if necessary for the 
welfare of the participant. Every effort should be made not to unblind the participant unless 
necessary. 
In the event that unblinding has occurred, the circumstances ar ound the unblinding (eg, date, 
reason and person performing the unblinding) must be documented promptly, and the 
Sponsor Clinical Director notified as soon as possible. Once an emergency unblinding has 
taken place, the principal investigator, site personne l, and Sponsor personnel may be
unblinded so that the appropriate follow -up medical care can be provided to the participant .
Calibration of Equipment
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinical study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
08FZ0N
Product:   MK-3475 101
Protocol/Amendment No.: 789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialcalibrated and /ormaintained to ensure that the data obtained is reliable and/or rep roducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study site.
Efficacy Assessments 
Tumor Imaging and Assessment of Disease
The process for image collection and transmission to the central imaging vendor can be 
found in the Site Imaging Manual. CT scans arepreferred over other tumor imaging methods . 
For the abdomen and pelvis, contrast -enhanced magnetic resonance imaging (MRI) may be 
used when CT with iodinated contrast is contraindicated, or when mandated by [CONTACT_53154]. MRI is the strongly preferred modality for imaging the brain. The same type of
scan, ideally the same scanner, and the use of contrast should be used in a participant 
throughout the study to optimize the reproducibility of the assessment of existing and new 
tumor burden and improve the accuracy of the response assessment. Note: for the purposes of 
assessing tumor imaging, the term “Investigator” refers to the local investigator at the site 
and/or the radiological reviewer located at the site or at an offsite facility.
Brain MRI will be done for all participants at screening. If MRI i s medically contraindicated, 
then CT with contrast is an acceptable alternative.
Participant eligibility will be determined using local assessment (Investigator assessment) 
based on RECIST 1.1. All scheduled images for all study participants from the sites will be 
submitted to the central imaging vendor. In addition, images (including via other modalities) 
that are obtained at an unscheduled time point to determine disease progression, as well as 
imaging obtained for other reasons, but which demonstrate rad iologic progression, should 
also be submitted to the central imaging vendor.
When the Investigator identifies radiographic progression per RECIST 1.1, the central 
imaging vendor will perform expedited verification of radiologic PD and communicate the 
resul ts to t he study site and Sponsor (See Section [IP_ADDRESS] and Figure 3). Treatment should 
continue until PD has been verified. Regardless of whether PD is verified, if the Investigator 
considers the participant has progressed, but elects to implement iRECIST, the Investigator 
will assess for confirmation of progression by [CONTACT_19434] (Section 
1.2, Figure 3). Images should continue to be submitted to the central imaging vendor. 
Initial Tumor Imaging
The site’s study team must have reviewed pre -trial images from at least [ADDRESS_321959]:   MK-3475 102
Protocol/Amendment No.: 789-[ADDRESS_321960] on -study imaging a ssessment should be performed at 6weeks ( 42days +7days) 
from the date of randomization. Subsequent tumor imaging should be performed every 9
weeks ( 63days ±7 days) or more frequently if clinically indicated. After 51weeks, 
participants who remain on t reatment will have imaging performed every 12weeks ( 84days 
±7 days). Imaging timing should follow calendar days and should not be adjusted for delays 
in cycle starts. Imaging should continue to be performed until disease progression is 
identified by [CONTACT_264834] (unless the 
Investigator elects to continue treatment and follow iRECIST), the start of a new anti -cancer 
treatment, pregnancy, withdrawal of consent, death , or the end of the study . All imaging must 
be submitted to the central imaging vendor. 
Objective response should be confirmed by a repeat imaging assessment. Tumor imaging to 
confirm PR or CR should be performed at least [ADDRESS_321961] indication of a 
response is observed. Participants wi ll then return to regular scheduled imaging, starting with 
the next scheduled imaging time point. Participants who receive additional imaging for 
confirmation do not need to undergo the next scheduled tumor imaging if it is less than 4 
weeks later; tumor i maging may resume at the subsequent scheduled imaging time point. 
Note:  Response does not typi[INVESTIGATOR_264793].
On-study brain or bone imaging should be performed if clinically indicated or to confirm CR
(if other lesions indicate CR and brain or bone lesions existed at baseline).
Per iRECIST (Section [IP_ADDRESS] ), disease progression should be confirmed by [CONTACT_779] [ADDRESS_321962] unconfirmed disease progression may continue on 
their assigned study treatment at the discretion of the Investigator until progression is 
confirmed by [CONTACT_779] (Section 1.2, Figure 3) and provided they have met the conditions 
detailed in Section [IP_ADDRESS] . Participants who receive confirmatory imaging do not need to 
undergo the next scheduled tumor imaging if it is less than 4 weeks later; tumor imaging may 
resume at the subsequent scheduled imaging time point, if clinically stable. Participants ,who 
have confirmed disease progression by [CONTACT_19393], as assessed by [CONTACT_779], will discontinue 
study treatment. Exceptions are detailed in Section [IP_ADDRESS].
End of Treatment and Follow -up Tumor Imaging
For participants who discontinue study treatment, tumor imaging should be performed at the 
time of treatment discontinuation (±4 week window). If previous imaging was obtained 
within [ADDRESS_321963]:   MK-3475 103
Protocol/Amendment No.: 789-[ADDRESS_321964].
For participants who discontinue study tr eatment without documented disease progression, 
tumor imaging using the same imaging schedule used while on treatment (every 9weeks in 
Year 1 or every 12weeks after Year 1) or according to local standard of care imaging 
intervals should be used to monito r disease status until the start of new anti -cancer treatment, 
disease progression, pregnancy, death, withdrawal of consent, or the end of the study, 
whichever occurs first.
Second Course (Retreatment) and Crossover Tumor Imaging
Tumor imaging must be perf ormed within 28days prior to starting/ restarting tr eatment with 
pembrolizumab. The Investigator, working with local radiology will be used to determine 
eligibility. Imaging should be submitted to the central imaging vendor for quality control, 
storage, and possible retrospective review.
The first on -study imaging assessment should be performed at 12weeks (±7days) after the 
restart of treatment. Subsequent tumor imaging should be performed every 12weeks 
(±7days) or more frequently, if clinica lly indicated.
Per iRECIST (Section [IP_ADDRESS] ), if tumor imaging shows initial PD, tumor assessment should 
be repeated [ADDRESS_321965] tumor imaging indicating PD.
For participants who discontinue Second Course study treatment, tumor imaging should be 
performed at the time of treatment discontinuation (±4 week window). If previous imaging 
was obtained within 4 weeks prior to the date of discontinuation, then imaging at treatment 
discontinuation is not mandatory. For participants who discontinue study treatment due to 
documented disease progression, this is the final required tumor imaging.
For participants who disc ontinue Second Course study treatment without documented disease 
progression, radiologic tumor imaging using the same imaging schedule used while on 
treatment (ie, every 12 weeks ±7 days) or according to local standard of care imaging 
intervals should be u sed to monitor disease status until the start of new anti -cancer treatment, 
disease progression, pregnancy, death, withdrawal of consent, or the end of the study, 
whichever occurs first.
RECIST 1.[ADDRESS_321966] 1.1 will be used by [CONTACT_264835] t he primary measure for assessment of tumor response, 
date of disease progression, and as a basis for all protocol guidelines related to disease status 
(eg, discontinuation of study treatment). Although RECIST 1.[ADDRESS_321967]:   MK-3475 104
Protocol/Amendment No.: 789-[ADDRESS_321968], as assessed by [CONTACT_737], and the 
participant continues to be clinically stable, study treatment may continue and follow the 
regular imaging schedule. If PD is confirmed, participants will be discontinued from study 
treatment.
If a participant has confirmed ra diographic progression (iCPD) as defined in Section 10, 
study treatment should be discontinued; however, if the participant is achieving a clinically 
meaningful benefit, an exception to continue study treatment may be considered following 
consultation with the Sponsor. In this case, if study treatment is continued, tumor imaging 
should continue to be performed following the intervals as outlined in Section 1.3and 
submitted to the central imaging vendor. 
A description of the adaptations and iRECIST process is provided in Section 10, with 
additional details in the iRECIST publication [Seymour, L., et al 2017] . A summary of 
imaging and treatment requirements after first radiologic evidence of progression is provide d 
in Table 8and illustrated as a flowchart in Figure 5.
08FZ0N
Product:   MK-3475 105
Protocol/Amendment No.: 789-[ADDRESS_321969] 1.1 that has 
been verified by [CONTACT_264836] 4 to 
8weeks to confirm PD.May continue study treatment at 
the Investigator’s discretion 
while awaiting confirmatory 
tumor imaging by [CONTACT_91079].Repeat imaging at 4 to 
8weeks to confirm PD per 
Investigator’s discretion 
only.Discontinue treatment
Repeat tumor imaging 
confirms PD (iCPD) by 
[CONTACT_264837].Discontinue treatment 
(exception is possible upon 
consultation with Sponsor).No additional imaging 
required.Not applicable
Repeat tumor imaging 
shows iUPD by [CONTACT_264838] 4 to 
8weeks to confirm PD. 
May occur at next 
regularly scheduled 
imaging visit.Continue study treatment at the 
Investigator’s discretion.Repeat imaging at 4 to 
8weeks to confirm PD per 
Investigator’s discretion 
only.Discontinue treatmen t
Repeat tumor imaging 
shows iSD, iPR, or iCR by 
[CONTACT_264839].Continue regularly 
scheduled imaging 
assessments.Continue study treatment at the 
Investigator’s discretion.Continue regularly 
scheduled imaging 
assessments.May restart study treatment if 
condition has improved and/or 
clinically stable per Investigator’s 
discretion. Next tumor imaging 
should occur according to the 
regular imaging schedule.
iCPD=iRECIST confirmed progressive disease; iCR=iRECIST complete response; iRECIST=modified Response Evaluation Criteria in Solid Tumors 1.1 for immune -based 
therapeutics; iSD=iRECIST stable disease; iUPD=iRECIST unconfirmed progressive disease; PD=progressive disease; RECIST 1.1=Re sponse Evaluation Criteria in Solid Tumors 
1.1; VOP=verification of progression
Note:  If progressi ve disease (PD) has been centrally verified, further management is by [CONTACT_779], based on iRECIST. Any further imaging should still be submitted to the cent ral 
imaging vendor, but no real -time review will occur. If RECIST 1.[ADDRESS_321970]:   MK-3475 106
Protocol/Amendment No.:   789-[ADDRESS_321971] Radiologic 
Evidence of PD Assessed by [CONTACT_264840] -5D-5L,EORTC QLQ -C30, and EORTC QLQ -LC13 questionnaires will be 
administered by [CONTACT_264841] s in the 
following order: EQ -5D-5Lfirst, then EORTC QLQ -C30, then EORTC QLQ -LC13 . The 
questionnaires should be administered prior to dosing at every cycle through Cycle 7, then 
every 3rd cycle through Cycle 1 9, then every 4th cycles through Cycle 35 (eg, Cycles 1 -7, 
10, 13, 16, 19, 23, 27, 31, and 35) , at the Treatment Discontinuation Visit, and at the [ADDRESS_321972] practice and strongly recommended that electronic patient reported outcomes 
(ePROs) are administered to randomized participant s prior to drug ad ministration, adverse 
event evaluation, and disease status notification. If the participant does not complete the 
ePROs at a scheduled time point, the MISS_MODE form must be completed to capture the 
reason the assessment was not performed.
Safety Assessmen ts
Details regarding specific safety procedures/assessments to be performed in this study are 
provided below.
Planned time points for all safety assessments are provided in the SoA.
08FZ0N
Product:   MK-3475 107
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Physical Examinations
A complete (full) physical examination will be conducted by [CONTACT_113803] (consistent with local requirements) as per institutional standard during 
the Screening period and at Discontinuation . 
For cycles that do not require a full physical exam ination, a brief directed physical 
exam ination will be conducted as per institutional standard. 
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
Vital Signs
Vital signs will be collected at Screening , prior to the administration of each dose of study 
treatment , EOT/ Discontinuation and/or30 days after the last dose of study treatment (follow -
up)as outline d in the SoA in Section 1.3. Vital signs measurements include temperature, 
pulse, respi[INVESTIGATOR_697], weight, and blood pressure. Height will be measured at Screening
only. Refer to Section 10. 12 for country -specific requirements. 
Electrocardiograms
A single 12-lead electrocardiogram (ECG) will be obtained and reviewed by [CONTACT_123669] (consistent with local requirements) at Screening and at 
EOT /Discontinuation using local standard procedures as outl ined in the SoA in Section 1.3. 
Clinically signific ant abnormal findings at Screening should be recorded as medical history. 
Additional ECGs may be performed as clinically necessary.
Clinical Safety Laboratory Assessments
Refer to Section 10.[ADDRESS_321973] of clinical laboratory tests to be performed and to the SoA 
for the timing and frequency. 
●The investigator or medically qualified designee (consistent with local requirements)
must review the laboratory report, document this review, and re cord any clinically 
relevant changes occurring during the study in the AE section of the case report form 
(CRF). The laboratory reports must be filed with the source documents. Clinically 
significant abnormal laboratory findings are those which are not ass ociated with the 
underlying disease, unless judged by [CONTACT_55885]'s condition.
●All protocol -required laboratory assessments, as defined in Section 10.5, must be 
conducted in accordance with the lab oratory manual and the SoA Section 1.3.
●If laboratory values from non -protocol specified laboratory assessments performed at 
the institution’s local laboratory require a change in study participant management or 
are considered clinically significant by t he investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
08FZ0N
Product:   MK-3475 108
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential●For any laboratory tests with values considered clinically significantly abnormal 
during participation in the study or within 30daysafter the last dose of study 
treatment, every attempt should be made to perform repeat assessments until the 
values return to normal or baseline or if a new baseline is established as determined 
by [CONTACT_093]. 
Details regarding specific laborator y procedures/assessments to be performed in this study 
are provided below. The total amount of blood/tissue to be drawn/collected over the course 
of the study (from pre -study to post -study visits), including approximate blood/tissue 
volumes drawn/collected by [CONTACT_264842] i n the 
Procedures Manual. Refer to the SoA inSection 1.3for the timing of laboratory assessments.
Laboratory Safety Evaluations (Hematology, Chemistry, and Urinalysis)
Laboratory tests for hematology, chemistry, and urinalysis are specified in Section 10.5.
Pregnancy Test
●All women who are being considered for participation in the study, and who are not 
surgically sterilized or p ostmenopausal, must be tested for pregnancy within [ADDRESS_321974] be excluded/discontinued from the study in the 
event of a posit ive test result. Repeated Pregnancy test (such as monthly testing) may 
be conducted if required by [CONTACT_427] . 
Adverse Events (AEs), Serious Adverse Events (SAE s),and Other Reportable 
Safety Events 
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE ,and other reportable safety event reports can be found in Section 10.4, Appendix 4.
Progression of the cancer under study is not considered an AEas described in Section 8.4.5 
and Section 10.4 .
AE, SAEs, and other reportable safety events will be reported by [CONTACT_2299] (or, when 
appropriate, by a caregiver, surrogate, or the participant's legally authorized representati ve). 
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety events.
Investigators remain responsible for following up AE, SAEs ,and other reportable safety 
events for outcome according to Section 8.4.3.
The investigator, who is a qualified physician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality.
Adverse events will not be collected for participants during the prescreening period (for 
determination of archival tissue status) as long as that participant has not undergone any 
protocol -specified procedure or intervention. If the participant requires a blood draw, fresh 
tumor biopsy etc., the participant is first required to provide consent to the main study and 
AEs will be captured according to guidelines for standard AE reporting.
08FZ0N
Product:   MK-3475 109
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Time Period and Frequency fo r Collecting AE, SAE ,and Other Reportable 
Safety Event Information
All AEs, SAEs ,and other reportable safety events that occur after the participant provides 
documented informed consent but before treatment allocation/randomization must be 
reported by [CONTACT_3433] e investigator if the participant is receiving placebo run -in or other run -in 
treatment, if the event cause sthe participant to be excluded from the study , or is the result of 
a protocol -specified intervention, including but not limited to washout or disco ntinuation of 
usual therapy, diet, or a procedure. 
All AEs from the time of treatment allocation/randomization through [ADDRESS_321975] be reported by [CONTACT_093]. 
All AEs meeting serious criteria, from the time of treatment allocation/randomization 
through [ADDRESS_321976] be reported by [CONTACT_093]. 
All pregnancies and exposure during breastfeeding, from the time of treatment 
allocation/randomization through [ADDRESS_321977] be reported by [CONTACT_093]. 
Additionally, any SAE brought to the attention of an investigator at any time outside 
of the time period specified above must be reported immediately to the Sponsor if the 
event is considered to be drug -related.
Investigators are not obligated to actively seek AE or SAE or other reportable safety events 
in former study participants. However, if the investigator learns of any SAE, including a 
death, at any time after a participant has been discharged from the study , and theinvestigator
considers the event to be reasonably related to the study treatment or study participation, the 
investigator must promptly notify the Sponsor.
All initial and follow -up AEs, SAEs and other reportable safety events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 9.
08FZ0N
Product:   MK-3475 110
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialTable 9 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safety Events
Type of EventTime Period Time Frame 
to Report 
Event and 
Follow -up 
Information 
to 
SPONSOR:Consent to 
Randomization/ 
AllocationRandomization/ 
Allocation through 
Protocol -Specified 
Follow -up PeriodAfter the Protocol 
Specified Follow -
up Period
Non-Serious Adverse 
Event (NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
Serious Adverse 
Event (SAE)
including Cancer and 
OverdoseReport if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Report if:
-drug/vaccine 
related.
(Follow ongoing to 
outcome )Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if 
participant has 
been exposed to 
any protocol -
specified 
intervention (eg, 
procedure, 
washout or run -in 
treatment 
including placebo 
run-in)Report all Previously reported 
–Follow to 
completion/terminat
ion; report outcomeWithin [ADDRESS_321978] (require 
regulatory reporting)Report if:
-due to 
intervention
-causes exclusionReport
-Potential drug-
induced liver injury 
(DILI )
-Require regulatory 
reportingNot required Within [ADDRESS_321979] (Do not 
require regulatory 
reporting)Report if:
-due to 
intervention
-causes exclusionReport
-non-DILI ECIs and 
those not requiring 
regulatory reportingNot required Within [ADDRESS_321980]:   MK-3475 111
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE and/or SAE and other reportable 
safety events. Open -ended and nonleading verbal questioning of the participant is the 
preferred method to inquire about AE occurrence .
Follow -up of AE, SAE and Other Reportable Safety Event Information 
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE, SAE ,and other reportable safety events 
including pregnancy and exposure during breastfeeding, ECIs , Cancer and Overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3). In addition, the investigator will 
make every attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Section 10.4 .
Regulatory Reporting Requir ements for SAE
Prompt notification (within 24 hours) by [CONTACT_264843] a study treatment under clinical investig ation are met. 
The Sponsor has a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study treatment under clinical 
investigation. All AEs will be reported to regulatory authorities, IRB/IECs and 
investigators in accordance with all applicable global laws and regulations, ie,per 
ICH Topic E6 ( R2) Guidelines for GCP .
Investigator safety reports must be prepared for suspected unexpected serio us adverse 
reactions (S[LOCATION_003]R s) according to local regulatory requirements and Sponsor policy 
and forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing a nSAE or other 
specific safety information (eg, summary or listing of SAE) from the Sponsor will file 
it along with the IBand will notify the IRB/IEC, if appropriate according to local 
requirements.
Disease -related Events and/or Disease -related Outcomes Not Qualifying as AEs 
or SAEs
Efficacy endpoints as outlined in this section will not be reported to the Spons or as described 
in Section 8.4.1 . 
Specifically, the suspected/actual events covered in this exception include any event that is 
disease progression of the cancer under study.
The Spons or will ensure that unblinded aggregated efficacy endpoint events and safety data
are monitored to safeguard the participants in the study . 
08FZ0N
Product:   MK-3475 112
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the study are repor table to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy. 
Any pregnancy complication will be reported as an AE or SAE. 
The medical reason (example: maternal health or fetal disease) for an elective te rmination of 
a pregnancy will be reported as an AE or SAE. Prenatal testing showing fetus will be born 
with severe abnormalities/congenital anomalies that leads to an elective termination of a 
pregnancy will be reported as an SAE for the fetus. 
Pregnancy outcomes of ectopic pregnancy, spontaneous abortion, missed abortion, benign 
hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage ,and stillbirth 
must be reported as serious events (Important Medical Events). If the pregnancy cont inues to 
term, the outcome (health of infant) must also be reported.
Events of Clinical Interest (ECI s)
Selected nonserious and serious adverse events are also known as ECIsand must be reported 
to the Sponsor.
Events of clinical interest for this study include: 
1.an overdose of Sponsor's product, as defined in Section 8.5, that is not associated with 
clinical symptoms or abnormal laboratory results.
2. an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit 
of normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the upper limit of normal, as determined by [CONTACT_13149] -specified laborato ry 
testing or unscheduled laboratory testing.*
*Note:  These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require 
an additional evaluation for an u nderlying etiology. The study site guidance for 
assessment and follow -up of these criteria can be found in the Investigator Trial File 
Binder (or equivalent).
ECIs that occur after the participant provides documented informed consent , but before 
treatment randomization, must be repo rted by [CONTACT_264844] a protocol -specified 
intervention.
08FZ0N
Product:   MK-3475 113
Protocol/Amendment No.:   789-[ADDRESS_321981] igator to Sponsor in accordance 
with the reporting time period described in Table 9.
Treatmen t of Overdose
For this study, an overdose of pembrolizumab will be defined as any dose of 1000 mg or 
greater ( ≥5 times the indicated dose). 
No specific information is available on the treatment of overdose of pembrolizumab. In the 
event of overdose, the participant sho uld be observed closely for signs of toxicity. 
Appropriate supportive treatment should be provided if clinically indicated.
If an adverse event(s) is associated with (“results from”) the overdose of Sponsor's product or 
vaccine, the adverse event(s) is rep orted as a serious adverse event, even if no other 
seriousness criteria are met.
If a dose of Sponsor's product or vaccine meeting the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory results, the ove rdose is 
reported as a non -serious E CI, using the terminology “accidental or intentional overdose 
without adverse effect.”
All reports of overdose with and without an adverse event must be reported by [CONTACT_23514] 24 hours to the Sponsor either by [CONTACT_26365]. Electronic 
reporting procedures can be found in the electronic data collection (EDC) data entry 
guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or 
equivalent) .
Pharmacokinetics
PK par ameters will not be evaluated in this study.
Pharmacodynamics
Pharmacodynamic parameters will not be evaluated in this study.
Biomarkers
To identify novel biomarkers, the following biospecimens to support exploratory analyses of 
cellular components (eg, pr otein, RNA, DNA, metabolites) and other circulating molecules 
will be collected from all participants in this study as specified in the SoA :
Blood for ctDNA, Genetics, and RNA Analyses
Blood for Serum and Plasma Analyses
Archival tumor specimen
Sample collection, storage and shipment instructions for the exploratory biomarker 
specimens will be provided in the laboratory manual.
The sample for genetic analysis should be drawn for planned exploratory biomarker research. 
This sample will not be coll ected at the site if there is either a local law or regulation 
prohibiting collection, or if the IRB/IEC does not approve the collection of the sample for 
08FZ0N
Product:   MK-3475 114
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialthese purposes. If the sample is collected, leftover extracted DNA will be stored for future 
biomedic al research if the participant provides documented informed consent for future 
biomedical research .If the genetic sample collection is not approved, but future biomedical 
research is approved and consent is given, this sample will be collected for the pur pose of 
future biomedical research.
Future Biomedical Research Sample Collection 
If the participant provides documented informed consent for the biomedical research , the 
following specimens will be obtained as part of future biomedical research :
Leftover DNA for future research
Leftover main study tumor stored for future research
Leftover main study serum/ plasma from biomarker analyses stored for future 
research
Leftover main study RNA stored for future research
Leftover plasma or derivative for ctDNA
Medical Resource Utilization and Health Economics
All-cause hospi[INVESTIGATOR_264794], 
from the time of treatment allocation/randomization through 90 days following cessation of 
study treatment, or 30 days following cessation of study treatment, if the participant initiates 
new anti-cancer therapy, which ever is earlier.
Visit Requirements
Screening
Within 42 days prior to treatment allocation/randomization, potential participants will be 
evaluated to determine that they fulfill the entry requirements as set forth in Section 5. 
Screening procedures may be repeated after consultation with the Sponsor.
Documented informed consent must be obtained prior to performing any protocol -specific 
procedure. Results of a test performed prior to the participant providing documented 
informed consent as part of routine cl inical management are acceptable in lieu of a screening 
test if performed within the specified time frame. Screening procedures are to be completed 
within 42days prior to the first dose of study treatment except for the following:
Laboratory tests are to be performed within [ADDRESS_321982] dose of study 
treatment. An exception is hepatitis and/or HIV (if required by [CONTACT_264845]) testing 
which may be done up to [ADDRESS_321983] dose of study treatment.
Evaluation of ECOG is to be performe d within [ADDRESS_321984] dose of 
study treatment but before randomization (see Section 10.6) .
For women of reproductive potential, a urine or serum pregnancy test will be 
performed within [ADDRESS_321985]:   MK-3475 115
Protocol/Amendment No.:   789-[ADDRESS_321986] will be 
required (performe d by [CONTACT_79428]).
Archival tumor sample collection is not required to be obtained within 42days 
prior to the first dose of study treatment. Newly obtained tumor tissue may be 
obtained within 90 days of treatment initiation.
Participan ts may be rescreened after initially failing to meet the inclusion/exclusion 
criteria. Results from assessments during the initial screening period are acceptable in 
lieu of a repeat screening test if performed within the specified time frame and the 
corre sponding inclusion/exclusion criteria is met. Participants who are rescreened will 
retain their original screening number.
Initial Treatment Phase 
Visit requirements are outlined in the SoA (Section 1.3). Specific procedure -related details 
are provided in Section 8.1.
Crossover Treatment Phase
Participants who experience BICR-verified disease progression and are unblinded (Section 
1.2, Figure 3)will h ave the opportunity to crossover to receive pembrolizumab monotherapy . 
At the time of documented disease progression as confirmed by [CONTACT_54618] 1.1 
(Section 8.2.1 ), participants may have treatment assignment unblinded ( Figure 3). 
Participants who received saline placebo in combination with chemotherapy may be eligible 
to receive pembrolizumab monotherapy for a total of 35 administrations in the Crossover 
Treatment Phas e. 
Participants who received pembrolizumab in combination with chemotherapy, but are 
deemed to be benefiting clinically despi[INVESTIGATOR_264786], may continue study treatment 
beyond progression and receive pembrolizumab monotherapy in the Crossover Treatme nt 
Phase to complete a total of up to 35 pembrolizumab administrations. 
Study treatment may continue until participant reaches a discontinuation criterion (Section 
7.1), examples of which include subsequent documented progression, unacceptable adverse 
event(s), intercurrent illness that prevents further administration of treatment, investigator ’s
decision to withdraw the participant, participant withdraws consent, pregnancy of the 
participant, noncompliance with study treatment or procedure requirements, o r for 
administrative reasons.
Crossover Qualifications:
Participants will be considere dforcrossover topembrolizumab monotherapy after
documented, progressive disease assessed based onRECIST 1.1verified by [CONTACT_264846].Participants who permanently discontinue chemothera pyduetoanadverse 
event, withdraw consent ,orforanyreason other than progressive disease, willnotbeeligible 
forcrossover. Crossover participants must notinitiate treatment with pembrolizumab any
earlier than [ADDRESS_321987]:   MK-3475 116
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialCrossover isoptional andisatthediscretion of theInvestigator and with Sponsor 
consultation . Participants who meet thefollowing criteria are eligible for crossover :
Document ed verification of progressive disease by [CONTACT_19377] ;
Adverse events (except alopecia) due to therapy must have improved to CTCAE 
(Version 4.0) ≤Grade 1;
ECOG Performance Status 0 -1
Participa nt has not received anyother cytotoxic anticancer therapi[INVESTIGATOR_264795];
If required, completed palliative radiothera py(30Gyorless) ≥7days before
the first dose of crossover study treatment .
Participant has adequate organ function as indicated by [CONTACT_264847] 5.1(Inclusion Criteria) .
If progressive disease is centrally verified but participant does not qualify for Crossover per 
the above listed criteria ,unblinding may be considered after consulting with Sponsor.
NOTE: If a participant is clinically unstable as a result of a new or progressing CNS 
metastasis(es) the participant will not be eligible for crossover .
Crossover Assessments and Procedures
Crossover participants must notinitiate treatment with pembrolizumab any earlier than
21daysafter their lastdose ofchemothera py regardless ofthetime ofprogression. The
participant willthen start the Crossover Phase as outlined in Crossover Treatment Phase SoA 
inSection 1.3.2 . Crossover entry procedures need to be completed within 28 daysof 
confirmed progressive diseas e (or up to [ADDRESS_321988] dose if recovering from adverse 
event) . All procedures andassessments completed atthetime ofwithdrawal from theInitial 
Treatment Phase maybe used asappropriate forthestart oftheCrossov erTreatment Phase
ofthestudy. Thetumor imag eused to determine progressive disease canbeused asthe
new baseline image fortheCrossover Phase if:1)28daysprior toreceiving thefirst
dose ofpembrolizumab monotherap yand2)No studytreatment between theimage and
firstdoseofpembrolizumab monotherap y,otherwis eanew baseline image must be
performed prior topembrolizumab monothera py treatment.
Participants entering the Crossover Treatment Phase will be treated with pembrolizumab 
monotherapy. Chemotherapy will not be dosed in the Crossover Treatment Phase.
Pembrolizumab monotherapy will be dosed every 21 days ± 3 days (1 cycle). Treatment may 
continue until a discontinuation criterion is met (Section 7.1).
Second Cou rse Retreatment Phase
Seco nd Course Phase v isit requirements are outlined in the SoA (Section 1.3.3 ). Specific 
procedure -related details are provided in Section 8.1.
Participants who stop study treatment with a SD or better may be eligible for up to an 
additional 17 cycles (approximately 1 year) of pembrolizumab monotherapy treatment if they 
progress after stoppi[INVESTIGATOR_264796]. This retreatment is 
08FZ0N
Product:   MK-3475 117
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialtermed Second Course Phase and is only available if the study remains open and the 
participant meets the following conditions:
Either
Stopped initial treatment with study treatment after attaining an investigator -
determined confirmed CR based on RECIST 1.1, and
o Was treated w ith at least [ADDRESS_321989] 2 treatments with pembrolizumab beyond the date when the 
initial CR was declared
OR
Had SD, PR, or CR and stopped study treatment after completion of 35 
administrations (approximately 2 years) of study treatment for reasons other than 
disease progression or intolerability
AND , regardless of what is true above
Experienced an investigator -determined radiographic disease progression by
[CONTACT_393] 1.[ADDRESS_321990] dose of study 
treatment , and
o The participant meets all of the safety parameters listed in the inclusion criteria 
andnone of the safety parameters listed in the exclusion criteria, and 
o The study isongoing.
Participants who enter the Second Course Phase will be retreated with open -label 
pembrolizumab monotherapy . Chemotherapy will not be dosed in Second Course Phase.
Pembrolizumab will be dosed every 21 days (1 cycle) for up to 17 administrations
(approximately 1 year). Treatment may continue until a discontinuation criterion is met 
(Section 7.1).
An objective response or progression of disease that occurs during the Second Course Phase 
for a participant will not be counted as an event inthe primary analys es in this trial .
Participants Discontinued From Study Intervention but Continuing to be 
Monitored in the Study
All participants who discontinue study treatment prior to completion of the protocol -
specified treatment period will still continue to participate in the study as specified in Section 
1.3. 
Descriptions of the study follow -up visit s including required proce dures are provided in 
Section 8.11.[ADDRESS_321991]:   MK-3475 118
Protocol/Amendment No.:   789-[ADDRESS_321992] dose of study treatment andbefore the initiation of a new anti-cancer treatment. 
Participants w ho are eligible for crossover and/or retreatment with pembrolizum ab 
monotherapy may have up to 2safety follow -up visits; [ADDRESS_321993] every 12 weeks ±7days to 
monitor disease status , including tumor imaging . Follow -up Visits may be scheduled to 
coincide with Follow -up imaging (eg, [ADDRESS_321994] imaging if after Week 51). Follow -up visits and imaging continue 
until BICR -verified PD, the start of new an ti-cancer treatment, pregnancy, participant 
withdraws consent, participant becomes lost to follow -up,participant death , or end of the 
study .Participants who completed all efficacy assessments and/or will not have further 
efficacy assessments must enter t he Survival Follow -up Phase .
Participants discontinuing treatment with BICR -verified PD proceed directly to survival 
follow -up or Crossover Treatment Phase, if applicable. 
The Sponsor may request survival status to be assessed at additional time points du ring the 
course of the study (not to exceed approximately 12 weeks). Every effort should be made to 
collect information regarding disease status until disease pr ogression, death, end of study or 
if the participant begins Second Course R etreatment Phase with pembrolizumab as detailed 
in Section 8.11.[ADDRESS_321995] -study anticancer treatment will be collected if 
new treatment is initiated.
Participants who are eligible to receive retreatment with pembrolizumab according to the 
criteria in Secti on 8.11.4 will move from the Follow -Up Phase to the Second Course Phase 
when they experience disease progression. Details are provided in the Study Flow Chart 
(Section 1.2) for retreatment with pembrolizumab.
Survival Follow -upAssessments
Participants who experience BICR-verified disease progression will move into the Survival 
Follow -Up Phase and should be contact[CONTACT_13110] [ADDRESS_321996]. Survival status can be done in a variety of ways including phone, email, chart 
review, or review of public records . Survival status information (whether by [CONTACT_756], 
review of public records, etc.) should be officially documented by [CONTACT_779].
08FZ0N
Product:   MK-3475 119
Protocol/Amendment No.:   789-[ADDRESS_321997] survival follow -up assessment should be sc heduled as described below: 
For participants who discontinue treatment intervention and who will not enter the efficacy 
follow -up phase, the first survival follow -up assessment will be scheduled 12 weeks after the 
discontinuation visit and/or safety follo w-up visit (whichever is last).  
For participants who completed assessments in the efficacy follow -up phase, the first 
survival follow -up assessment will be scheduled [ADDRESS_321998] efficacy assessment 
follow -up visit has been performed.
Survival Status
To ensure current and complete survival data is available at the time of database locks, 
updated survival status may be requested during the course of the study by [CONTACT_1034]. For 
example, updated survival status may be requested prior to but not limited to an external Data 
Monitoring Committee (eDMC) review, interim and/or final analysis. Upon Sponsor 
notification, all participants who do not/will not have a scheduled study visit or study contact 
[CONTACT_264848] (excluding 
participants that have a previously recorded death event in the collection tool). Survival 
status can be done in a variety of ways including phone, email, chart review, or review of 
public records. Survival status information (whether by [CONTACT_756], review of public records, 
etc.) should be officially documented by [CONTACT_779].
9.Statistical Analysis Plan 
This section outlines the statistical analysis strategy and procedures for the study. If, after the 
study has begun, changes made to primary and/or key secondary hypotheses, or the statistical 
methods related to those hypotheses, then the protocol will be amended (consistent with ICH 
Guideline E -9). Changes to exploratory or other non -confirmatory analyses made after th e 
protocol has been finalized, will be documented in a supplemental Statistical Analysis Plan
(sSAP) and referenced in the Clinical Study Report (CSR) for the study. Post hoc exploratory 
analyses will be clear ly identified in the CSR. Separate analysis pla ns (ie,separate 
documents from the sSAP) may be developed to detail other planned analyses ( ie,those 
specific to the analysis of patient -reported outcomes and future biomedical research) . 
08FZ0N
Product:   MK-3475 120
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Statistical Analysis Plan Summary
Key elements of the statistical analysis plan are summarized below; the comprehensive plan 
is provided in Sections 9.2to 9.11.  
Study Design Overview A Randomized, Double -Blind, Phase 3 Study of Pemetrexed + Platinum 
Chemotherapy with or without Pembroli zumab (MK -3475) in TKI -
resistant EGFR -mutated Tumors in Metastatic Non -squamous Non -small 
Cell Lung Cancer (NSCLC) Participants (KEYNOTE -789)
Treatment Assignment Participants will be randomized in a 1:1 ratio to receive pembrolizumab 
or saline placebo in combination with pemetrexed plus platinum 
chemotherapy, with pemetrexed maintenance . Stratification factors are in 
Section [IP_ADDRESS] . This is a randomized double -blinded study.
Analysis Populations Efficacy: Intentio ntoTreat(ITT)
Safety: AllParticipants asTreated (APaT)
Primary Endpoint(s) 1)Progressio n-free Survival (PFS )perRECIST 1.1assessed by
[CONTACT_19377]
2)Overall survival (OS)
Key Secondary Endpoints 1)Objective response rate (ORR) per RECIST 1.[ADDRESS_321999]. The HRwill be estimated 
using a stratified Cox regression model. Event r ates over time will be 
estimated within each treatment group using the Kaplan -Meier method. 
The stratified M&N method with sample size weights will be used for 
analysis of ORR.
Statistical Methods for Key 
Safety AnalysesThe analysis of safety results will follow a tiered approach. There are no 
Tier 1 safety parameters in this trial. All safety parameters are considered 
either Tier 2 or Tier 3. Tier 2 parameters will be assessed via point 
estimates with 95% confidence intervals provided for betw een-group 
comparisons; only point estimates by [CONTACT_264849] 3 safety parameters. The between -treatment difference will be 
analyzed using the Miettinen and Nurminen method.
In the primary safety comparison, participant s who crossover to 
pembrolizumab monotherapy are censored at time of crossover ( ie,AEs 
occurring during treatment with pembrolizumab are excluded for 
control -arm participant s). Additional safety summary may be conducted 
for the crossover population includ ing all safety events starting from the 
date of the first dose of pembrolizumab. Safety data from the Second 
Course Treatment Phase will be summarized separately and will not be 
included in the primary safety comparison.
08FZ0N
Product:   MK-3475 121
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialInterim Analyses Three interim analyses willbe performed in this study. Results will be 
reviewed by [CONTACT_4617]. The primary purpose 
of the interim analyses is to demonstrate superior efficacy. Safety data will 
also be reviewed at each planned interim analysis to assess the overall risk: 
benefit. These interim analyses and the FAare summarized below. Details 
are provided in Section 9.7. 
IA 1: 
oTiming: To be performed at approximately [ADDRESS_322000] participant hasbeen randomized (estimated ~ 30months 
after the first participant randomized)
oTesting: 1) To demonstrate superiority of pembrolizumab in 
combination with platinum and pemetrex ed in PFS; 2) To 
demonstrate superiority of pembrolizumab in combination 
with platinum and pemetrexed in OS .
IA 2 (Final PFS analysis) :
oTiming: To be performed ~[ADDRESS_322001] been observed (estimated ~ 40months 
after the first participant randomized ).
oTesting: 1) To demonstrate superiority of pembrolizumab in 
combination with platinum and pemetrexed in PFS; 2) To 
demonstrate superiority of pembrolizumab in combination 
with platinum and pemetrexed in OS .
IA 3:
oTiming: To be performed at ~29months after the last 
participant has been randomized (estimated ~ 53months after 
the first participant randomized) .
oTesting: To demonstrate superiority of pembrolizumab in 
combination with platinum and pemetrexed in OS .
FA:
oTiming: To be performed at~42months after the last 
participant has been randomized AND approximately
423deaths have occurred (estimated ~ 66months after the 
first participant randomized).
oTesting: To demonstrate superiority of pembrolizumab in 
combination with platinum and pemetrexed in OS .
Note that for the FA, if the OS events accrue slower than expected
such that the targeted number of eve nts cannot be reached in the 
anticipated timeframe , the Sponsor may conduct the analysis with 
approximately 2additional months of follow -up, or when the specified 
number of events is observed, whichever occurs first . If the observed 
number of OS events at the time of IA3 is very close to the target 
number of events at FA(if more than ~98% info rmation fraction, ie,
~415 OS events), then IA3 will becom e the FAusing the remaining 
alpha that has not been spent at the earlier analyses , and will be 
performed at ~[ADDRESS_322002]:   MK-3475 122
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialMultiplicity The study uses an extension of the graphical method of Maurer and Bretz 
[Maurer, W. and Bretz, F. 2013] to control multiplicity for multiple 
hypotheses as well as interim analyses. According to this approach, study 
hypotheses may be tested more than once, and when a particular null 
hypothesis is rejected, the alpha allocated to that hypothesis can be 
reallocated to other hypothesis tests. The overall type I error is controlled 
at 0.025 (one -sided) for the hypothesis testing of ORR, PFS and OS. The 
pre-allocated alpha is 0, 0.0125and 0. 0125for ORR, PFS,and OS, 
respectively.
Sample Size and Power The planned sample size is 492participant s assuming 24months of 
enrollment. The FAwill occur after approximately 423deaths have been 
observed. With 492 participants , the study has ~86% power to detect a 
HR of 0.7 2on OS at 0.0 125(one-sided) alpha -level, and ~91% power to 
detect a HR of 0. 7on PFS at 0. 0125(one-sided) alpha -level .
Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the 
Clinical Biostatistics department of the Sponsor .
The Sponsor will generate the randomized allocation schedule(s) for study treatment
assignment for this protocol, and the randomization will be implemented in IVRS .
This trial is double blinded with a Crossover Phase. At the time of documented progression, 
participant s may have treatment assignment unblinded and be able to continue thera py in the 
Crossover Phase (please refer to Section 4,Study Design for details). In addition, the BICR
will be perform ed by [CONTACT_264850].
Blinding issues related to the planned interim analyses are described in Section 9.7 .  
Hypotheses/Estimation
Objectives and hypotheses of the study are stated in Section 3.
Analysis Endpoints
Efficacy and safety endpoints that will be evaluated for within -and/or between -treatme nt 
differences are list ed below .
Efficacy Endpoints
Dual Primary
Progression -free survival (PFS) –RECIST 1.1 assessed by [CONTACT_264851] -free-survival (PFS) is defined as the time from randomization to the first 
documented disease progression per RECIST 1.[ADDRESS_322003]:   MK-3475 123
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialOverall Survival
Overall Survival (OS) is defined as the time from randomization to death due to any cause. 
Participant s without documented death at the time of analysis will be censored at the date of 
last known contact. 
Secondary
Objective response rate (ORR) –RECIST 1.1 assessed by [CONTACT_264852] (ORR) is defined as the proportion of participant swho have a CRor 
a partial response (PR). Responses are based on confirmed assessments by [CONTACT_264853] 1.1.
Duration of Response (DOR) –RECIST 1.1 assessed by [CONTACT_264854] s who demonstrated CR or PR, duration of response (DOR) is defined as the 
time from first documented evidence of CR or PR until disease progression or d eath. 
Response duration for participant s who have not progressed or died at the time of analysis 
will be censored at the date of their last tu mor assessment. Response duration will be 
calculated for RECIST 1.1 based on BICR by [CONTACT_260492] .
Safety Endpoints
Safety measurement s are described in Section [IP_ADDRESS] .
PRO Endpoints
The secondary patient -reported outcome ( PRO )endpoints include the global health 
status/quality of life scale of the QLQ -C30 (items 29 and 30) and TTD in the composite 
endpoint of cough (LC13 Q1), chest pain (LC13 Q10) or dyspnea (C30 Q8). The TTD is
defined as the time from baseline to first onset of 10 points or more deterioration from 
baseline with confirmation by [CONTACT_19465] 10 points or more deterioration from 
baseline in any of the 3 items .  
Additional scales of EORTC QLQ -C30, EORTC QLQ -LC13, and EQ -5D-5L are exploratory 
PRO endpoi nts as described in Section 3and will also be evaluated. Details will be provided 
in the sSAP.
Analysis Populations
Efficacy Analysis Populations
The Intention -to-Treat (ITT) population will serve as the population for primary efficacy 
analysis. All randomized participant s will be included in this population. Participant s will be 
included in the treatment group to which they are randomized.
Safety A nalysis Populations
The All Participant s as Treated ( APaT) population will be used for the analysis of sa fety data 
in this study. The AP aT population consists of all randomized participant s who received at 
least one dose of study treatment. Participant s will be included in the treatment group 
corresponding to the study treatment they actually received for the analysis of safety data 
using the APaT population. For most participant s this will be the treatment group to which 
08FZ0N
Product:   MK-3475 124
Protocol/Amendment No.:   789-[ADDRESS_322004] treatment for all other cycles will be analyzed according to the 
participant ’s randomized treatment group and a narrative will be provided for any events that 
occur during the cycle for which the participant was incorrectly dosed. 
At least one labora tory or vital sign measurement obtained subsequent to at least one dose of 
study treatment is required for inclusion in the analysis of each specific parameter. To assess 
change from baseline, a baseline measurement is also required.
PRO Analysis Populati ons
The PRO analyses are based on the PRO full analysis set (FAS) population, defined as 
participants who have at least one PRO assessment available and have received at least one 
dose of study medication.
Statistical Methods
Statistical testing and inference for safety analyses are described in Section 9.6.[ADDRESS_322005] ess the primary and secondary 
objectives. Methods related to exploratory objectives will be described in the supplemental 
SAP.
All statistical tests, unless otherwise specified, will be stratified for the stratification factors .
Progression -free Survival ( PFS)
The non -parametric Kaplan -Meier method will be used to estimate the PFS curve in each 
treatment group. The treatment difference in PFS will be assessed by [CONTACT_113821] -rank 
test (based on the stratif ication factors defined in Section [IP_ADDRESS] ). Astratified Cox 
proportional hazard model with Efron's method of tie handling will be used to assess the 
magnitude of the treatment difference ( ie,HR) between the treatment arms. The HRand its 
95% confidence interval from the stratified Cox model with Ef ron's method of tie handling 
and with a single treatment covariate will be reported. The stratification factors used for 
randomization (See Section [IP_ADDRESS] )will be applied to both the stratified log -rank test and the 
stratified Cox model. 
Since disease p rogression is assessed periodically, progressive disease (PD) can occur any 
time in the time interval between the last assessment where PD was not documented and the 
assessment when PD is documented. The true date of disease progression will be 
approximate d by [CONTACT_193440] 1.[ADDRESS_322006]:   MK-3475 125
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialassessment. Sensitivity analyses will be performed for comparison of PFS based on 
investigator's assessment.
In order to evaluate the robustness of the PFS endpoint per RECIST 1.1 via BICR b y the 
imaging vendor , one primary and 2sensitivity analyses with a different set of censoring rules
will be performed . For the primary analysis, if the events (PD or death) are immediately after 
more than one missed disease assessment, the data are censored at the last disease assessment 
prior to missing visits. Also data after new anti -cancer therapy are censored at the last disease 
assessment prior to the initiation of new anti -cancer therapy. The first sensitivity analysis 
follows intention -to-treat principle s. That is, PDs/deaths are counte d as events regardless of 
missed study visits or initiation of new anti -cancer therapy . For t he second sensitivity 
analysis ,it considers discontinuation of treatment or initiation of an anti-cancer treatment 
subsequent to discontinuation of study -specifie d treatments, whichever occurs later, to be a 
PD event for participant s without documented PD or death. If a participant meets multiple 
criteria for censoring, the censoring criterion that occurs earliest will be applied. The 
censoring rules for primary an d sensitivity analyses are summarized in Table 10.
Table 10 Censoring Rules for Primary and Sensitivity Analyses of Progression -free 
Survival
Situation Primary Analysis Sensitivity Analysis 1 Sensitivity Analysis 2
Progressive disease 
(PD)or death 
documented after ≤ 1 
missed disease 
assessment; and before 
new anti -cancer 
therapy, if anyProgressed at date of 
documented PD or deathProgressed at date of 
documented PD or deathProgressed at date of 
documented PD or death
PD or death 
documented 
immediately after ≥[ADDRESS_322007] disease 
assessment prior to 
theearlier date of  ≥ 2 
consecutive missed 
disease assessment and 
new anti -cancer therapy, if 
anyProgressed at date of 
documented PD or deathProgressed at date of 
documented PD or death
No PD and no death; 
and new anti-cancer
treatment is not 
initiatedCensored at last disease 
assessment Censored at last disease 
assessment Progressed at treatment 
discontinuation due to 
reasons other than complete 
response; otherwise 
censored at last disease 
assessment if still on study 
or completed study 
treatment
No PD and no death; 
new anti-cancer
treatment is initiatedCensored at last disease 
assessment before new 
anti-cancer treatmentCensored at last disease 
assessment Progressed at date of new 
anti-cancer treatment
In case the proportional hazards assumpti on is not valid, supportive analyses using Restricted 
Mean Survival Time (RMST) method may be conducted for PFS to account for the possible 
non-proportional hazards effect.
Further details of sensitivity analyses will be described in sSAP as needed.
08FZ0N
Product:   MK-3475 126
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Overal l Survival (OS)
The non -parametric Kaplan -Meier method will be used to estimate the survival curves. The 
treatment difference in survival will be assessed by [CONTACT_113821] -rank test (based on the 
stratification factor defined in Section [IP_ADDRESS] ). A st ratified Cox proportional hazard model 
with Efron's method of tie handling will be used to assess the magnitude of the treatment 
difference ( ie,the HR). The HRand its 95% confidence interval from the stratified Cox 
model with a single treatment covariate will be reported. The stratification factors used for 
randomization (See Section [IP_ADDRESS] ) will be applied to both the stratified log -rank test and the 
stratifi ed Cox model. The Restricted Mean Survival Time (RMST) method may be 
conducted for OS to account for the possible non -proportional hazards effect and to estimate 
the absolute benefit of experimental treatment. Acure rate model may be applied to estimate 
the long -term effect.
Since participant s in the control arm are allowed to switch to the pembrolizumab treatment 
after progressive disease, adjustment for the effect of crossover on OS may be performed 
based on recognized methods, eg,a two -stage method or the Rank Preserving Structural 
Failure Time (RPSFT) model, based on an examination of the appropriateness of the data to 
the assumptions required by [CONTACT_264855].
Further details of sensitivity analyses will be described in sSAP as needed.
Objective Response Rate (ORR) and Duration of Response (DOR)
The stratified Miettinen and Nurminen method will be used for the comparison of the ORR 
between the 2treatment groups. The difference in ORR and its 95% confidence interval from 
the stratified M iettinen and Nurminen method with strata weighting by [CONTACT_264856]. The stratification factors used for randomization (See Section [IP_ADDRESS] ) will be 
applied to the analysis.
If sample size permits, DOR will be summarized descriptively using Kaplan -Meier medians 
and quartiles. Only the subset of participant s who show a confirmed complete response or 
partial response will be included in this analysis. Censoring rules for DOR are summarized in 
Table 11. 
For each DOR analysis, a corresponding summary of the reasons responding participants are 
censored will also be provided. Responding participants who are alive, have not progressed, 
have not initiated new anti -cancer treatment, have not been determined to be lost to 
follow -up, and have had a disease assessment within ~[ADDRESS_322008]:   MK-3475 127
Protocol/Amendment No.:   789-[ADDRESS_322009] adequate disease assessment Censor
(non-event)
No progression nor death, new anti -cancer 
therapy initiatedLast adequate disease assessment before new anti -
cancer therapy initiatedCensor
(non-event)
Death or progression immediately after ≥[ADDRESS_322010] adequate disease assessment 
prior to ≥2 missed adequate disease assessments 
and new anti -cancer therapy, if anyCensor
(non-event)
Death or progression af ter ≤1 missed disease 
assessments and before new anti -cancer 
therapy, if anyPD or death End of response
(event)
A missed disease assessment includes any assessment that is not obtained or is considered inadequate for evaluation of 
response.   
Analysis Strategy for Key Efficacy Endpoints
Theprimary analysis approach for the primary and key secondary efficacy endpoints are 
summarized in Table 12. Sensitivit y analysis methods are described above for each endpoint 
as applicable.
The strategy to address multiplicity issues with regard to multiple efficacy endpoints, and 
interim an alyses is described in Section 9.7, Interim Analyses and in Section 9.8,
Multiplic ity.
Table 12 Analysis Strategy for Key Efficacy Variables
Endpoint/Variable
(Description, Time Point)Statistical Method† Analysis 
PopulationMissing Data Approach
Dual Primary Endpoints
PFS per RECIST 1.1 by [CONTACT_193400] 
(BICR) by [CONTACT_264857]: Stratified Log -rank test 
to assess the treatment 
difference
Estimation : Stratified Cox 
model with Efron’s tie 
handling method to assess the 
magnitude of treatment 
differenceITTPrimary censoring rule
Sensitivity analysis 1
Sensitivity analysis [ADDRESS_322011]: Stratified Log -rank test 
to assess the treatment 
difference
Estimation : Stratified Cox 
model with Efron’s tie 
handling method to assess the 
magnitude of treatment 
differenceITTModel based
(censored at the last date the 
participant was known to be 
alive)
08FZ0N
Product:   MK-3475 128
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialEndpoint/Variable
(Description, Time Point)Statistical Method† Analysis 
PopulationMissing Data Approach
Key Secondary Endpoints
ORR per RECIST 1.1 by [CONTACT_193400] 
(BICR) by [CONTACT_264858] : Stratified 
M&N method with sample 
size weights††ITTParticipant s without 
assessments are considered 
non-responders and 
conservatively included in 
denominator
DOR per RECIST 1.1 by [CONTACT_193400] 
(BICR) by [CONTACT_264859] -Meier estimate of 
medianParticipant s in ITT 
population with an 
objective response
  †Statistical models are described in further detail in the text. For stratified analyses, the stratification factors used for 
randomizat ion (Section [IP_ADDRESS] )will be applied to the analysis.
††Miettinen and Nurminen method
Abbreviations: DOR=duration of response; ITT=intention -to-treat; ORR=objective response rate; OS=overall survival; 
PFS=progression -free survival; RECIST=Response Evaluation Criteria in Solid Tumors 1.1; 
Statistical Methods for Safety Analyses
Safety and tolerability will be assessed by [CONTACT_113824], laboratory tests and vital signs. In the primary safety comparison, participants who 
crossover to pembrolizumab monotherapy are censored at time of crosso ver (ie, AEs 
occurring during treatment with pembrolizumab are excluded for control -arm participants). 
Additional safety summary may be conducted for the crossover population including all 
safety events starting from the date of the first dose of pembroliz umab. Safety data from the 
Second Course Treatment Phase will be summarized separately and not be included in the 
primary safety comparison.
Adverse Events
Adverse events will be coded using the standard MedDRA and grouped system organ class. 
Adverse events will be graded by [CONTACT_264860] (CTCAE), version 4.0.
Tiered Approach
The analysis of safety results will follow a tiered approach ( Table 13). The tiers differ with 
respect to the analyses that will be performed. Adverse experiences (specific terms as well as 
system organ class terms) and events that meet predefined limits of change in la boratory and
vital signs parameters are either pre-specified as Tier -1 endpoints , orwill be classified as 
belonging to "Tier 2" or "Tier 3", based on the number of events observed.  
Tier [ADDRESS_322012] that are identified a priori 
constitute “Tier 1” safety endpoints that will be participant to inferential testing for statistical 
significance with p values and 95% confidence intervals to be provided for between -
treatment comparisons. For this protocol, there are no Tier 1 events.  
Tier 2 Events
Tier 2 parameters will be assessed via point estimates with 95% confidence intervals 
provide d for between -treatment differences in the proportion of par ticipants with events .
08FZ0N
Product:   MK-3475 129
Protocol/Amendment No.:   789-[ADDRESS_322013] 10% of participants in any treatment group exhibit 
the event. The threshold of at least 10% participant s was chosen because patient population 
enrolled in this study are in critical condit ions and usually experience various adverse events 
of similar types regardless of treatment, events reported less frequent than 10% of 
participant s would obscure the assessment of overall safety profile and add little to the 
interpretation of potentially m eaningful treatment differences. Because many 95% 
confidence intervals may be provided without adjustment for multiplicity, the confidence 
intervals should be regarded as a helpful descriptive measure to be used in review, not a 
formal method for assessing the statistical significance of the between -group differences in 
adverse experiences and safety parameters that meet predefined limits of change.
In addition to individual events that occur in ≥10% or more participants in any treatment 
group, the broad AE categories consisting of the proportion of participants with Grade 3 to 5 
AEs ( ≥2%of participants in 1 of the treatment groups) and SAEs ( ≥2%of participants in 1 of 
the treatment groups) will be considered Tier 2 endpoints. The 95% confidence int ervals will 
be provided for between -treatment differences in the percentage of participant s with events; 
these analyses will be performed using the Miettinen and Nurminen method, an 
unconditional, asymp totic method .
Tier [ADDRESS_322014]:   MK-3475 130
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialTable 13 Analysi s Strategy for Safet y Parameters
Safety 
TierSafety Endpoint95% CI for 
Treatment 
ComparisonDescriptive Statistics
Tier 2 Grade 3 to 5 AE (incidence ≥2% of participants in one of the 
treatment groups)X X
Serious AE (incidence ≥2% of participants in one of the 
treatment groups)X X
AEs (incidence ≥10% of participants in one of the treatment 
groups)X X
Tier 3 Any AE X
Any Grade 3 to 5 AE X
Any Serious AE X
Any Drug -related AE X
Any Serious and Drug -related AE X
Any Grade 3 to 5 and Drug -related AE X
Discontinuation due to AE X
Death X
Specific AEs, SOCs (incidence <10% of participants in all 
of the treatment groups)X
Change from baseline results (lab toxicity shift) X
AE=adverse event; CI=confidence interval; SOC=system organ class.
Statistical Methods for PRO Analyses
To assess change from baseline inthe EORTC QLQ -C30 global health status/QoL scale 
score (items 29 and 30), theconstrained longitudinal data analysis (cLDA) mode lwill be 
applied for treatment comparison of pembrolizumab + chemotherapy versus saline placebo + 
chemotherapy . The response variable consists of baseline values and the values observed at 
each pre specified post -baseline time point for primary analysis. T he model will be adjusted 
fortreatment by [CONTACT_264861]. Least square mean 
change from baseline will be summarized.
The Kaplan -Meier method will be used to estimate the TTD survival curve for the composite 
endpoint of cough (LC13 Q1), chest pain (LC13 Q10) ordyspnea (QC30 Q8) in each 
treatment group. The TTD is defined as the time to the fir st onset of [ADDRESS_322015] pain, or dyspnea from baseline with confirmation by [CONTACT_19378] 10 points or more deterioration from baseline in any of these 3symptoms. 
A str atified Cox PH model with Efron's method of tie handling will be used to assess the 
magnitude of the treatment difference for the pembrolizumab + chemotherapy a nd saline 
placebo + chemotherapy regimen. Stratification factors used for randomization will be used 
in the stratified Cox PH model.
Details of additional PRO analyses will be included in the sSAP.
08FZ0N
Product:   MK-3475 131
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Summaries of Baseline Characteristics, Demographics, and Other Analyses
Demographic and Baseline Characteristics
The comparability of the treatment groups for each relevant demographic and baseline
characteristic will be assessed by [CONTACT_113827]/or graphs. No statistical hypothesis 
tests will be performed on these characteristics. The number and percentage of participant s 
screened, randomized, the primary reasons for screening failure, and the primary reason for 
discontinuation will be displayed. Demographic variables (eg,age, gender) ,baseline 
characteristics, and prior and concomitant therapi[INVESTIGATOR_264797].
Interim Analyses
An external data monitoring committee (eDMC) will be convened to review the unblinded 
efficacy results and accumulating safety at the planned interim analyses. An external 
unblinded statistician and programmer will be responsible for conducting and presenting the 
interim analyses results to the eDMC. The eDMC responsibilities and review sched ules will 
be outlined in the eDMC charter. The recommendation of the eDMC will be communicated 
to an executive oversight committee of the Sponsor. In the event of a recommendation to halt 
the trial early due to safety concerns, the Sponsor will communicate this to the appropriate 
regulatory agencies. If the eDMC recommends modifications to the design of the protocol or 
discontinuation of the study, this executive oversight committee may be unblinded to results 
at the treatment level in order to act on these recommendations.
A limited number of additional Sponsor personnel may be unblinded, if required, in order to 
act on the recommendations of the eDMC. The extent to which individuals are unblinded to 
the results will be documented. Additional logistical det ails, revisions to the above plan and 
data monitoring guidance will be provided in the eDMC Charter .
Efficacy Interim Analyses
Three IAsare planned in addition to the FAfor this study. For the interim and final analyses, 
all randomized participants will be included. The primary purpose of the IAs is to 
demonstrate superior efficacy. Safety data will also be reviewed at each planned IAto assess 
the overall risk: benefit. Details on the b oundaries for establishing statistical significance 
with regard to efficacy are discussed further in Section 9.8. The trial will continue until the 
number of deaths ( see Section 9.9) is approximately equal to the targeted number for the FA, 
irrespective of the outcome from the IAs. 
The analyses planned, endpoints evaluated, and drivers of timing are summarized in 
Table 14.
08FZ0N
Product:   MK-3475 132
Protocol/Amendment No.:   789-[ADDRESS_322016] 
Participant RandomizedPrimary Purpose of 
Analysis
IA1 PFS
OS~6 month safter the 
lastparticipant has
been randomized .~30months  Demonstrate PFS 
superiority
Demonstrate OS  
superiority
IA2(Final 
PFS 
Analysis)PFS
OS~[ADDRESS_322017] 
been observed.~40 months Demonstrate PFS 
superiority
Demonstrate OS  
superiority
IA3 OS ~29 months after the 
lastparticipant has
been randomized .~53months Demonstrate OS  
superiority
FA OS ~[ADDRESS_322018] 
occurred for the final 
OS analysis.~66 months Demonstrate OS 
superiority
Note: For the final analysis , if the events accrue slower than expected such that the targeted number of events 
cannot be reached in the anticipated timeframe , the Sponsor may conduct the analysis with approximately [ADDRESS_322019]. If 
the observed number of OS events at the time of IA3 is very close to the target number of events at final 
analysis (if more than ~98% info rmation fraction, ie ,~415 OS events), then IA3 will become the final analysis
using the remaining alpha that has not been spent at the earlier analys es,andwill be performed at ~[ADDRESS_322020] occurred .
FA=final analysis; IA=interim analysis; ORR=objective response rate; OS=overall survival; PFS=progression -
free survival.
Safety Interim Analyses
Accumulating safety data will be reviewed approximately every [ADDRESS_322021] 
participant is randomized. Interim safety analyses will also be performed at each planned IA
described in S ection 9.7.1 to assess the overall risk: benefit. Further details on the timing of 
safety monitoring will be specified in the eDMC charter .
Multiplicity
The trial uses an extension of the graphical method of Maurer and Bretz [Maurer, W. and 
Bretz, F. 2013] to provide strong multiplicity control for multiple hypotheses while making 
the interim and final analysis timing be more flexible [Anderson and Gause, manuscript 
submitted] . According to Maurer and Bretz approach, study hypotheses may be tested in a 
group sequential fashion , and when a particular null hypothesis is rejected, the alpha 
allocated to that hypothesis can be reallocated to other hypothesis tests. The extended 
graphical method spends a lpha as a function of the minimum of the actual event information 
fraction and the expected event information fraction. This en sures that spending will be no 
more aggressive than the information fraction method, while at the same time ensuring not 
08FZ0N
Product:   MK-3475 133
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialall alpha is spent prior to final planned analysis calendar time .Figure 6shows the initial one -
sided alpha allocation fo r each hypothesis in the ellipse representing the hypothesis. The 
weights for reallocation from each hypothesis to the others are represented in the boxes on 
the lines connecting hypotheses.
Note: If both PFS and OS null hypotheses are rejected, the rea llocation strategy allows re -testing of ORR at alpha=0.025 based on the 
p-value at IA1
ORR=objective response rate; OS=overall survival; PFS=progression -free survival
Figure 6Type I Error Reallocation Strategy
Objective Response Rate
The study does not allocate initial alpha to ORR. ORR will be formally tested only if the 
hypotheses for PFS and /orOS issignificant. The testing of ORR will be based on all 
randomized subjects. If the null hypotheses for OS and PFS are reje cted at IA1 or at a time 
later than IA1, the p -value of ORR from the IA1 analysis will be compared to theαlevel 
passed to ORR from PFS and/or OS .Power at the possible alpha -levels as well as the 
approximate treatment difference required to reach the bou nd (ORR difference) are shown in
Table 15assuming underlying 34% and 5 4% response rates in the control and experimental 
groups, respectively. 
08FZ0N
Product:   MK-3475 134
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialTable 15 Possible Alpha -levels and Approximate Objective Response Rate (ORR)
Difference Required to Demonstrate Efficacy for ORR at Interim Analysis 1
Alpha ORR difference Power
0.0000125 ~0.19 0.60
0.025 ~0.09 0.99
Progression -Free Survival 
The PFS hypothesis may be tested at alpha =0.0125(initially allocated alpha), or 
alpha= 0.0249875 (if OS null hypothesis is rejected ),or alpha= 0.025 (if both OS and ORR 
null hypothesis arerejected ).Table 16shows the boundary properties for each of these alpha -
levels, which were derived using a Lan -DeMets O'Brien -Fleming spending fu nction based on 
predicted number of events at the planned time of interim analysis . Note that the final row 
indicates the total power to reject the null hypothesis for PFS at each alpha -level. Also n ote 
that if the OS null hypothesis is rejected at an interim or final analysis, each PFS interim and 
final analysis test may be compared to its updated bounds considering the alpha reallocation 
from the OS hypothesis.
Table 16 Efficacy Boundaries and Properties for Progression -free Survival Analyses
Analysis Value =0.0125 =0.0249875 =0.025
IA1: 88%*
N: 492
Events: 367
Month: 30Z 2.4121 2.1158 2.1155
p (1-sided)§0.0079 0.0172 0.0172
HR at bound0.7772 0.8017 0.8017
P(Cross) if HR=1†0.0079 0.0172 0.0172
P(Cross) if HR=0. 7#0.8435 0.9038 0.9038
IA2: 100%*
N: 492
Events: 4 14
Month: 40Z 2.3169 2.0491 2.0489
p (1-sided)§0.0103 0.0202 0.0202
HR at bound0.7963 0.8176 0.8176
P(Cross) if HR=1†0.0125 0.0250 0.025
P(Cross) if HR=0. 7#0.9135 0.9492 0.9492
*Percentage of expected number of events at FA
§p (1-sided) is the nominal alpha for testing.
HRat bound is the approximate HR required to reach an efficacy bound
†P(Cross if HR=1) is the cumulative probability of crossing a bound under the null hypothesis
#P(Cross if HR=0. 7) is the cumulative probability of crossing a bound under the alternative hypothesis
Abbreviation s: FA=final analysis; HR=hazard ratio ; IA=interim analysis .
The bounds provided in the table above are based on the assumption that the expected 
number of events at IA 1and IA2are 367and [ADDRESS_322022]:   MK-3475 135
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialfunction to determine the alpha spending at the IA will be based on the minimum of the 
expected information fraction and the actual information fraction at each analysis. 
Specifically :
In the scenario that the events accrue slower than expected and the observed number of 
events is less than the expected number of events at a given analysis, the information 
fraction will be calculated a s the observed number of events at the IAover the target 
number of events at FA. 
In the scenario that the events accrue faster than expected and the observed number of 
events exceeds the expected number of events at a given analysis, then the information
fraction will be calculated as the expected number of events at the IAover the target 
number of events at FA.
The FAwill use the remaining Type I error that has not been spent at the earlier analyses. 
The event counts for all analyses will be used to co mpute correlations.
Ofnote, while the information fraction used for alpha spending calculation will be the 
minimum of the actual information fraction and the expected information fraction, the 
correlations required for deriving the bounds will still be computed using the actua l 
information fraction based on the observed number of events at each analysis over the target 
number of events at FA.
The minimum spending approach assumes timing is not based on any observed Z -value and 
thus the Z test statistics used for testing conditi oned on timing are multivariate normal. Given 
the probabilities derived with the proposed spending method, the correlations based on actual 
event counts are used to compute bounds that control the Type I error at the specified alpha 
level for a given hypot hesis conditioned on the IAtiming. Since this is true regardless of 
what is conditioned on, the overall Type I error for a given hypothesis is unconditionally 
controlled at the specified level. By [CONTACT_264862], 
power can be retained to detect situations where the treatment effect may be delayed.
Overall Survival
The OS hypoth esis may be tested at alpha=0.0 125(initially allocated alpha), or 
alpha=0. 0249875 (if the PFS null hypothesis is rejected) or alpha=0. 025 (if both the PFS and 
ORR null hypothesis are rejected) . Table 17demonstrates the bounds and boundary 
properties for OS hypothesis testing derived usi ng a Lan -DeMets O'Brien -Fleming spending 
function based on predicted number of events at the planned time of interim analysis .Note 
that if the PFS null hypothesis is rejected at an interim or final analysis, each OS int erim and 
final analysis test may be compared to its updated bounds considering the alpha reallocation 
from the PFS hypothesis.
08FZ0N
Product:   MK-3475 136
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialTable 17 Efficacy Boundaries and Properties for Overall Survival Analyses
Analysis Value =0.0125 =0.0249875 =0.025 
IA1: 57%*
N: 492
Events: 242
Month: 30Z 3.1029 2.7437 2.7434
p (1-sided)§0.0010 0.0030 0.0030
HR at bound 0.6710 0.7027 0.7027
P(Cross) if HR=1†0.0010 0.0030 0.0030
P(Cross) if HR=0.7 2#0.2938 0.4269 0.4270
IA2: 76%*
N: 492
Events: 321
Month: 40Z 2.6699 2.3635 2.3632
p (1-sided)§0.0038 0.0091 0.0091
HR at bound 0.7420 0.7678 0.7678
P(Cross) if HR=1†0.0041 0.0100 0.0100
P(Cross) if HR=0.7 2#0.6135 0.7254 0.7254
IA 3: 91%*
N: 492
Events: 385
Month: 53Z 2.4311 2.1545 2.1542
p (1-sided)§0.0075 0.0156 0.0156
HR at bound 0.7804 0.8028 0.8028
P(Cross) if HR=1†0.0088 0.0187 0.0188
P(Cross) if HR=0.7 2#0.7959 0.8666 0.8666
FA: 100%*
N: 492
Events: 423
Month: 66Z 2.3405 2.0788 2.0786
p (1-sided)§0.0096 0.0188 0.0188
HR at bound 0.7964 0.8170 0.8170
P(Cross) if HR=1†0.0125 0.0250 0.0250
P(Cross) if HR=0.7 2#0.8644 0.9147 0.9147
*Percentage of expected number of events at FA
§p (1-sided) is the nominal α for testing.
HR at bound is the approximate HR required to reach an efficacy bound
†P(Cross if HR=1) is the cumulative probability of crossing a bound under the null hypothesis
#P(Cross if HR=0.7 2) is the cumulative probability of crossing a bound under the alternative hypothesis
Abbreviations: FA=final analysis; HR=hazard ratio; IA=interim analysis.
The bounds provided in the table above are based on the assumption that the expected 
number of events at IA 1, IA2, IA3 ,and FA are 242, 321, [ADDRESS_322023] reasonable alpha for the FA, the 
minimum alpha spending strateg y will be implemented for OS in the same manner as PFS 
(Section 9.8.2) .
Safety Analyses
The eDMC has responsibility for assessment of overall risk: benefit. At each planned interim 
analysis, eDMC will review the accumulating safety data in addition to the unblinded 
efficacy results. No separate safety interim analysis is planned; therefore, i t will not require a 
08FZ0N
Product:   MK-3475 137
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialseparate multiplicity adjustme nt as they are associated with the planned efficacy interim 
analysis .
Sample Size and Power Calculations
With 414PFS events, the study has ~ 91% power for detecting a HR of 0. 7at initially 
assigned 0. 0125(one-sided) significance level, ~95% power for detecting a HR of 0. 7at 
0.025(one-sided) significance level. 
With 423deaths, the study has ~ 86% power for detecting a HR of 0.7 2at 0.0 125(one-sided) 
significance level and ~ 91% power for detecting a HR of 0.7 2at 0.025(one-sided) 
significance level. The assumption of HR of 0.7 2does not take into account the crossover
treatment in this study . The actual power could be lower than 91% if the HR for OS is larger 
than 0.[ADDRESS_322024].  
With ~ 492participant s at IA1, the study has ~ 60% power for detecting a 2 0% difference in 
ORR (5 4% vs 34%) at 0.0000125 (one-sided) significance level if one of PFS or OS 
hypothesis isrejected .The study has ~9 9% power for detecting a 2 0% difference in ORR 
(54% versus 34%) at 0.025 (one -sided) significance level if both PFS and OS hypotheses are
rejected .
Theplanned sample size is approximately 492participant s assuming: (1) the enrollment 
period ofapproximate ly24months; (2) the duration of PFS and OS follow exponential 
distribution; (3) median PFS is 5.4 months in the control group and the true HRis 0.7; (4) 
median OS is 15 months in the control group and the true HRis 0.7 2, as estimated
approximately from Cortellini , IMPRESS , FLAURA ,and AURA3 studies based on prior 
treatment history of osimertinib [Papadimitrakopoulou, V. A., et al 2020] [Cortellini, A., et al 
2020] [Ramalingam, S. S., et al 2020] [Soria, J. C., et al 2015] [Mok, T. S. K., et al 2017] ; 
(5) the annual dropout ra te is 15% for PFS (as estimated approximately from KEYNOTE -
189) and 1% for OS; ( 6) the number of events and alpha levels of IAsand FAare as 
specified in Section 9.7and Section 9.8.
Subgroup Analyses
To determine whether the treatment effect is consistent across various subgroups, the 
estimate of the between -group treatment effect (with a nominal 95% CI) for the primary 
endpoint will be estimated and plotted within each category of each subgroup. The following 
are examples of classification varia bles:
Age category (< 65 vs ≥65 years)
Sex (female, male)
Race (white, non -white)
Geographic region (East Asia vsNon-East Asia)
Smoking history (never , current/former )
Treatment history (osimertinib, no osimertinib)
T790M mutation (positive, negative , unkn own)
08FZ0N
Product:   MK-3475 138
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialEGFR mutation (L858R, DEL19)
PD-L1 expression (TPS ≥50% vsTPS <50%;TPS ≥1% vs TPS <1% ; TPS <1% vs 
1%≤TPS≤49% vsTPS ≥50% )
Platinum chemotherapy (cisplatin, carboplatin)
The consistency of the treatment effect will be assessed using descriptive statistics for each 
category of the subgroup variables listed above. If the number of participants in a category of 
a subgroup variable is <10% of the ITT population, the subgroup a nalysis will not be 
performed for this category of the subgroup variable, and this subgroup variable will not be 
displayed in the forest plot. 
Extent of Exposure
The extent of exposure will be summarized as duration of treatment in cycles. Summary 
statistics will be provided on extent of exposure for All Subjects As Treated ( ASaT )
population.
08FZ0N
Product:   MK-3475 139
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential10.Supporting Documentation and Operational Considerations
Appendix 1: Regulatory, Ethical and Study Oversight Considerations
Code of Conduct for Interve ntional Clinical Trials
[COMPANY_006] Sharp & Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD)
I.Introduction
A. Purpose
[COMPANY_006] Sharp & Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD), through its subsidiaries, conducts clinical trials worldwide 
to evaluate the safety and effectiveness of our products. As such, we are committed to designing, planning, 
conducting, analyzing, and reporting these trials in compliance with the highest ethical and scientific standards. 
Protection of participants in clinical trials is the overrid ing concern in the design and conduct of clinical trials. In all 
cases, MSD clinical trials will be conducted in compliance with MSD’s global standards, local and/or national 
regulations (including all applicable data protection laws and regulations), and International Council for 
Harmonisation Good Clinical Practice (ICH GCP) E6 and ICH General Considerations for Clinical Studies E8, and 
in accordance with the ethical principles that have their origin in the Declaration of Helsinki . 
B. Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts ). This Code is not intended to apply to trials that are observational in nature, or which 
are retrospective. Further, this Code does not apply to investigator -initiated trials, which are not under the full control 
of MSD .
II.Scientific Issues
A. Trial Co nduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy, 
and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD may 
conduct outc omes research trials, trials to assess or validate various endpoint measures, or trials to determine 
patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific purpose 
of the tria l and shall respect the data protection rights of all participants, trial site staff and, where applicable, third 
parties. Input may be considered from a broad range of stakeholders, including patient advocacy groups/patients 
representing the trial populat ion, caregivers, and healthcare providers to ensure operational feasibility. Trial design 
also includes proactive identification of critical to quality factors using a risk -based approach. Plans are then 
developed to assess and mitigate risks to those fact ors as appropriate during the trial. All trial protocols are and 
will be assessed for the need and capability to enroll underrepresented groups. Participants must meet protocol 
entry criteria to be enrolled in the trial .
2.Site Selection
MSD’s clinical tr ials are conducted globally in many different countries and in diverse populations, including 
people of varying age, race, ethnicity, gender, and accounting for other potential disease related factors. MSD 
selects investigative sites based on medical exper tise, access to appropriate participants, adequacy of facilities and 
staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial initiation, sites are 
evaluated by [CONTACT_26397] (or individuals acting on behalf of MS D) to assess the ability to successfully conduct 
the trial. Individuals involved in trial conduct receive training commensurate with their role prior to their 
becoming involved in the trial.
Where appropriate, and in accordance with regulatory authority gu idance, MSD will make concerted efforts to 
raise awareness of clinical trial opportunities in various communities. MSD will seek to engage underrepresented 
groups and those disproportionately impacted by [CONTACT_26398]. MSD will support clinical t rial 
investigators to enroll underrepresented groups and expand access to those who will ultimately use the products 
under investigation . 
08FZ0N
Product:   MK-3475 140
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential3.Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus source 
documentation according to standard operating procedures. Per MSD policies and procedures, if potential fraud, 
scientific/research misconduct, privacy incidents/breaches or Clinical Trial -related Significant Quality Issues are 
reported, such matters are investigated. When necessary, appropriate corrective and/or preventative actions are 
defined and regulator y authorities and/or ethics review committees are notified .
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, ac cording to the prespecified plans for data analysis. To the extent 
scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important to 
patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_264798]; in such cases, publication of results may not be appropriate since the trial may be underpowered 
and the analyses complicated by [CONTACT_19482].
MSD’s policy on author ship is consistent with the recommendations published by [CONTACT_26399] (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications .
III. Participant Protection
A.Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics 
Committee [IEC])
All protocols and protocol amendments will be submitted by [CONTACT_26400]/authorization 
prior to implementation of the trial or amendment, in co mpliance with local and/or national regulations.
The protocol, protocol amendment(s), informed consent form, investigator’s brochure, and other relevant trial 
documents must be reviewed and approved by [CONTACT_2717]/IEC before being implemented at each site, in c ompliance 
with local and/or national regulations and ICH Guidelines. Changes to the protocol that are required urgently to 
eliminate an immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee 
approval. MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance 
with local and/or national regulations . 
B.Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary import ance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a 
minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntar y. Participants enter the trial only after informed consent is 
obtained. Trial designs include procedures and systems for the identification, monitoring, and reporting of safety 
concerns. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
During trial planning, the need for an independent Data Monitoring Committee (DMC) is assessed. DMC review of 
data accumulated during the conduct of the tri al is integral to the well -being of trial participants .
C.Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible, as well as all applicable 
data protection rights. Unless required by [CONTACT_2371], only the inv estigator, Sponsor (or individuals acting on behalf of 
MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records that might 
identify the participant by [CONTACT_2300] .
D.Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_88709].
E.Trial Results
At the time of providing informed consent and in accordance with local laws and regulations, participants should be 
informed about the plans for availability of trial results.
08FZ0N
Product:   MK-3475 141
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialIV.Financial Considerations
A.Payments to Investigators
Clinical trials are time -and labor -intensive. It is MSD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work p erformed in support of MSD trials. MSD does not pay incentives to enroll 
participants in its trials. However, when enrollment is particularly challenging, additional payments may be made to 
compensate for the time spent in extra recruiting efforts.
MSD doe s not pay for participant referrals. However, MSD may compensate referring physicians for time spent on 
medical record review and medical evaluation to identify potentially eligible participants .
B.Clinical Research Funding 
Informed consent forms will di sclose that the trial is sponsored by [CONTACT_19487], and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may wish 
to alter the wording of the disclosure statement to be c onsistent with financial practices at that institution. As noted 
above, all publications resulting from MSD trials will indicate MSD as a source of funding .
C.Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (eg, to scientific meetings, investigator meetings, etc) will be 
consistent with local guidelines and practices . 
V.Investigator Commitment
Investigators will be expected to review MSD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards .
Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor's responsibility to determine, based on these regulations, whether a reque st for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility to comply with any such request. 
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to pr ovide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certi fication/Disclosure Form, commonly known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may invo lve the 
transmission of information to countries that do not have laws protecting personal data.
Data Protection
The Sponsor will conduct this study in compliance with all applicable data protection 
regulations.
Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information which would make the participant identifiable w ill not be transferred. 
The participant must be informed that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
08FZ0N
Product:   MK-3475 142
Protocol/Amendment No.:   789-[ADDRESS_322025] be informed that his/her medical records may be examined by [CONTACT_19491], by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668] .
Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB , IEC,or similar or expert committee; af filiated institution and 
employees, only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by [CONTACT_19493], except to t he extent that it is included in a 
publication as provided in the Publications section of this protocol.
Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regu latory authority representatives may consult and/or copy study documents in 
order to verify worksheet/ CRF data. By [CONTACT_17317], the participant agrees to 
this process. If study documents will be photocopi[INVESTIGATOR_264799]/ CRF information, the participant will be identified by [CONTACT_19494]; full 
names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in co nnection with this study in accordance with all applicable privacy laws, rules 
and regulations.
Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study . The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records available for 
regulatory agency review upon requ est by [CONTACT_19496].
Committees Structure
Executive Oversight Committee
The Executive Oversight Committee (EOC) is comprised of m embers of Sponsor Senior 
Management. The EOC will receive and decide upon any recommendations made by [CONTACT_264863] .
Data Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study . The voting members of the committee are external 
to the Sponsor. The member s of the DMC must not be involved with the study in any other 
way (eg, they cannot be study investigators) and must have no competing interests that could 
affect their roles with respect to the study . 
08FZ0N
Product:   MK-3475 143
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialThe DMC will make recommendations to the EOC regarding steps to ensure both participant 
safety and the continued ethical integrity of the study . Also, the DMC will review interim 
study results, consider the overall risk and benefit to study participants (see Section 9.7) and 
recommend to the EOC whether the study should continue in accordance with the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by [CONTACT_63548].
Publication Policy
The results of this study may be published or presented at scientific meetings. The Sponsor 
will comply with the requirements for publication of study results. In accordance with 
standard editorial and ethical practice, the Sponsor will generally support p ublication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating investigator [INVESTIGATOR_12992].
If publication activity is not directed by [CONTACT_1034], the investigator agrees to s ubmit all 
manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect 
proprietary information and to provide comments. 
Authorship will be determined by [CONTACT_175067].
Compliance with Study Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study is solely responsible for determining whether the study and its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD , as Sponsor of this study , will 
review this protocol and submit the information necessary to fulfill these requirements. MSD
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify potentially appropriate studies for their 
disease conditions and pursue participation by [CONTACT_3379] a central contact n umber for further 
information on appropriate study locations and site contact [CONTACT_3031]. 
By [CONTACT_12570], the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive or other locally mandated regi stries are that of the 
Sponsor and agrees not to submit any information about this study or its results to those 
registries.
Compliance with Law, Audit, and Debarment
By [CONTACT_12570], the investigator agrees to conduct the study in an efficient a nd 
diligent manner and in conformance with this protocol; generally accepted standards of GCP
(eg, International Co uncil for Harmonisation of Technical Requirements for Pharmaceuticals 
08FZ0N
Product:   MK-3475 144
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialfor Human Use of Technical Requirements for Registration of Pharmaceuti cals for Human 
Use Good Clinical Practice: Consolidated Guideline and other generally accepted standards 
of GCP ); and all applicable federal, state and local laws, rules and regulations relating to the 
conduct of the clinical study .
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_19487] , is provided in this appendix 
under the Code of Conduct for Clinical Trials.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers or from government programs for procedures included as part of the study
reimbursed to the investigator by [CONTACT_1034].
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study .
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection, and will p rovide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on clinical studies by [CONTACT_19500]’s studie s.The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189]. 
Detailed information regarding Data Management procedures for this protocol will be 
provided separately.
The investigator must maintain accurate documentation (source d ata) that supports the 
information entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents. 
Study documentation will be prompt ly and fully disclosed to the Sponsor by [CONTACT_63551], 
copying, review and audit at reasonable times by [CONTACT_193448]. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_264864] a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/ CRFs .
The Sponsor or de signee is responsible for the data management of this study including 
quality checking of the data. 
08FZ0N
Product:   MK-3475 145
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialStudy monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by [CONTACT_1191] , complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all appl icable regulatory requirements. 
Records and documents, including participants' documented informed consent , pertaining to 
the conduct of this study must be retained by [CONTACT_1732] 15 years after study 
completion unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period without the written approval of the 
Sponsor. No records may be transferred to another location or party without written 
notification to the Sponsor. 
Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must b e explained. The 
investigator may need to request previous medical records or transfer records, depending on 
the study. Also, current medical records must be available.
Study and Site Closure
The Sponsor or its designee may stop the study or study site pa rticipation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP. 
In the event the Sponsor prematurely terminates a particular study site, the Sponsor will 
promptly notify tha t study site’s IRB/IEC.
Refer to Section 10.[ADDRESS_322026]:   MK-3475 146
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Appendix 2: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.Biomarker:  A biological molecule found in blood, other body fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease. A biomarker may be 
used to see how well the body responds to a treatment for a disease or condition.1
b.Pharmacogenomics:  The investigation of variations of D NA and RNA characteristics as 
related to drug/vaccine response.2
c.Pharmacogenetics:  A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug/vaccine response.2
d.DNA:  Deoxyribonucleic acid.
e.RNA:  Ribonuc leic acid.
2.Scope of Future Biomedical Research3,4
The specimens consented and/or collected in this study as outlined in Section 8.9will be 
used in various experiments to understand:
oThe biology of how drugs/vaccines work
oBiomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_193451]/vaccines may interact with
oThe biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately 
improve publi c health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_63558].
3.Summary of Procedures for Future Biomedical Research3,4
a.Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in 
future biomedical research .
b.Informed Consent
Informed consent for specimens ( ie,DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, at a 
study visit by [CONTACT_90094]. Informed consent for future 
biomedical research should be presented to the participants on the visit designated in 
the SoA. If delayed, prese nt consent at next possible Participant Visit. Consent forms 
08FZ0N
Product:   MK-3475 147
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialsigned by [CONTACT_88723]. 
A template of each study site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository.
c.eCRF Documentation for Future Biomedical Research Specimens
Documentation of participant consent for future biomedical research will be captured 
in the eCRFs. Any specimens for which such an informed consent cannot b e verified 
will be destroyed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical research will be performed as outlined 
in the SoA. In general, if additional blood specimens are being collected for future 
biomedical res earch , these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4.Confidential Participant Information for Future Biomedical Research3,4
In order to optimize the research that can be conducted with future biomedical research
specimens, it is critical to link participant' clinical information with future test results. In 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow spec ific analyses to be conducted. Knowing 
participant characteristics like gender, age, medical history and treatment outcomes are 
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens ob tained for future 
biomedical research , the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below. 
At the clinical study site, unique codes will be placed on the future biomedical research
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifie rs will 
appear on the specimen tube. 
5.Biorepository Specimen Usage3,[ADDRESS_322027] party (eg, a university investigator) designated by 
[CONTACT_1034]. The investigator conducting the analysis will follow the Sponsor’s privacy 
and confidentiality requirements. Any contracted third party analyses will conform to the
specific scope of analysis outlined in future biomedical research protocol and consent . 
Future biomedical research specimens remaining with the third party after specific 
analysis is performed will be reported to the Sponsor.
6.Withdrawal From Future Bio medical Research3,[ADDRESS_322028]:   MK-3475 148
Protocol/Amendment No.:   789-[ADDRESS_322029] the Sponsor 
using the designated mailbox (clinical.specime n.management@ MSD .com). 
Subsequently, the participant's specimens will be flagged in the biorepository and 
restricted to main study use only. If specimens were collected from study participants 
specifically for future biomedical research , these specimens wi ll be removed from the 
biorepository and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. It is the responsibility of the investigator to 
inform the participant of completion of the withdraw al and/or destruction, if applicable. 
Any analyses in progress at the time of request for withdrawal/destruction or already 
performed prior to the request being received by [CONTACT_259711]. No new analyses would be generated 
after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by [CONTACT_264865]) or the specimens have been completely anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed. 
7.Retention of Specimens3,[ADDRESS_322030] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9.Reporting of Future Biomedical Research Data to Participants3,4
No information obtained from exploratory laboratory studies will be reported to the 
partici pant, family, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability, and concerns regarding misinterpretation.
08FZ0N
Product:   MK-3475 149
Protocol/Amendment No.:   789-[ADDRESS_322031] security, policies and procedures to address participant 
data privacy concerns. Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In this highly unlikely situation there is risk that the 
information, like all medical information, may be misused.
12.Questions
Any questions related to the future biomedical research should be e -mailed directly to 
clinical.specimen.management@ MSD .com.
13.References
1.National Cancer Institute [Internet] : Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Co uncil for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use [Internet] : E15: Definitions for Genomic 
Biomarkers , Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy/efficacy -single/article/definitions -
for-genomic -biomarkers -pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html
3.Industry Pharmacogenomics Working Group [Internet] : Understanding the Intent, 
Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/
4.Indus try Pharmacogenomics Working Group [Internet] : Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at 
http://i -pwg.org/
08FZ0N
Product:   MK-3475 150
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Appendix 3 :  Contraceptive Guidance and Pregnancy Testing
Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below) 
Women in the following categories are not considered WOCBP:
●Premenarchal
●Premenopausal female with 1 of the following:
○Document ed hysterectomy
○Documented bilateral salpi[INVESTIGATOR_1656]
○Documented bilateral oophorectomy
Note:  Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.
●Postmenopausa l female
○A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. 
▪A high follicle stimulating hormone (FSH) level in the postmenopausal range may 
be used to confirm a postmenopausal state in women not using ho rmonal 
contraception or hormon ereplacement therapy (HRT). However, in the absence 
of 12 months of amenorrhea, confirmation with 2FSH measurements in the 
postmenopausal range is required. 
○Females on HRT and whose menopausal status is in doubt will be r equired to use one 
of the non -hormonal highly effective contraception methods if they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment.
08FZ0N
Product:   MK-3475 151
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Contraception Requirements
Male Participants
Male participants with female partners of childbearing potential are eligible to participate if 
they agree to one of the following during the protocol defined time frame in Section 5.1: 
●Be abstinent from penile -vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent.
●Use a male condom plus partner use of an additional contraceptive method when having 
penile -vaginal intercour se with a WOCBP who is not currently pregnant.
oThe following are not acceptable methods of contraception:
▪Periodic abstinence (calendar, symptothermal, postovulation methods), 
withdrawal (coitus interruptus), spermicides only, and lactational amenorrh ea
method (LAM).
▪Male and female condom cannot be used together.
○A combination of male condom with either cap, diaphragm or sponge with 
spermicide are considered acceptable, but not highly effective, birth control methods.
○Note: Men with a pregnant o r breastfeeding partner must agree to remain abstinent 
from penile -vaginal intercourse or use a male condom during each epi[INVESTIGATOR_191202] .
Female Participants
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception consistently and correctly as described in Table [ADDRESS_322032]:   MK-3475 152
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialTable 18 Highly Effective Contraception Methods
Highly Effective Contraceptive Methods That Are User Dependent a
Failure rate of <1% per year when used consistently and correctly.
●Combined (estrogen -and progestogen -containing ) hormonal contraception b, c
○Oral 
○Intravaginal 
○Transdermal 
○Injectable
●Progestogen -only hormonal contraception b, c
○Oral 
○Injectable 
Highly Effective Methods That Have Low User Dependency 
Failure rate of <1% per year when used consistently and correctly.
●Progestogen -only contraceptive implant b, c 
●Intrauterine hormone -releasing system (IUS)b
●Non-hormonal i ntrauterine device (IUD)
●Bilateral tubal occlusion
●Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been 
confirmed. If not, an additional highly effective method of contraception should be used. 
●Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the study 
treatment. The reliability of sexual abstinence needs to be evaluated in relation to the 
duration of the study and the preferred and usual lifestyle of the participant.
Notes: 
Use should be consistent with local regulations regarding the use of contraceptive methods 
for participants of clinical studies. 
a) Typi[INVESTIGATOR_63485] -use failure rates (ie, when used 
consistently and correctly). 
b) If hormonal contraception efficacy is potentially decreased due to interaction with study 
treatment, condoms must be used in addition to the hormonal contraception during the 
treatment period and for at least [ADDRESS_322033] do se of study treatment.
c)If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) 
guidelines, acceptable hormonal contraceptives are limited to those which inhibit ovulation. 
08FZ0N
Product:   MK-3475 153
Protocol/Amendment No.:   789-[ADDRESS_322034]:   MK-3475 154
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Appendix 4: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Definition of AE
AE definition
●An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study treatment, whether or not considered 
related to the study treatment.
●NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study treatment.
●NOTE: for purposes of AE definition, study treatment (also referred to as Sponsor’s 
product) includes any pharmaceutical product, biological product, vaccine, device, 
diagnost ic agent, medical device, combination product, or protocol specified 
procedure whether investigational (including placebo or active comparator product) 
or marketed, manufactured by, licensed by, provided by [CONTACT_264866] .
Events meeting the AE definition
●Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the investigator .
●Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.
●New co nditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
Note: Congenital disorders (eg, present from birth) not detected or diagnosed prior to 
study intervention administrat ion do not qualify for reporting as AE.
●Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
●Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication. 
●For all reports of overdose (whether accidental or intentional) with an associated AE, 
the AE term should reflect the clinical symptoms or abnormal test result. An overdose 
of study treatment without any associated clinical symptoms or abnormal laboratory 
results is reported using the terminology “accidental or intentional overdose without 
adverse effect.”
08FZ0N
Product:   MK-3475 155
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential●Any new cancer (that is not a condition of the study). 
Note: Progression of the cancer under study is not a reportable event. Refer to 
Section 8.4.5 for additional details.
Events NOT meeting the AE definition 
●Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.
●Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
●Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start o f the study that do not worsen.
●Surgery planned prior to informed consent to treat a pre -existing condition that has 
not worsened.
●Refer to Section 8.4.[ADDRESS_322035] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
●The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_8686]
●Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing condition that has not 
worsened is not a nSAE . A pre -existing condition is a clinical condition that is diagnosed 
prior to the use of a nMSD product and is documented in the patient’s medical history.
d.Results in persistent or significant disability/incapacity
●The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
08FZ0N
Product:   MK-3475 156
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential●This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated heada che, nausea, vomiting, diarrhea, influenza, and 
accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life 
functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
●in offspring of pa rticipant taking the product regardless of time to diagnosis
f.Other important medical events:
●Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may not 
be immediately life -threatening or result in death or hospi[INVESTIGATOR_264800]. These events should usual ly be considered 
serious.
●Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency department or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or develo pment of drug dependency or 
drug abuse.
Additional Events Reported in the Same Manner as SAE
Additional events which require reporting in the same manner as SAE
●In addition to the above criteria, AEs meeting either of the below criteria, although 
not serious per ICH definition, are reportable to the Sponsor in the same time frame as 
SAEs to meet certain local requirements. Therefore, these events are considered serious 
by [CONTACT_264867].
●Is a new cancer (that is not a condition of the study);
●Is associated with an overdose.
Recording AE and SAE
AE and SAE recording
●When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.
●The investigator will record all relevant AE/SAE information on the AE
CRFs /worksheets at each examination.
08FZ0N
Product:   MK-3475 157
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential●It is notacceptable for the investigator to send photocopie s of the participant’s 
medical records to the Sponsor in lieu of completion of the AE CRF page.
●There may be instances when copi[INVESTIGATOR_193368]. In this case, all participant identifiers, with the exce ption of 
the participant number, will be blinded on the copi[INVESTIGATOR_12997].
●The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In su ch cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of intensity
●An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
●The investigator will make an assessment of intensity for each AE and SAE (and 
other reportable safety event) according to the NCI Common Terminology Criteria 
for Adverse Events (CTCAE), version 4]. Any AEwhich changes CTCAE grade over 
the course of a given epi[INVESTIGATOR_264801] /worksheets.
●Grade 1: Mild; asymptomatic or mi ld symptoms; clinical or diagnostic 
observations only; intervention not indicated.
●Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living ( ADL ).
●Grade 3: Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_155190] n ofhospi[INVESTIGATOR_374]; disabling; limiting 
self-care ADL.
●Grade 4: Life threatening consequences; urgent intervention indicated.
●Grade 5: Death related to AE.
Assessment of causality
●Did the Sponsor's product cause the AE?
●The determination of the likelihood that the Sponsor's product caused the AE will 
be provided by [CONTACT_19427] a qualified physician. The investigator’s 
signed/dated initials on the source document or work sheet that supports the 
causality noted on the AE form, ensures that a medically qualified assessment of 
causality was done. This initialed document must be retained for the required 
regulatory time frame. The criteria below are intended as reference guide lines to 
assist the investigator in assessing the likelihood of a relationship between the test 
product and the AEbased upon the available information
08FZ0N
Product:   MK-3475 158
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential●The following components are to be used to assess the relationship between 
the Sponsor's product and t he AE; the greater the correlation with the 
components and their respective elements (in number and/or intensity), the more 
likely the Sponsor's product caused the AE:
●Exposure:   Is there evidence that the participant was actually exposed to the 
Sponsor' s product such as:  reliable history, acceptable compliance assessment 
(pi[INVESTIGATOR_692], diary, etc.), expected pharmacologic effect, or measurement of 
drug/metabolite in bodily specimen?
●Time Course:   Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor's product? Is the time of onset of the AE 
compatible with a drug -induced effect (applies to studies with investigational 
medicinal product)?
●Likely Cause:   Is the AE not reasonably explained by [CONTACT_264868], other drug(s)/vaccine(s), or other host or environmental 
factors
●Dechallenge: Was the Sponsor's product discontinued or 
dose/exposure/frequency reduced?
●If yes, did the AE resolve or improve?
●If yes, this is a positive dechallenge. 
●If no, this is a negative dechallenge.
(Note:  This criterion is not applicable if:  (1) the AE resulted in death or 
permanent disability; (2) the AE resolved/improved despi[INVESTIGATOR_77992]'s product ; (3) the study is a single -dose drug study ); or (4) 
Sponsor's product(s) is/are only used one time.)
●Rechallenge:   Was the participant re -exposed to the Sponsor's product in this 
study ?
●If yes, did the AE recur or worsen?
●If yes, this is a positive rechallenge. 
●If no, this is a negative rechallenge.
(Note:  This criterion is not applicable if:  (1) the initial AE resulted in death 
or permanent disability, or (2) the study is a single -dose drug study ); or (3) 
Sponsor's product(s) is/are used only o ne time.)
NOTE:  IF A RECHALLENGE IS PLANNED FOR AN AEWHICH WAS SERIOUS 
AND WHICH MAY HAVE BEEN CAUSED BY [CONTACT_26370]'S PRODUCT, OR IF 
RE-EXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL 
POTENTIAL SIGNIFICANT RISK TO THE PARTICIPANT THEN THE 
RECHALLENGE MUST BE APPROVED IN ADVANCE BY [CONTACT_193450], AND IF REQUIRED, THE IN IRB/IEC.
08FZ0N
Product:   MK-3475 159
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential●Consistency with Study treatment Profile: Is the clinical/pathological 
presentation of the AE consistent wi th previous knowledge regarding the 
Sponsor's product or drug class pharmacology or toxicology?
●The assessment of relationship will be reported on the CRFs /worksheets by [CONTACT_26368] a qualified physician according to their best clinical judgment, 
including consideration of the above elements.
●Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor's product relationship).
●Yes, there is a reasonable possibility of Sponsor's product relationship:
There is evidence of exposure to the Sponsor's product. The temporal sequence of 
the AE onset relative to the administration of the Sponsor's produ ct is reasonable. 
The AE is more likely explained by [CONTACT_1034]'s product than by [CONTACT_5748]. 
●No, there is not a reasonable possibility of Sponsor's product relationship:
Participant did not receive the Sponsor's product OR temporal sequence of the AE 
onset relative to administration of the Sponsor's product is not reasonable OR the 
AE is more likely explained by [CONTACT_26372]’s product. (Also 
entered for a participant with overdose without an associated AE.)
●The investigator must review and provide an assessment of causality for each 
AE/SAE and document this in the medical notes .
●There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the Sponsor. However, it is very 
important that the investigator always make an assessment of causality for every event 
before the initial transmission of the SAE data to the Sponsor.
●The investigator may change their opi[INVESTIGATOR_264802]-up 
information and send an SAE follow -up report with the updated causality assessment.
●The causality assessment is one of the criteria used when determining regulatory 
reporting requirements
●For studies in which multiple agents are administered as part of a combination 
regimen, the investigator may attribute each AEcausality to the combination regimen 
or to a single agent of the combination. In general, causality attribution should be 
assigned to the combination regimen ( ie,to all agents in the re gimen). However, 
causality attribution may be assigned to a single agent if in the investigator’s opi[INVESTIGATOR_1649], 
there is sufficient data to support full attribution of the AEto the single agent.
08FZ0N
Product:   MK-3475 160
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialFollow -up of AE and SAE
●The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_171622]/or causality of the AE or SAE as fully as possible. This 
may include additional la boratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.
●New or updated information will be recorded in the CRF.
●The investigator will submit any updated SAE data to the Sponsor within 24 h ours of 
receipt of the information.
Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor
AE, SAE, and other reportable safety event reporting to Sponsor via electronic data 
collection tool
●The primary mechanism for reporting to the Sponsor will be the electronic data 
collection (EDC) tool. 
●Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
●If the electronic system is unavailable for more than 24 hours, then the site will 
use the paper AE Reporting form. 
●Reference Section 8.4.1 for reporting time requirements 
●The site will enter the SAE data into the electronic system as soon as it becomes 
available.
●After the study is completed at a giv en site, the EDC tool will be taken off -line to 
prevent the entry of new data or changes to existing data.
●If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the EDC tool has been taken off -line, then the 
site can report this information on a paper SAE form or by [CONTACT_756] (see next 
section).
●Contacts for SAE reporting can be found in the Investigator Trial File Binder (or 
equivalent).
08FZ0N
Product:   MK-3475 161
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialSAE reporting to the Sponsor via paper CRF
●If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
●In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_181813] a copy of the SAE data collection tool sent by [CONTACT_19515].
●Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time fr ames.
●Contacts and instructions for SAE reporting and paper reporting procedures can be 
found in the Investigator Trial File Binder (or equivalent).
08FZ0N
Product:   MK-3475 162
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Appendix 5: Clinical Laboratory Tests 
The tests detailed in Table 19will be performed by [CONTACT_264869] 
(Section 1.3). 
Protocol -specific requirements for inclusion or exclusion of participants are detailed 
in Section 5 of the protocol.
Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_11006]. Refer to Section 10. 12 
for country -specific requirements. 
Table 19 Protocol -required Safety Laboratory Assessments
Laboratory 
AssessmentsParameters
Hematology Platelet Count WBC count with Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hemoglobin
Hematocrit
Absolute 
Neutrophil Count
Absolute 
Lymphocyte 
Count
Chemistry Blood Urea 
Nitrogen (BUN)
or urea (one or 
the other should 
be collected per 
institutional 
standard; both 
tests are not
required)Potassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic -
Oxaloacetic 
Transaminase 
(SGOT)Total bilirubin 
(and direct 
bilirubin, if total 
bilirubin is 
elevated above 
the upper limit of 
normal)
Albumin A measure of 
carbon dioxide 
(CO2or 
Bicarbonate )aChloride Phosphorous
CreatininebSodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic -Pyruvic 
Transaminase 
(SGPT)Total Proteina
Glucose 
[Indicate if 
fasting or 
nonfasting]Calcium Alkaline 
phosphataseLactate 
Dehydrogenase
Coagulation PT/INR
aPTT/PTTc
08FZ0N
Product:   MK-3475 163
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialLaboratory 
AssessmentsParameters
Routine 
UrinalysisSpecific gravity
Glucose, protein, blood, ketones by [CONTACT_5230]
Microscopic examination (if blood or protein is abnormal)
Other Screening 
TestsdThyroid panele: T3/FT3, FT4, TSH
Follicle -stimulating hormone (FSH) (as needed in women of non -
childbearing potential only)
Highly sensitive s erum or urine human chorionic gonadotropin (hCG) 
pregnancy test (as needed for WOCBP )
Hepatitis Serology -hepatitis B surface antigen [HBsAg], hepatitis B virus 
(HBV )-DNA, hepatitis C virus ( HCV )-RNA, HCV antibody ( if HCV -RNA is 
not the local st andard of care), if required per local regulations .
HIV-RNA (if required by [CONTACT_427])
NOTES :
a.If these tests are not done as part of standard of care in your region then these tests do not need to be performed. 
The carbon dioxide may be either a measurement of CO 2or bicarbonate as an electrolyte.
b.Creatinine: GFR (measured or calculated) or creatinine clearance can be used in place of creatinine . Creatinine 
Clearance should be calculated using the Cockcroft -Gault Method: Refer to Section 10.8 for the appropriate 
calculation.
c.Coagulation factors (PT/INR and aPTT/PTT) should be tested as part of the screening procedure s for all 
participant s.Any participant receiving anticoagulant therapy should have coagulation factors monitored closely 
throughout the trial.
d.May use central lab only if local lab is not capable.
e.T3 is preferred. If not available, Free T3 (FT3) may be tested.
All protocol -required safety laboratory assessments will be performed by a local laboratory.
The investigator (or medically qualified designee) must document their review of each laboratory safety report.
08FZ0N
Product:   MK-3475 164
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Appendix 6: Eastern Cooperative Oncology Group (ECOG) Perform ance Status
GRADE ECOG PERFORMANCE STATUS
0 Fully active, able to carry on all pre-disease performance without restriction
1Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, eg, light house work, office work
2Ambulatory and capable of all self-care but unable to carry out any work 
activities; up and about more than 50% of waking hours
3Capable of only limited self-care; confined to bed or chair more than 50% of 
waking hours
4Completely disabled; cannot carry on any self-care; totally confined to bed or 
chair
5 Dead
As published in Am. J. Clin. Oncol.: Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, 
T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative 
Oncology Group. Am J Clin Oncol 5:[ADDRESS_322036]:   MK-3475 165
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Appendix 7:   MASCC 2016 Guidelines
Rolia F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the 
prevention of chemotherapy -and radiot herapy -induced nausea and vomiting and of nausea and 
vomiting in advanced cancer patients. Ann Oncol (2016) 27 (suppl_5): v119 -v133, 2016.
http://www.mascc.org/antiemetic -guidelines
Investigators may use local equivalent or more current guidelines, if avai lable.
08FZ0N
Product:   MK-3475 166
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Appendix 8: Calculated Creatinine Clearance
Original, Weight -Based Cockcroft and Gault Formula for Calculated Creatinine
Clearance for Men
For serum creatinine concentration in mg/dL:
CrCl =
(mL/min)(140–agea)(wtb)1.0
72serum creatinine (mg/dL)
For serum creatinine concentration in mol/L:
CrCl =
(mL/min)(140–agea)(wtb)1.0
0.81 serum creatinine (mol/L)
aAge in years.
bWeight (wt) in kilograms.
Source: Cockcroft and Gault 1976.
Original, Weight -Based Cockcroft and Gault Formula for Calculated Creatinine
Clearance for Women
For serum creatinine concentration in mg/dL:
CrCl =
(mL/min)(140–agea)(wtb)0.85
72serum creatinine (mg/dL)
For serum creatinine concentration in mol/L:
CrCl =
(mL/min)(140–agea)(wtb)0.85
0.81 serum creatinine (mol/L)
aAge in years.
bWeight (wt) in kilograms.
Source: Cockcroft and Gault 1976.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31 –[ADDRESS_322037]:   MK-3475 167
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Appendix 9:Abbreviations
Abbreviation Expanded Term
1L first-line (therapy)
AE adverse event
ALK anaplastic lymphoma kinase
ALT alanine aminotransferase
APaT All Participants as Treated
AST aspartate aminotransferase
ATP adenosine triphosphate
AUC area under curve
BCG Bacillus Calmette -Guérinvaccine
BICR blinded independent central review
C1D1 Cycle [ADDRESS_322038]:   MK-3475 168
Protocol/Amendment No.:   789-[ADDRESS_322039] ratio
HRQoL health related quality of life
HRT hormone replacement therapy
IA interim analysis
IB Investigator’s Brochure
ICF informed consent form
iCPD iRECIST confirmed progressive disease
iCR iRECIST complete response
IEC independent ethics committee
08FZ0N
Product:   MK-3475 169
Protocol/Amendment No.:   789-[ADDRESS_322040] unconfirmed progressive disease
IV intravenous
IVRS/IWRS interactive voice response system/ integrated web response system
KL-6 Krebs von den Lungen 6 ; biomarker for ILD
mAb monoclonal antibody
MASCC Multinational Association of Supportive Care in Cancer
MRI magnetic resonance imaging
mTOR mammalian target of rapamycin
NCI CTCAE National Cancer Institute Common Terminology Criteria for 
Adverse Events
NSCLC non-small cell lung cancer
ORR objective response rate
OS overall survival
PBPK physiological based pharmacokinetics
PD progressive disease
PD-[ADDRESS_322041]:   MK-3475 170
Protocol/Amendment No.:   789-[ADDRESS_322042]:   MK-3475 171
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Appendix 10: Description of the iRECIST Process for Assessment of Disease
Progression
Assessment at Screening and Prior to RECIST 1.[ADDRESS_322043] for participant management (see Table 8and 
Figure 3). This decision by [CONTACT_246136]’s overall 
clinical condition.
Clinical stability is defined in Section 7.1.
Any participant deemed clinically unstable should be discontinued from study treatment at
central verification of site -assessed first radiologic evidence of PD, and is not required to 
have repeat tumor imaging for confirmation of PD by [CONTACT_19393].
If the Investigator decides to continue treatment, the participant may continue to receive 
study treatment and the tumor assessment should be repeated [ADDRESS_322044] 1.1, 
including:
Increase in the sum of diameters of target lesion(s) iden tified at baseline to ≥20% and 
≥5mm from nadir
oNote: the iRECIST publication uses the terminology “sum of measurements”, but 
“sum of diameters” will be used in this protocol, consistent with the original 
RECIST 1.1 terminology.
Unequivocal progression of non-target lesion(s) identified at baseline
Development of new lesion(s)
iRECIST defines new response categories, including iUPD (unconfirmed progressive 
disease) and iCPD (confirmed progressive disease). For purposes of iRECIST assessment, 
the first visit showing progression according to RECIST 1.1 will be assigned a visit (overall) 
response of iUPD, regardless of which factors caused the progression.
At this visit, target and non -target lesions identified at baseline by [CONTACT_393] 1.[ADDRESS_322045] 1.1. From measurable new 
lesions, up to 5 lesions total (up to 2 per organ), may be selected as New Lesi ons –Target. 
The sum of diameters of these lesions will be calculated, and kept distinct from the sum of 
08FZ0N
Product:   MK-3475 172
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidentialdiameters for target lesions at baseline. All other new lesions will be followed qualitatively 
as New Lesions –Non-target.
Assessment at the Confirmatory Imaging
On the confirmatory imaging, the participant will be classified as progression confirmed 
(with an overall response of iCPD), or as showing persistent unconfirmed progression (with 
an overall response of iUPD), or as showing disease sta bility or response (iSD/iPR/iCR).
Confirmation of Progression
Progression is considered confirmed, and the overall response will be iCPD, if ANY of the 
following occurs:
Any of the factors that were the basis for the initial iUPD show worsening
oFor target lesions, worsening is a further increase in the sum of diameters of 
≥5mm, compared to any prior iUPD time point
oFor non -target lesions, worsening is any significant growth in lesions overall, 
compared to a prior iUPD time point; this does not have to meet the 
“unequivocal” standard of RECIST 1.1
oFor new lesions, worsening is any of these:
An increase in the new lesion sum of diameters by ≥5mm from a prior iUPD 
time point 
Visible growth of new non -target lesions 
The appearance of additional new lesio ns
Any new factor appears that would have triggered PD by [CONTACT_393] 1.1
Persistent iUPD
Progression is considered not confirmed, and the overall response remains iUPD, if:
None of the progression -confirming factors identified above occurs AND
The target lesio n sum of diameters (initial target lesions) remains above the initial PD 
threshold (by [CONTACT_393] 1.1)
Additional imaging for confirmation should be scheduled 4 to 8 weeks from the imaging on 
which iUPD is seen. This may correspond to the next visit in the ori ginal visit schedule. The 
assessment of the subsequent confirmation imaging proceeds in an identical manner, with 
possible outcomes of iCPD, iUPD, and iSD/iPR/iCR.
08FZ0N
Product:   MK-3475 173
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
ConfidentialResolution of iUPD
Progression is considered not confirmed, and the overall response becomes iSD/iPR/iCR, if:
None of the progression -confirming factors identified above occurs, AND
The target lesion sum of diameters (initial target lesions) is not above the initial PD 
threshold. 
The response is classified as iSD or iPR (depending on the sum of diameters of the target 
lesions), or iCR if all lesions resolve.
In this case, the initial iUPD is considered to be pseudo -progression, and the level of 
suspi[INVESTIGATOR_19367] “reset”. This means that the next visit that shows radiographic 
progres sion, whenever it occurs, is again classified as iUPD by [CONTACT_19393], and the 
confirmation process is repeated before a response of iCPD can be assigned.
Management Following the Confirmatory Imaging
If repeat imaging does not confirm PD per iRECIST, as assess ed by [CONTACT_737], and the 
participant continues to be clinically stable, study treatment may continue and follow the 
regular imaging schedule. If PD is confirmed, participants will be discontinued from study 
treatment.
NOTE: If a participant has conf irmed radiographic progression (iCPD) as defined above, but 
the participant is achieving a clinically meaningful benefit or if RECIST 1.1 PD has not been 
verified centrally , an exception to continue study treatment may be considered following 
consultation with the Sponsor. In this case, if study treatment is continued, tumor imaging 
should continue to be performed following the intervals as outlined in Section 8.2 and 
submitted to the central imaging vendor.
Detection of Progression at Visits After Pseudo -progression Resolves
After resolution of pseudo -progression (ie, achievement of iSD/iPR/iCR), iUPD is indicated 
by [CONTACT_19518]:
Target lesions
oSum of diameters reaches the PD threshold ( ≥20% and ≥5 mm increase from 
nadir) either for the firs t time, or after resolution of previous pseudo -progression. 
The nadir is always the smallest sum of diameters seen during the entire trial, 
either before or after an instance of pseudo -progression.
Non-target lesions
oIf non -target lesions have never shown unequivocal progression, their doing so for 
the first time results in iUPD.
08FZ0N
Product:   MK-3475 174
Protocol/Amendment No.:   789-[ADDRESS_322046] shown previous unequivocal progression, and this 
progression has not resolved, iUPD results from any significant further growth of 
non-target lesions, taken as a whole.
New lesions
oNew lesions appear for the first time
oAdditional new lesions appear
oPreviously identified new target lesions show an increase of ≥5mm in the new 
lesion sum of diameters, from the nadir value of that sum
oPreviously i dentified non -target lesions show any significant growth
If any of the events above occur, the overall response for that visit is iUPD, and the iUPD 
evaluation process (see Assessment at the Confirmatory Imaging above) is repeated. 
Progression must be conf irmed before iCPD can occur.
The decision process is identical to the iUPD confirmation process for the initial PD, with 
one exception:  if new lesions occurred at a prior instance of iUPD, and at the confirmatory 
imaging the burden of new lesions has incr eased from its smallest value (for new target 
lesions, the sum of diameters is ≥5 mm increased from its nadir), then iUPD cannot resolve 
to iSD or iPR. It will remain iUPD until either a decrease in the new lesion burden allows 
resolution to iSD or iPR, or until a confirmatory factor causes iCPD.
Additional details about iRECIST are provided in the iRECIST publication [Seymour, L., et 
al 2017] .
08FZ0N
Product:   MK-3475 175
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Appendix 11: Common Terminology Criteria for Adverse Events V4.0 (CTCAE)
The descriptions and grading scales found in the revised NCI Common Terminology Criteria 
for Adverse Events (CTCAE) version 4.0 will be utilized for adverse event reporting. 
(http://ctep.cancer.gov/reporting/ctc.html ).
08FZ0N
Product:   MK-3475 176
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
Appendix 12: Country -specific Requirements
Sweden -specific Information
1.Section [IP_ADDRESS] Safety Endpoints
Safety parameters commonly used for evaluating investigational systemic anticancer 
treatments are included as safety endpoints including, but not limited to, the incidence 
of, causality, and outcome of adverse events (AEs)/serious adverse events (SAEs); 
and changes in vital signs and laboratory values. Adverse events will be assessed as 
defined by [CONTACT_3989], Version 4.0. 
2.Section 10.1 Appendix 1 Regulatory , Ethical and Study Oversight Considerations 
Code of Conduct for Clinical Trials
oIII. Participant Protection
–A. Ethics Committee Review (Institutional Review Board 
[IRB]/Independent Ethics Committee [IEC]) and Health Authorities
The protocol, protocol amendments, ICF, Investigator Brochure, and 
other relevant documents must be submitted to and approved by [CONTACT_264870]/IEC before the study is 
initiated in accordance with EU Directive 2001/20/EC, Article 10 (a) 
and/or local requirements. Any amendments to the protocol will 
require IRB/IEC and Competent Authority approval before 
implementation of changes made to the study design, except for 
changes necessary to eliminate an immediate hazard to study 
participants [2001/20/EC, Article 10 (c)].
Study and Site Closure
The Sponsor or its designee may stop the study or study site participation in the 
study for medical, safety, regulatory, administrative, or other reasons consistent 
with applicable laws, regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the 
Sponsor will promptly notify that study site’s IRB/IEC.
In the EU [CT -1 (2010/C 82/01)], the sponsor must send immediate end -of-study 
notification to the national competent authority and the E thics Committee of the 
Member State concerned. The end -of-study notification must be sent within [ADDRESS_322047]:   MK-3475 177
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential
[LOCATION_013] -specific Information
1.Section 1.3 .1Schedule of Activities for Initial Treatment Phase
HIV testing is required at screening.
Hepatitis B and Hepatitis C testing is required at screening .
2.Section 5.2 Exclusion Criteria
Exclusion Criterion 17: HIV testing is required for participants who are residents 
of [LOCATION_013].
Exclusion Criterion 18: Hepatitis B and C testing is required for parti cipants who 
are residents of [LOCATION_013].
Exclusion Criterion 19: TB testing is required for participants who are residents of 
[LOCATION_013].
3.Section 1.3.2 Schedule of Activities for Crossover Treatment Phase
Monthly urine pregnancy testing is required during treatm ent as well as at the end of 
study treatment.
4.Section 1.3.3 Schedule of Activities for Second Course Retreatment Phase
Monthly urine pregnancy testing is required during treatment as well as at the end of 
study treatment.
5.Section 10.3 Appendix 3: Contraceptive Guidance and Pregnancy Testing
Monthly urine pregnancy testing after randomization is required during treatment as 
well as at the end of study treatment.
6.Section 10.5 Appendix 5: Clinical Laboratory Tests
TB added to Other Tests
Japan -specific Information
Section 1.3 Schedule of Activities –footnotes
1.For the assistance to early diagnosis of pneumonitis/ILD in study participants, the 
following items such as pulse oximetry monitoring (SpO 2), C-reactive protein ( CRP ), 
Krebs von den Lungen 6 (KL-6), and surfactant protein D ( SP-D)will be measure din 
this study. These items should be measured in the following timing :
oSpO2: at the timing of vital sign assessment.
oCRP, KL -6 and SP -D: at Screening*, pre -dose onDay 1 of every cycle, end of 
treatment and safety follow -up visit ([ADDRESS_322048] dose).
* should be measured at the timing of clinical laboratory tests (such as 
hematology/ chemistry).
08FZ0N
Product:   MK-3475 178
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential2.In the case that pneumonitis/ILD occurs ,regardless of causality with study 
medic ation, an independent ILD evaluation committee will conduct adjudication of 
cases of the pneumonitis/ILD. For this purpose, relevant data such as chest imaging 
(from the baseline to the recovery of pneumonitis/ILD) will be submitted to MSD 
K.K.
08FZ0N
Product:   MK-3475 179
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential11. References
[Aaronson, N. K., et al 
1993]Aaronson NK, Ahmedzai S, Bergman B, 
Bullinger M, Cull A, Duez NJ, et al. The 
European Organization for Research and 
Treatment of Cancer QLQ -C30: a quality -of-life 
instrument for use in international clinical trials in 
oncology. J Natl Cancer Inst 1993;85(5):365 -76.[03Q3QL]
[Bergman, B., et al 
1994]Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, 
Sullivan M. The EORTC QLQ -LC13: a modular 
supplement to the EORTC core quality of life 
questionnaire (QLQ -C30) for us e in lung cancer 
clinical trials. Eur J Cancer 1994;30A(5):635 -42.[00VTZB]
[Chemnitz, J. M., et al 
2004]Chemnitz JM, Parry RV, Nichols KE, June CH, 
Riley JL. SHP -1 and SHP -2 associate with 
immunoreceptor tyrosine -based switch motif of 
programmed death 1 upon primary human T cell 
stimulation, but only receptor ligation prevents T 
cell activation. J Immunol 2004;173:945 -54.[00VMPN]
[Cortellini, A., et al 
2020]Cortellini A, Leonetti A, Catino A, Pi[INVESTIGATOR_264803] P, 
Ricciuti B, De Giglio A, et al. Osimertinib 
beyond disease progression in T790M EGFR -
positive NSCLC patients: a multicenter study of 
clinicians' attitudes. Clin Transl Oncol. 
2020;22:844 -51.[05NW9Q]
[Disis, M. L. 2010] Disis ML. Immune regulation of cancer. J Clin 
Oncol 2010;28(29):4531 -8.[058SQL]
[Dudley, M. E., et al 
2005]Dudley ME, Wunderlich JR, Yang JC, Sherry 
RM, Topalian SL, Restifo NP, et al. Adoptive cell 
transfer therapy following non -myeloablative but 
lymphodepleting chemotherapy for the treatment 
of patients with refractory metastatic melanoma. J 
Clin Oncol 2005;23(10):2346 -57.[00VMPR]
[Francisco, L. M., et al 
2010]Francisco LM, Sage PT, Sharpe AH. The PD -[ADDRESS_322049] in tolerance and autoimmunity. Immunol 
Rev 2010;236:219 -42.[058SQP]
[Greenwald, R. J., et al 
2005]Greenwal d RJ, Freeman GJ, Sharpe AH. The B7 
family revisited. Annu Rev Immunol 
2005;23:515 -48.[00VMQL]
08FZ0N
Product:   MK-3475 180
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential[Hodi, F. S., et al 2014] Hodi FS, Ribas A, Daud A, Hamid O, Robert C, 
Kefford R, et al. Patterns of response in patients 
with advanced melanoma treated with 
Pembrolizumab (MK -3475) and evaluation of 
immune -related response criteria (irRC). J 
Immunother Cancer. 2014;2(Suppl 3):P103.[0465RW]
[Hunder, N. N., et al 
2008]Hunder NN, Wallen H, Cao J, Hendricks DW, 
Reilly JZ, Rodmyre R, et al. Treatment of 
metastati c melanoma with autologous CD4+ T 
cells against NY -ESO -1. N Engl J Med 
2008;358(25):2698 -703.[00VMPX]
[IB Edition 15 2017] KEYTRUDA (pembrolizumab) Investigator’s 
Brochure, Edition Number 15, 18 -Sep-2017.[04R9W6]
[Maurer, W. and Bretz, 
F. 2013]Maurer W and Bretz F. Multiple testing in group 
sequential trials using graphical approaches. Stat 
Biopharm Res 2013;5(4):311 -20.[03XQVB]
[Mok, T. S. K., et al 
2017]Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang 
JJ, Ahn MJ, et al. Gefitinib plus chemotherapy 
versus chemotherapy in epi[INVESTIGATOR_264804] -positive non -small -cell lung 
cancer resistant to first -line gefitinib (IMPRESS): 
overall survival and biomarker analyses. J Clin 
Oncol. 2017 Dec 20;35(36):4027 -34.[05NXVP]
[Mok, T. S., et a l 2009] Mok TS, Wu Y -L, Thongprasert S, Yang C. -H., 
Chu D -T, Saijo N, et al. Gefitinib or carboplatin -
paclitaxel in pulmonary adenocarcinoma. N Engl 
J Med 2009;361:1 -11.[00WBF3]
[Mok, T. S., et al 2017] Mok TS, Wu Y -L, Ahn M -J, Garassino MC, Kim 
HR, Rama lingam SS. et al. Osimertinib or 
Platinum -Pemetrexed in EGFR T790M -Positive 
Lung Cancer. N Engl J Med. 2017 Feb 
16;376(7):629 -640.[04RCST]
[Morgillo, F., et al 2016] Morgillo F, Della Corte CM, Fasano M, 
Ciardiello F. Mechanisms of resistance to EGFR -
targeted drugs: lung cancer. ESMO Open. 2016 
May 11;1(3):e000060.eCollection 2016.[04T0HB]
08FZ0N
Product:   MK-3475 181
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential[National Cancer 
Institute 2016]National Cancer Institute. SEER Stat Fact Sheets: 
Lung and bronchus cancer [Internet]. Bethesda, 
MD: National Cancer Institut e; 2016. Available 
from: http://seer.cancer.gov/statfacts/.[04FJVR]
[Okazaki, T., et al 2001] Okazaki T, Maeda A, Nishimura H, Kurosaki T, 
Honjo T. PD -1 immunoreceptor inhibits B cell 
receptor -mediated signaling by [CONTACT_193444] 2 -domain -contai ning tyrosine 
phosphatase 2 to phosphotyrosine. Proc Natl 
Acad Sci U S A 2001;98(24):[ZIP_CODE] -71.[00VMQ6]
[Papadimitrakopoulou, 
V. A., et al 2020]Papadimitrakopoulou VA, Mok TS, Han JY, Ahn 
MJ, Delmonte A, Ramalingam SS, et al. 
Osimertinib versus platinum -pemetrexed for 
patients with EGFR T790M advanced NSCLC 
and progression on a prior EGFR -tyrosine kinase 
inhibitor: AURA3 overall survival analysis. Ann 
Oncol. 2020;31(11):1536 -44.[05NW9P]
[Parry, R. V., et al 2005] Parry RV, Chemnitz JM, Frauwirth KA, 
Lanfranco AR, Braunstein I, Kobayashi SV, et al. 
CTLA -[ADDRESS_322050] mechanisms. Mol Cell Biol 
2005;25(21):9543 -53.[00VMQ7]
[Paz-Ares, L. G., et al 
2013]Paz-Ares LG, de Marinis F, Dediu M, Thomas M, 
Pujol JL, Bidoli P, et al. PARAMOUNT: Final 
overall survival results of the phase III study of 
maintenance pemetrexed versus placebo 
immediately after induction treatment with 
pemetrexed plus cisplatin for advanced 
nonsquamous non -small -cell lung cance r. J Clin 
Oncol. 2013 Aug 10;31(23):2895 -902.[04804Z]
[Pi[INVESTIGATOR_19323], A. S., et al 
2007]Pi[INVESTIGATOR_19370], Neary MP, Cella D. Estimation of 
minimally important differences in EQ -5D utility 
and VAS scores in cancer. Health Qual Life 
Outcomes 2007;5:1 -8.[00W0FM]
[Rabin, R. and de 
Charro, F. 2001]Rabin R and de Charro F. EQ -5D: a measure of 
health status from the EuroQol group. Ann Med 
2001;33:337 -43.[03QM46]
08FZ0N
Product:   MK-3475 182
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential[Ramalingam, S. S., et al 
2020]Ramalingam SS, Vansteenkiste J, Planchard D, 
Cho BC, Gray JE, Ohe Y, et al. Overall survival 
with osimertinib in untreated, EGFR -mutated 
advanced NSCLC. N Engl J Med. 2020 Jan 
2;382(1):41 -50.[05NW9R]
[Ramalingam, S., et al 
2017]Ramalingam S, Reungwetwattana T, 
Chewaskulyong B, et al. Osimertinib vs standard 
of care (SoC) EGFR -TKI as first -line therapy in 
patients (pts) with EGFRm advanced NSCLC: 
FLAURA. Presented at: 2017 ESMO Congress; 
Madrid, Spain; September 9 -12, 2017.[04SRRG]
[Reck, M., et al 2016] Reck M, Rodriguez -Abreu D, Robinson AG, Hui 
R, Csoszi T, Fulop A, et al. Pembrolizumab 
versus Chemotherapy for PD -L1-Positive Non -
Small -Cell Lung Cancer. N Engl J Med. [ADDRESS_322051] 
8. [Epub ahead of print].[04JNM3]
[Reck, M., et al 2017] Reck M, Socinski MA, Cappuzzo F, Orlandi F, 
Stroyakovskii D, Nogami N, et al. Primary PF S 
and safety analyses of a randomized phase III 
study of carboplatin + paclitaxel +/ -
bevacizumab, with or without atezolizumab in 1L 
non-squamous metastatic nsclc 
(IMPOWER150)[abstract]. Annals of Oncology. 
2017 November;28([ADDRESS_322052]):xi31. Abstract no. 
LBA1_PR.[04T70N]
[Reck, M., et al 2017] Reck M, Socinski MA, Cappuzzo F, Orlandi F, 
Stroyakovskii D, Nogami N, et al. Primary PFS 
and safety analyses of a randomised phase lll 
study of carboplatin + paclitaxel +/ -
bevacizumab, with or without atezolizumab in 1L 
non squamous metastatic NSCLC (lMpower150). 
Poster session presented at: ESMO immuno -
oncology congress; 2017 Sep 8 -12; Madrid, 
Spain.[04T6DH]
[Riley, J. L. 2009] Riley JL. PD -1 signaling in primary T cells. 
Immunol Rev 2009;229:114 -25.[00VMQ9]
08FZ0N
Product:   MK-3475 183
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential[Scagliotti, G. V., et al 
2008]Scagliotti GV, Parikh P, von Pawel J, Biesma B, 
Vansteenkiste J, Manegold C. et al. Phase III 
study comparing cisplatin plus gemcitabine with 
cisplatin plus pemetrexed in chemotherapy -naive 
patients with advanced -stage non -small-cell lung 
cancer. J Clin Oncol. 2008 Jul 20;26(21):3543 -
51.[04Q3DV]
[Seymour, L., et al 
2017]Seymour L, Bogaerts J, Perrone A, Ford R, 
Schwartz LH, Mandrekar S, et al. iRECIST: 
guidelines for response criteria for use in trials 
testing immunotherap eutics. Lancet Oncol. 2017 
Mar;18(3):e143 -52.[04P9RV]
[Sheppard, K -A, et al 
2004]Sheppard K -A, Fitz LJ, Lee JM, Benander C, 
George JA, Wooters J, et al. PD -1 inhibits T -cell 
receptor induced phosphorylation of the 
ZAP70/CD3zeta signalosome and downstrea m 
signaling to PKCtheta. FEBS Lett. 2004;574:37 -
41.[00VMQC]
[Smith, T. J., et al 2015] Smith TJ, Bohlke K, Lyman GH, Carson KR, 
Crawford J, Cross SJ, et al. Recommendations for 
the Use of WBC Growth Factors: American 
Society of Clinical Oncology Clinical Practice 
Guideline Update. J Clin Oncol. [ADDRESS_322053] 
1;33(28):3199 -212.[04KHR8]
[Soria, J. C., et al 2015] Soria JC, Wu YL, Nakagawa K, Kim SW, Yang 
JJ, Ahn MJ, et al. Gefitinib plus chemotherapy 
versus placebo plus chemotherapy in EGFR -
mutation -positive n on-small -cell lung cancer after 
progression on first -line gefitinib (IMPRESS): a 
phase 3 randomised trial. Lancet Oncol. 2015 
Aug;16(8):990 -8.[04SRRQ]
[Sulpher, J. A., et al 
2013]Sulpher JA, Owen SP, Hon H, Tobros K, 
Shepherd FA, Sabri E, et al. Factors influencing a 
specific pathologic diagnosis of non -small -cell 
lung carcinoma. Clin Lung Cancer. 2013 
May;14(3):238 -44.[040565]
08FZ0N
Product:   MK-3475 184
Protocol/Amendment No.:   789-08
MK-3475 -789-08 Final P rotocol 24-Jul-2023
Confidential[Wolchok, J. D., et al 
2009]Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid 
O, LebbéC, et al. Guidelines for the evaluati on of 
immune therapy activity in solid tumors: 
immune -related response criteria. Clin Cancer 
Res 2009;15(23):7412 -20.[00VMNZ]
[World Health 
Organization 2012]Globocan 2012: Lung Cancer Estimated 
Incidence, Mortality and Prevalence Worldwide 
in 2012 [Int ernet]. Lyon (FR): World Health 
Organization, International Agency for Research 
on Cancer (IARC). c2014 –[updated [ADDRESS_322054] 
3]. Available from: 
http://globocan.iarc.fr/Pages/fact_sheets_cancer.a
spx[0402K4]
[Yu, H. A., et al 2013] Yu HA, Arcila ME, Rekhtm an N, Sima CS, 
Zakowski MF, Pao W, et al. Analysis of tumor 
specimens at the time of acquired resistance to 
EGFR -TKI therapy in 155 patients with EGFR -
mutant lung cancers. Clin Cancer Res. 2013 Apr 
15;19(8):2240 -7.[04SRR3]
[Zhang, X., et al 2004] Zhang X, Schwartz J -CD, Guo X, Bhatia S, Cao 
E, Chen L, et al. Structural and functional 
analysis of the costimulatory receptor 
programmed death -1. Immunity 2004;20:337 -47.[00VMQJ]
[Zhang, Y. L., et al 
2016]Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, 
Threapleton D, et al. The prevalence of EGFR 
mutation in patients with non -small cell lung 
cancer: a systematic review and meta -analysis. 
Oncotarget. 2016 Nov 29;7(48):[ZIP_CODE] -[ZIP_CODE].[04SRRX]
08FZ0N